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Chapter One 
 
INTRODUCTION 
 
Obesity: The impact on women’s health. 
 
A review of present literature concerning obesity 
and its impact on the pathophysiology of 
vascular disease in pregnancy and later life. 
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1  Introduction 
The 2002-2004 Confidential Enquiries into Maternal and Child Health has highlighted 
obesity as a significant risk for maternal death. More than half of all the women who died 
from Direct or Indirect causes, were either overweight or obese.  
For the mother maternal obesity increases the risk of obstetric complications during the 
antenatal, intrapartum and postnatal period as contributing to the technical difficulties of 
fetal assessment . The offspring of obese mothers also have a higher peri-natal morbidity 
and long term health problems  
In 2000 the World Health Organisation estimated as many as 300 million people 
worldwide were clinically obese. This figure could double by the year 2025 if no action is 
taken against this threat (1). With obesity comes the increased risk of diabetes, 
cardiovascular disease, cancer and stroke. The influence of obesity on women’s health is 
evident throughout both reproductive life and the menopause. Obesity increases the risks 
of gynaecological pathology such as infertility, menstrual disorders and endometrial 
cancer, making obese women more likely to attend the gynaecology clinic. In obstetrics, 
obesity increases the risk of antepartum, intrapartum and postpartum complications for 
the mother as well as contributing to the technical difficulties of fetal assessment. The 
offspring of obese mothers also have a higher perinatal morbidity and long term health 
problems. 
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1.1 Epidemiology of obesity          
The prevalence of obesity, defined as a body mass index (BMI) of 30 kg/m² or more has 
significantly increased during the last three decades, both in the United States (USA) and 
other first world countries. American trends are now seen among the European 
population as the Department of Health, for the United Kingdom (UK) Health survey for 
England reports that thirty two percent of 35- to 64-year-old women are overweight (BMI 
25–30 kg/m
2) and 21% obese (BMI > 30 kg/m
2) (2). In a British Women’s Heart and 
Health Study, one quarter of the 4000 participants in England, Scotland and Wales were 
found to be clinically obese (3). One fifth of the women were inactive and two fifths did 
not eat a portion of fresh fruit a day. The department of Health has predicted that if 
current trends continue, by 2010 six million women will be obese in England (2). In line 
with this, a large Scottish maternity hospital has observed a twofold increase in the 
proportion of women with a booking body mass index (BMI) >30kg/m
2 over the past 
decade (2) Obesity amongst women is of world-wide concern as shown in Australia by 
Callaway et al, in 2006 (5). They noted that thirty-five percent of Australian women 
between the ages of 25 and 35 years were overweight or obese.  Obesity accounts for 
more than 280,000 deaths annually
 in the United States and will soon overtake smoking 
as the primary
 preventable cause of death if current trends continue (6). 
 
According to the Health Survey for England pubished by the Department of Health It is 
estimated that in 2010 around 6,658,953 men will be obese, increasing from 
This watermark does not appear in the registered version - http://www.clicktoconvert.com15 
around 4,302,588 in 2003. For women, it is estimated that a further 1,230,573 women 
will be obese in 2010 than in 2003. Forecast projections showed that in 2010, a increase 
in the proportion and number of boys who are obese can be expected, rising from 
746,662 in 2003 to 792,321 in 2010. The greatest increases are expected among girls, 
with around a six percentage point increase in obesity rates between 2003 and 2010. It is 
estimated that around 910,630 girls will be obese in 2010. 
   
Obesity has now become pandemic in the U.S. where currently 
 2 in 3 American adults 
are classified as overweight or obese, compared
 with fewer than 1 in 4 in the early 1960s 
(3). Although still
 viewed more as a cosmetic rather than a health problem by the
 general 
public, excess weight is a major risk factor for premature
 mortality, cardiovascular 
disease, type 2 diabetes mellitus,
 osteoarthritis, certain cancers, and other medical 
conditions.
 Obesity accounts for more than 280,000 deaths annually
 in the U.S. and will 
soon overtake smoking as the primary
 preventable cause of death if current trends 
continue (3).   
As shown in Figure 1-1, the prevalence of obesity varies widely among countries that are 
geographically not very distant (e.g., Netherlands and neighbouring Germany) and is 
increasing in most European countries as well as in the U.S. 
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Figure 1-1. Time trends in the prevalence of obesity [BMI (in kg/m²) >30] in some 
European countries and in the U.S. Adapted from (4) 
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 In White populations living in the west and north of Europe, Australia, and the U.S. the 
prevalence of obesity is similarly high in men and women (5). Australia has a prosperous 
Western-style capitalist economy, and spends approximately 830 million dollars on the 
direct health care costs of obesity. For Australians, it is now more common to have a 
weight problem, with 48% of men and 30% of women being overweight and obesity 
affecting a further 19% of men and 22% of women (6). National survey data from the 
U.S. show that the prevalence of overweight and obesity among adults remained 
relatively constant over the 20-year period from 1960 to 1980 began to increase around 
the mid-1980s and has continued to increase (5). American trends are now being seen 
among the European population with 10% of children and 20% of adults in the UK now 
being classified as clinically obese (7). 
Obesity and sedentary lifestyle is a health issue affecting large numbers of women. The 
British Women’s Heart and Health Study, is a large study looking at lifestyle health 
issues among 4000 women in England, Scotland and Walse.  One quarter of the 4000 
participants were found to be clinically obese (8). One fifth of the women were inactive 
and two fifths did not eat a portion of fresh fruit a day. 
In 1999 Reilly et al examined data on 2630 children, a nationally representative sample. 
He describes the alarming increase in prevalence of obesity among children (see table1-1) 
(7). 
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  BMI > 85
th percentile  BMI > 95
th percentile 
AGED 6 YEARS            22%            10% 
AGED 15 YEARS            31%            17% 
Table 1-1. Trends in childhood obesity;Reilly J et al. Table showing the percentage 
children above the 85
th and 95
th centiles for BMI at age 6 years and 15 years (7). 
 
Among populations ethnic variations exist in terms of obesity rates. One Norwegian 
study looking at 8,000 immigrants found high proportions of overweight and obese 
subjects from Pakistan and Turkey, but low proportions among those from Vietnam. 
Subjects from Sri Lanka and Pakistan had the highest waist hip ratio for any given value 
of BMI (9). 
Obesity greatly increases risks for many serious and morbid conditions, including 
diabetes mellitus, hypertension, dyslipidemia, coronary artery disease, and some cancers. 
The challenges of the epidemic are not limited to merely aesthetic concerns. The 
disabilities caused by obesity are not only physiological but also psychosocial. The 
increased waist to hip girth is associated with increased risk of cardiovascular disease, 
hyperlipidaemia, hypertension, and diabetes. Obesity also has been related directly to 
increased risk of sleep apnoea, cancer, gallbladder disease, musculoskeletal disorders, 
severe pancreatitis, diverticulitis, infertility, urinary incontinence, and idiopathic 
intracranial hypertension. The psychosocial factors concerning quality of life in the obese 
population have also been documented. Although there is some debate, the obese have 
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been found to be twice as likely to suffer from anxiety, impaired social interaction and 
depression when compared with the non obese population (10). 
1.2 Influence of obesity on gynaecological issues 
Obesity in adolescence has increased significantly over the past 30-40 years and a recent 
international comparison study (13 European countries, Israel and the US) showed that 
the highest prevalence in adolescents was found in the US (12.6% in 13 year old boys, 
10.8% in girls; 13.9% in 15 year old boys and 15.1% in 15 year old girls) and the lowest 
in Lithuania. This increase in adolescence is a public health concern, because most obese 
adolescents continue their obesity into adulthood with serious risk for chronic disease. 
Focus should therefore be on prevention programmes that increase healthier patterns of 
lifestyle and physical activity (11). Obesity in adolescence tends to persist into adulthood. 
Adolescent obesity is also connected to excess mortality. High BMI in adolescence seems 
to be predictive of both adult obesity and mortality (12). The obese teenager is becoming 
an increasingly common attendee at the gynaecology clinic. Presenting complaints 
include menstrual disorders, amenorrhoea, oligomenorrhoea and menorrhagia. Polycystic 
ovarian syndrome (PCOS), with its associated symptoms and signs including obesity, 
hirsuitism and infertility are commonly seen among younger women (see table 1-2)  
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Table 1-2. Clinical symptoms and signs in women with PCOS, adapted from 
(13) 
 
 
 
 
Percentage frequency of symptom or sign  
 
 
Balen et 
al.(1995) 
Franks 
(1989) 
Goldzieher et 
al.(1981)   
  n = 1741 (%) 
n = 300 
(%)  n = 1079 (%) 
No. of 
cases 
 
Menstrual cycle 
disturbance         
Oligomenorrhoea  47  52  29  547 
Amenorrhoea  19  28  51  640 
Hirsutism  66.2  64  69  819 
Obesity  38  35  41  600 
Acne  35  27  –  – 
Alopoecia   6  3  –  – 
Acanthosis nigricans   3  <1  –  – 
Infertility 
(primary/secondary)  20  42  74  596 
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The effects of diet and adiposity have been implicated in disturbances
 of female 
reproductive function. Obesity complicates approximately 50% of all cases of PCOS and 
may underlie or contribute to ovulatory dysfunction by augmenting both the insulin 
resistance and the hyperandrogenaemia present in this disorder (14). An association 
independent of PCOS, however, has also been demonstrated between truncal obesity and 
irregular menses (15), suggesting that obesity itself may negatively impact on fertility. 
The Nurses’ Health Study II, which examined prospectively collected data on adiposity 
for 830 cases of incident ovulatory infertility and 26,125 pregnancies, revealed an 
increased risk for ovulatory infertility with a BMI below 20.0 or above 24.0 kg/m² (16). 
Taken together, these findings demonstrate a U-shaped association between BMI and the 
relative risk for female infertility. Both smoking and obesity unfavourably affect the live 
birth rate after in-vitro fertilisation (IVF) (17). Incidentally, poor semen quality was 
found to be associated with sedentary lifestyle and obesity among the male population 
(18). Not only does the presence of obesity make a couple more likely to experience 
difficulties with regard to conception, it also infers a negative impact on efficacy of 
treatment. Weight reduction programmes and BMI limits prior to commencement of 
expensive assisted conception treatment programmes is a strategy now being used often 
by fertility centres throughout the United Kingdom. As there are a limited number of 
National Health Service funded treatment cycles available to them, pre treatment 
optimum BMI seems essential. 
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Obesity constitutes a relative contradiction for use of combined oral contraceptives (OCs) 
(19). Combined OCs may aggravate the obesity. Obesity on the other hand is a risk factor 
for cardiovascular incidents among OC users (19). The most serious risks to OC users 
who are over age 35 and smoke are deep vein thrombosis, pulmonary embolus, retinal 
thrombosis, or cardiovascular disease. Other risk factors for cardiovascular disease 
include obesity, diabetes, hypertension, increased serum cholesterol, and a family history 
of premature myocardial infarction. All users should have blood pressure checks 3 and 6 
months after commencing pill use. OC usage does not increase the risk of developing 
breast cancer, but can stimulate the growth of breast cancer once it has occurred (20). 
Obesity when present in the menopausal women poses problems with regard to treatment 
options. Clinical risk factors for venous thromboembolism (VTE) include obesity, 
smoking, lifestyle, and aging. These factors coupled with the inherent thrombotic risk of 
hormone replace therapy (HRT) can lead to a cumulative increased risk of VTE (21). The 
Heart and Oestrogen/progestin Replacement Study (HERS) looked at secondary 
prevention using HRT in women with established arteriosclerosis. No significant 
difference was observed between HRT and placebo, while a possible protection was 
postulated by year 4. The follow up HERS II study observed no sustained protection with 
longer term HRT use (22).  
Obesity has also been described as a risk factor for development of breast and 
endometrial cancer (23). Therefore prescription of HRT, also recently suggested to 
increase the risk of both these conditions (24), must be carefully considered in the obese 
woman.  
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1.3 Influence of obesity on pregnancy 
1.3.1 Maternal health issues: Antenatal 
The Swedish Birth registry published data in the Lancet this year which found that 
compared with women whose BMI changed between -1.0 and 0.9 units, the adjusted odds 
ratios for adverse pregnancy outcomes for those who gained 3 or more units during an 
average 2 years were: pre-eclampsia, 1.78 (95% CI 1.52-2.08); gestational hypertension 
1.76 (1.39-2.23); gestational diabetes 2.09 (1.68-2.61); caesarean delivery 1.32 (1.22-
1.44); stillbirth 1.63 (1.20-2.21); and large-for-gestational-age birth 1.87 (1.72-2.04) (25). 
These findings support the concept of obesity as a causative factor in adverse pregnancy 
outcomes. Obesity is associated with an increased risk of first trimester and recurrent 
miscarriage. One UK case-control study compared first trimester miscarriage rates 
between 1,644 obese nulliparous (first pregnancy) (BMI >30 kg/m²) and 3,288 age 
matched control nulliparous women (BMI 19-24.9kg/m²). The prevalence of first 
trimester miscarriage and recurrent early miscarriage was significantly higher among the 
obese women (odds ratios 1.2 and 3.5, 95% CI 1.01-1.46 and 1.03-12.01, respectively; P 
= 0.04, for both] (26). Obesity is associated with poor pregnancy outcome and 
miscarriage in both women with PCOS, and in those with normal ovarian morphology. A 
meta-analysis of thirteen studies looking at gonadotrophin induced ovulation in women 
with normo-gonadotrophic anovulatory infertility, found obesity and insulin resistance to 
be the most clinically useful predictors for poor clinical outcome. The pooled odds ratio 
for obese versus non-obese women for spontaneous miscarriage rate was 3.05 (95% CI: 
1.45-6.44) (27). 
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Several studies have shown an increased risk for neural tube defects (NTD) associated 
with pre-pregnancy maternal obesity. Those women with a higher BMI value have a 
higher risk of congenital malformations among their offspring (28). This association was 
confirmed by Watkins et al in a population-based case control study using information 
from the Atlanta Birth Defect Risk Factor Surveillance Study. The study concluded that 
for every incremental unit increase in BMI (kg/m
2), the risk of NTD increased by 7% 
(29). Werler et al evaluated 604 cases of NTD identified within 6 months of delivery and 
compared them with 1,658 controls with other major malformations and 93 controls with 
no malformations (30). The women were classified according to their folate intake as 
above or below the recommended daily amount of 400 µg. It was observed that this dose 
of folate was found to be protective against NTD in women whose absolute body weight 
was less than 70 kg and not protective in those greater than 70 kg. The risk of NTD was 
also found to increase with increasing maternal weight independent of folic acid intake 
(30). Data based on 56,857 children in an analysis from the National Institute of 
Neurological, Communicative Disorders and Stroke showed an increased incidence of 
major congenital malformations of 35% when mothers were overweight and of 37.5% 
when they were obese (31).  
Obstetric ultrasound is widely practised throughout the developed world. Initially its 
major indications were dating of pregnancy, detection of multiple pregnancies and 
detection of intrauterine growth restriction, more recently with increasing resolution of 
modern machines, detection of fetal anomalies has become possible. The limitations of 
obstetric ultrasound as a screening test are dictated by the expertise of the clinician, the 
quality of the equipment and by the habitus of the patient. This should be clearly 
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understood in order to prevent unrealistic expectations. One American study examined 
the sensitivity of ultrasound to visualise fetal cardiac structures in obese gravid women 
(32). They demonstrated that despite the use of advanced ultrasound equipment, maternal 
obesity significantly limits visualisation of the fetal heart. Suboptimal ultrasound views 
of the fetal heart were more frequent in the obese women and this was not improved with 
higher specification equipment (32). By absorbing the associated energy adipose tissue 
can significantly attenuate the ultrasound signal. Therefore a high frequency, higher 
resolution signal would be more significantly absorbed at a lesser depth, sacrificing 
image quality and depth of field. A worrying consequence of maternal obesity is the risk 
of missing fetal anomalies when present. 
Wolfe et al prospectively collected data on 1,622 ultrasounds performed in the second 
and third trimesters of women who delivered live, singleton infants (33). The average 
gestational age was 28.5 weeks at the time of ultrasound. Each ultrasound was classified 
as visualized or sub optimally visualized. In patients with BMI less than the 10th 
percentile visualization of the anatomic structures studied was reported as 90.2%. In 
patients with BMI in the 97.5th percentile, visualization decreased to 63%. The author 
also reported a 14.5% decrease in visualization of all organs systems in patients with a 
BMI greater than the 90th percentile compared with patients with normal BMIs. There 
was no improvement in examinations with increasing gestational age or length of time 
used to conduct the ultrasound examination in patients with higher BMIs (33). In diabetic 
mothers increased rates of fetal anomalies are well documented (reference), however the 
associated increased maternal habitus more prevalent among diabetic mothers results in a 
lower detection rate. An Australian study looking at fetal anomaly rates among diabetic 
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mothers found a fetal anomaly rate of 7.7% for major anomalies and 2.3% for minor 
anomalies in the fetuses of the diabetic women (34). Major fetal anomalies were more 
likely to be identified in obese mothers (78% vs. 37%; P < 0.05). Compared to the 'low-
risk' non-diabetic population from the same institution, the relative risk for a major 
congenital anomaly among the diabetic women was 5.9-fold higher (95% confidence 
interval, 2.9-11.9). Despite these statistics, the detection rate for major fetal anomalies 
was significantly lower for diabetic women (30% vs. 73%; P < 0.01), and as expected the 
mean BMI for the diabetic group was significantly higher (29 vs. 23 kg/m
2; P < 0.001) 
(34). 
Independent of pregnancy, hypertensive disorders are significantly more prevalent in 
obese women than in their lean counterparts. Elevated pre pregnancy BMI is an 
independent risk factor for development of pregnancy-induced hypertension (PIH) (35). 
Even when the degree of excess body fat is moderate, the occurrence of hypertension and 
pre eclampsia is significantly higher by comparison with control patients (31, 36-38). 
Maternal obesity, both in itself and as part of the insulin resistance syndrome, is an 
important risk factor for the development of pre eclampsia. O’Brien et al identified 
thirteen cohort studies, comprising nearly 1.4 million women. The risk of pre eclampsia 
typically doubled with each 5-7 kg/m
2 increase in pre pregnancy BMI. This relation 
persisted in studies that excluded women with chronic hypertension, diabetes mellitus or 
multiple gestations, or after adjustment for other confounders (39). In non pregnant 
subjects, hypertension is associated with upper-body rather than lower body fat. Body fat 
distribution is an important factor in the assessment of risk of cardiac disease. Similarly 
in pregnancy not only the pre pregnant BMI but also the body fat distribution may 
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provide a more sensitive risk estimate. One study looking at 22 patients with pre 
eclampsia and 126 controls, found that the ratio of upper to lower body fat was more 
accurately associated with the development of pre eclampsia rather than BMI (40). Sattar 
et al looked at early pregnancy waist hip ratio in 1,142 women. When the waist 
circumference was > 80cm the risk of pregnancy induced hypertension doubled (OR 1.8 
95% CI 1.1-2.9) and the risk of pre-eclampsia was almost tripled (OR 2.7 95% CI 1.1-
6.8) (41). This data reinforces the importance of central obesity as a predicting factor of 
adverse outcome as opposed to the less sensitive marker of BMI. 
Gestational diabetes mellitus (GDM) affects about 5% of all pregnancies (42). Being 
overweight is a risk factor for impairment of carbohydrate tolerance both in the non-
pregnant and pregnant state. Conversely half of the women who develop GDM have no 
identifiable risk factor (43). No firm definition of gestational diabetes is universally 
agreed. In 2001 the Scottish Intercollegiate Guidelines Network (SIGN) confirmed that as 
yet no consensus exists as regards the definition, management or treatment of GDM. 
Importantly this body felt that no clear criteria for screening were established. In 2002 the 
Society of Obstetricians and Gynaecologists of Canada (SOGC), published guidelines 
supporting target screening for those at higher risk of gestational diabetes. Obesity is 
included in their risk assessment. However in the UK in 2003 the National Institute of 
Clinical Excellence (NICE) stated that the available evidence did not support routine 
screening for GDM. The debate extends further as to the impact of treatment of GDM. 
Effective treatment does reduce the risk of macrosomia, however instrumental and 
operative delivery rates are increased even in the absence of fetal macrosomia (44). 
Crowther et al conducted a randomized clinical trial to determine whether treatment of 
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women with gestational diabetes mellitus reduced the risk of perinatal complications (see 
Table 1-3) (45).  
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Table 1-3. : Perinatal and maternal complications among women with 
gestational diabetes mellitus. Table taken from Crowther  et al showing that the rate of 
serious perinatal complications was significantly lower among the infants of the women in the 
intervention group than among the infants of the women in the routine-care group (1% versus 4%, 
p=0.01). However, more infants of women in the intervention group were admitted to the neonatal 
nursery (71 percent vs. 61 percent; adjusted relative risk, 1.13; 95 percent confidence interval, 
1.03 to 1.23; P=0.01). Women in the intervention group had a higher rate of induction of labour 
than the women in the routine-care group (39 percent vs. 29 percent; adjusted relative risk, 1.36; 
95% CI, 1.15 to 1.62; P<0.001), although the rates of caesarean delivery were similar (31 percent 
and 32 percent, respectively; adjusted relative risk, 0.97; 95 % CI, 0.81 to 1.16; P=0.73) (45) 
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No epidemiological investigation of any significant size assessing the importance of body 
fat distribution as a risk factor for GDM has been undertaken as yet. However being 
overweight clearly increases the risk of carbohydrate intolerance during pregnancy. Even 
being moderately overweight (BMI 25-30 kg/m²) increases the risk of GDM 1.8-6.5 fold 
when compared with normal weight controls (31, 36-38). In obese women (BMI >30 
kg/m²), the incidence of GDM is 1.4 to 20 fold higher than in normal weight controls (38, 
46). If GDM is diagnosed, tight metabolic control should be achieved through diet and, 
when indicated, insulin therapy. Insulin therapy is required more often in obese women 
with GDM than in lean women with the condition (47). Treatment of the condition using 
insulin reduces maternal and fetal morbidity (45, 48, 49) 
Women who suffered from impaired carbohydrate metabolism during pregnancy are 
more likely to develop diabetes later in their lives. One study investigating 200 women 
who had GDM diagnosed between 1980-1998 found that the risk of diabetes 
development was significantly higher (independently of the clinical type) in women who 
had GDM during their pregnancy (50). Mothers who develop gestational diabetes have a 
50% greater risk of developing diabetes during their lifetime (50).  
1.3.2 Intra partum issues    
Obesity and diabetes are independently associated with adverse pregnancy outcomes. 
Rosenberg et al undertook a large population based study in which they collected data 
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from the 1999, 2000, and 2001 New York City birth files for 329,988 singleton births 
containing information on pre pregnancy weight and antenatal weight gain (51). Pre 
pregnancy and gestational diabetes were significant risks for a primary caesarean section 
and for preterm birth. (51). During pregnancy, obese women were at increased risk for 
several adverse perinatal outcomes, including anaesthetic, peri-operative, and other 
maternal and fetal complications. A population-based observational study carried out in 
the UK, looked at a total of 60,167 deliveries (Table 1-4) (52). All women were 
primigravid, more than 37 weeks’ gestation and uncomplicated singleton pregnancies, 
height and weight were recorded at the booking visit. Risk of adverse clinical outcome 
among obese mothers is shown in table 1-4. 
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Adverse outcome 
 
Obese Odds ratio, (95% Confdence 
intervals) 
Induction of Labour  1.6 (13-1.9) 
Caesarean Section  1.6 (1.4-2) 
Macrosomia  2.1 (1.6-2.6) 
Shoulder dystocia  2.9 (1.4-5.8) 
Failed instrumental delivery  1.75 (1.1-2.9) 
Increased maternal complications e.g. 
blood loss more than 500 mls 
1.5 (1.2-1.8) 
Table 1-4. The impact of obesity on incidence of adverse intrapartum 
outcomes when compared to lean controls (52). 
 
Many reports have suggested increased rates of intrapartum, operative, and postpartum 
complications among obese mothers (38). Intrapartum complications include failed 
epidural, increased risk of aspiration during general anaesthesia, with difficulty of 
intubation being most commonly cited. Increased rates of caesarean delivery, 
macrosomia, shoulder dystocia, difficulty obtaining peripheral intravenous access, and 
inaccurate or difficult blood pressure monitoring are also reported for those with pre 
pregnancy obesity when compared with lean controls (53). Common operative 
complications include loss of landmarks making vascular access difficult and increased 
risk of respiratory complications such as aspiration and pneumonitis. Increased retention 
of lipid-soluble agents, increased drug distribution and more rapid desaturation have also 
been reported. In a prospective population-based cohort study, 3,480 women with morbid 
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obesity, defined as a BMI more than 40 kg/m², and 12,698 women with a BMI between 
35.1 and 40 kg/m² were compared with normal-weight women (BMI 19.8-26 kg/m²). The 
perinatal outcome of singletons born to these women was evaluated. Primary outcomes 
were, antenatally, the occurrence of preeclampsia, abruptio placenta, placenta previa, and 
stillbirths after 28 weeks of gestation among singleton pregnancies. Around-term 
variables evaluated were the rate of cesarean delivery, labor inductions, pre- and postterm 
delivery, instrumental delivery, anal sphincter injury, shoulder dystocia, postpartum 
hemorrhage, and epidural anesthesia. Small-for-gestational age infants were defined as 
those with birth weights more than 2 standard deviations below the mean birth weight for 
gestational age according to a Swedish reference curve, (54), and LGA infants were those 
with birth weight above 2 standard deviations. Estimated gestational age was in most 
cases based on second-trimester ultrasound screening. 
 In the group of morbidly obese mothers (BMI greater than 40 kg/m²) as compared with 
the normal-weight mothers, there was an increased risk of the following outcomes 
(adjusted odds ratio; 95% confidence interval): pre eclampsia (4.82; 4.04, 5.74), ante 
partum stillbirth (2.79; 1.94, 4.02), caesarean delivery (2.69; 2.49, 2.90), instrumental 
delivery (1.34; 1.16, 1.56), shoulder dystocia (3.14; 1.86, 5.31), meconium aspiration 
(2.85; 1.60, 5.07), fetal distress (2.52; 2.12, 2.99), early neonatal death (3.41; 2.07, 5.63), 
and large-for-gestational age (3.82; 3.50, 4.16). The associations were similar for women 
with BMIs between 35.1 and 40 kg/m² but to a lesser degree (55). 
Each one unit increase in pre pregnancy BMI increases the risk of caesarean section by 
7% (56).The association between maternal obesity and preterm delivery is disputed. 
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Studies report conflicting results from a lower incidence (57, 58), a similar incidence (36, 
38, 46) to a higher incidence (31) Cnattinguis et al who carried out a cohort study in 
167,750 women reported that among obese women an increased rate of preterm delivery 
(<32 weeks) is seen only in nulliparous women. Among parous women obesity is not a 
significant risk factor for pre-term delivery (59). 
Perlow studied the impact of maternal obesity (>300 lbs) on perioperative morbidity 
among patients undergoing caesarean delivery (38). This case–control study compared 43 
“massively” obese patients (weight >300 lbs) with 43 non-obese patients. In the obese 
group there was an increased rate of emergency caesarean delivery, prolonged delivery 
interval, increased total operative time, increased blood loss, multiple epidural 
placements, increased infection, and prolonged hospitalisation (38). Wolfe et al was 
among the first to compare the type of skin incision in the obese parturient with the risk 
of morbidity. In 107 obese women weighing greater than 200 lbs they reported that the 
type of incision was not related to operative morbidity (60). 
The anaesthetist has a major role to play in preventing serious complications and must be 
aware of the many potential hazards. Extra vigilance is required to guide these patients 
safely through the perioperative period. In spite of this there is a lack of predictors 
specifically on the use of epidural and spinal anaesthesia in the obese patient. However 
many case reports exist on the difficulty of technique and the reduction in drug dosage 
requirements for such patients. 
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1.3.3 Post partum issues   
Obesity is characterized by a specific pattern of circulating concentrations of fat-cell 
products interleukin-6 (IL-6), leptin, and adiponectin. Circulating IL-6 and leptin levels 
are positively associated with BMI (61). It is now recognized that adipose tissue produces 
a variety of bioactive peptides, collectively termed "adipokines". Alteration of adipose 
tissue mass in obesity, affects the production of most adipose secreted factors. Several 
adipokines are increased in the obese state and have been implicated in hypertension 
(angiotensinogen), impaired fibrinolysis (PAI-1) and insulin resistance (ASP, TNFa, IL-
6, resistin) (62). Pregnancy is a prothrombotic state secondary to an increase in activity of 
coagulation factors XII, X and VIII, as well as fibrinogen (63). In the puerperium, deep 
venous thrombosis, endometritis, postpartum haemorrhage, prolonged hospitalization, 
wound infection, and dehiscence are also seen with increased frequency in the obese 
parturient (53).   
The leading cause of maternal mortality remains venous thromboemolism (VTE) and the 
postpartum period is the time of greatest risk secondary to vascular damage of childbirth. 
The coagulation cascade is activated by inflammatory cytokines causing endothelial 
activation and obviously this is increased with obesity. Impaired fibrinolysis is a common 
finding in obese humans (64). This condition is now considered as an established risk 
factor for thromboembolic complications. Several studies have shown that obese patients 
have higher plasma concentrations of all pro-thrombotic factors (fibrinogen, 
vonWillebrand factor (vWF), and factor VII), as compared to non-obese controls, with a 
positive association with central fat (64-66). It has been proposed that the secretion of IL-
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6 by adipose tissue, combined with the actions of adipose tissue-expressed TNFa in 
obesity, could underlie the association of insulin resistance with endothelial dysfunction, 
coagulopathy, and coronary heart disease (66). 
 
1.4 Implications for the fetus of the obese mother 
1.4.1 Short term 
Lower Apgar scores have been reported amongst neonates of obese mothers when 
compared to those of lean mothers (67). However Sheiner et al did not observe this 
finding (68). Pre pregnancy BMI is a strong predictor of birth weight, with obese mothers 
having an increased incidence of delivering large-for-dates babies. Various studies have 
reported that the obese mother is 1.4-18 (O.R.) times more likely to deliver a large-for 
dates infant (46, 58, 69). Macrosomia increases the risk of shoulder dystocia, birth injury, 
incidence of low Apgar scores and perinatal death. A recent three year retrospective 
analysis examined mode of delivery of infants weighing > 4kg. The incidence of 
caesarean section among the macrosomic group was 25.8% as compared with 13.1% 
(p<0.0001) in the general population. The incidence of shoulder dystocia was 7.6% as 
compared with a background incidence of 0.48% (p<0.0001). There were 7 cases of Erb’s 
palsy all occurring among the macrosomic group (70). 
Infants born of obese mothers are more likely to require admission to neonatal intensive 
care (NICU). In a retrospective study performed in France, the percentage of infants 
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requiring admission to a NICU was 3.5 times higher when maternal obesity was present 
(71). In addition the higher incidence of diabetes mellitus and gestational diabetes in the 
obese population may contribute to this effect with an increased risk of neonatal 
admission to the NICU for glycaemic control. The increased incidence of macrosomia 
and consequent birth trauma may also contribute to increased rates of perinatal morbidity 
in the offspring of obese mothers. (72-74) 
One cohort study carried out in Denmark examined the relationship between maternal 
pre-pregnancy (BMI) and the risk of stillbirth and neonatal death (75). 24,505 singleton 
pregnancies were analysed and women were divided into 4 groups, underweight (BMI 
<18.5 kg/m²), normal weight (BMI 18.5-24.9 kg/m²), overweight (BMI 25-29.9 kg/m²) 
and obese (BMI >30 kg/m²) Maternal obesity was associated with a more than doubled 
risk of stillbirth (OR  2.8, 95% CI: 1.5-5.3) and neonatal death (OR 2.6, 95% CI: 1.2-5.8) 
compared with women of normal weight. This was not attenuated by adjustment for 
factors such as smoking, alcohol and caffeine intake, maternal age, height, parity, gender 
of the child, years of schooling, working status and cohabitation with partner, nor did 
exclusion of women with hypertensive disorders or diabetes mellitus. No single cause of 
neonatal death explained the higher mortality in children of obese women, but more 
stillbirths were caused by unexplained intrauterine death and fetoplacental dysfunction 
among obese women compared with normal weight women (75). 
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1.4.2 Long term 
Barker’s hypothesis describes a theory of intra-uterine programming which suggests that 
babies who are small at birth or during infancy, secondary to maternal starvation during 
pregnancy, have increased rates of cardiovascular disease and non-insulin-dependent 
diabetes (NIDDM) in adult life (76). More recently Hattersley et al has provided another 
explanation for the association between low birth weight and insulin resistance, 
hypertension, coronary-artery disease, and non-insulin-dependent diabetes (NIDDM) in 
adult life (77). The proposal is that genetically determined insulin resistance results in 
impaired insulin-mediated growth in the fetus as well as insulin resistance in adult life 
and that low birth weight, measures of insulin resistance in life, and ultimately glucose 
intolerance, diabetes, and hypertension could all be phenotypes of the same insulin-
resistant genotype. Insulin secreted by the fetal pancreas in response to maternal glucose 
concentrations is a key growth factor (77). Forsen et al showed that men whose mothers 
had a high BMI in pregnancy had an increased risk of coronary heart disease (78).
 The 
highest death rates were observed among men who were thin
 at birth with a low placental 
weight but whose mothers had a high
 BMI during pregnancy (78). While under nutrition 
is uncommon in the developed world, obesity and cardiovascular disease are common. 
The direct effects of maternal obesity on fetal programming are under researched. The 
concept of fetal programming being related to the quality of nutrition rather than the 
quantity needs to be addressed. One may hypothesise that in addition to maternal 
malnutrition secondary to famine, malnutrition secondary to an inappropriate diet of 
highly processed, high fat food, lacking in essential vitamins and nutrients, i.e. the 
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modern western diet, may contribute to long term adult health of offspring through fetal 
programming.  
A recent retrospective cohort study by Whitaker (79) in over 8400 children in the USA in 
the early 1990s reported that children who were born to obese mothers (based on BMI in 
the first trimester) were twice as likely to be obese by 2 years of age. If a women had a 
BMI >= 30 in the first trimester, the prevalence of childhood obesity (BMI > 95th 
percentile based on Center for Disease Control criteria) at ages 2, 3 and 4 years was 15.1, 
20.6 and 24.1%, respectively. This was between 2.4 and 2.7 times the prevalence of 
obesity observed in children of mothers whose BMI was in the normal range (18.5–24.9). 
This effect was only slightly modified by birthweight. 
There is an independent effect of maternal pregravid weight and diabetes not only on 
birthweight but also on the adolescent risk of obesity. Langer et al.(74) reported that in 
obese women with GDM, whose glucose was well controlled on diet alone, the odds of 
fetal macrosomia (birthweight > 4000 g) was significantly increased (OR 2.12) compared 
with those in women having a well-controlled (diet only) GDM with normal BMI.  
 
Dabelea et al carried out work with the PIMA Indians who live in an area of today’s 
southern Arizona and northwestern Mexico (80). These Native Americans successfully 
adapted to the desert life by elaborating an irrigation system and by hunting and gathering 
to supplement their cultivated crops. Diversion of their water supply by the increasing 
population of the area with people of European origin by the end of the 19th century 
disrupted their traditional agriculture and led to importantchanges in their way of life 
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(81). Today the Pimas suffer from several chronic diseases, mainly Type 2 diabetes and 
obesity, which may be conditions of relatively recent origin. The Pima Indians now have 
the world’s highest prevalence and incidence of Type 2 diabetes (82), with about half of 
all individuals over 35 years of age having the disease (82). The prevalence and incidence 
of Type 2 diabetes in the Pimas has been increasing during the last century, and it is 
higher in recent years than it was 30 years ago. Moreover, the disorder is now common 
even among Pima children (83). Because this disease occurs at young ages, 10–15% of 
pregnancies are complicated by diabetes (84). A longitudinal study of diabetes conducted 
in this population for the past 30 years identified women who developed diabetes before 
or during pregnancy, women who had normal glucose tolerance during pregnancy but 
who subsequently developed diabetes (prediabetic women, diagnosed in retrospect), as 
well as women who never developed diabetes. Data on diabetes are available from 
offspring of all three groups of women. In the 5–9 and 10–14 year age groups there is 
little diabetes, but when present, it is almost exclusively found among offspring of 
diabetic mothers. At older ages as well, the prevalence of diabetes is much higher in the 
offspring of women who had diabetes in pregnancy (that is, those who were exposed to 
the diabetic intrauterine environment) than in the offspring of women who developed 
diabetes only after the pregnancy or in offspring of women who remained nondiabetic. 
These findings indicate that exposure to the diabetic intrauterine environment is an 
important determinant of Type 2 diabetes, in addition to the genetic predisposition. 
Dabelea et al describe a viscious vicious cycle. The woman with diabetes, whether 
diagnosed before or during pregnancy, has a high-risk pregnancy with potential 
complications for herself and her offspring. The effects on the offspring extend well 
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beyond the neonatal period. The infant of the woman with diabetes is at high risk of 
becoming obese and of developing Type 2 diabetes at a young age. The young woman 
whose mother had diabetes during pregnancy is at risk of perpetuating the cycle by 
becoming obese and developing diabetes before or during her childbearing years. 
 
1.5 Cost implications with the obese patient 
A retrospective study carried out in 1995 found that the cost of antenatal care in 
overweight women was 5.4-16.2 fold higher when compared with normal weight controls 
(71). In 2000 researchers carried out a prospective analysis of cost of care in 435 women 
seen consecutively within their obstetric service. The average cost in terms of antenatal 
care and duration of hospital stay was 5 times higher for women who had a higher pre 
pregnancy BMI when compared to normal weight controls. In addition duration of 
hospital stay was 3.9-6.2 fold higher among the overweight mothers and a women with a 
pre pregnancy BMI>29kg/m² stayed in the hospital an average of 4.43 more days than her 
lean counterpart (85).  
The overall financial burden of obesity generally on the National Health Service is 
difficult to determine. The implications of the increased incidence of maternal obesity for 
maternity services are that of more medicalisation of labour and delivery, more pressure 
on neonatal services, antenatal and postnatal beds and ultimately increased financial 
burden.  
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1.6 Obesity and the influence on general health 
1.6.1 Cardiovascular disease 
Coronary heart disease (CHD) is the leading cause of mortality within the developed 
world. The association between obesity and in particular central obesity and elevated risk 
of cardiovascular disease is now well established (86, 87). One potential mechanism 
involves the relationship between insulin sensitivity and blood pressure. Abdominal fat 
rather than being inert tissue is an active source of free fatty acids (FFAs) and 
inflammatory cytokines which promote vascular inflammation and endothelial 
dysfunction. This pathophysiological mechanism has been suggested to predispose to 
impaired insulin sensitivity and microvascular disease. Therefore, cardiovascular 
morbidity and mortality is not only predetermined genetically, but may be influenced by 
lifestyle alterations such as weight loss and exercise. The Nurses Health Study claimed 
that women who maintain a desirable body weight, consume a healthy diet, exercise 
regularly, avoid smoking and drink alcohol in moderation reduce their risk of 
cardiovascular disease by 84% (88). Interventional studies have demonstrated an 
adjustment in cardiovascular disease risk profile with reduction in BMI and lifestyle 
changes. One study looking at a group of pre menopausal women who lost weight over a 
period of one year demonstrated a significant reduction in inflammatory cytokine 
concentrations as well as a reduction in adhesion molecule concentrations including 
ICAM-1, identified as an independent risk factor for coronary heart disease. Conversely 
these patients demonstrated a significant improvement in endothelial function (89). A 
randomised trial looking at 3000 patients with raised fasting plasma glucose 
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concentrations allocated patients to either lifestyle changes or medical therapy. The aim 
of intervention was to reduce the incidence of progression in these high risk patients to 
clinical disease, type 2 diabetes. The results showed that modification in lifestyle, i.e. 
weight reduction and exercise, was more effective than metformin in reducing the 
progression to type 2 diabetes (90). 
 
1.6.2 Diabetes 
Obesity is a known risk factor for type 2 diabetes. The prevalence of obesity in the U.S. 
has increased from 12% in 1991 to 18% in 1998 and to 20% in 2000 (91). A parallel 
increase in diabetes is also reported from 4.9% in 1990 to 7.3% and 7.9% in 2000 and 
2001 respectively (91). Until recently diabetes of onset in adolescence has been almost 
exclusively the consequence of type 1 diabetes, while type 2 diabetes has been the 
domain of adults. However, in the past few years several reports, mainly from North 
America, have documented the emergence of type 2 diabetes in young people that has 
paralleled an increased prevalence of obesity in this age group (92, 93). An increase in 
plasma free fatty acid (FFA) concentrations plays a key role in the pathogenesis of insulin 
resistance through specific actions that block insulin signal transduction. An increase in 
plasma FFA concentrations in normal subjects to levels comparable to those in the obese 
also results in the induction of oxidative stress, inflammation, and vascular dysfunction, 
in addition to causing insulin resistance (94). Because resistance to insulin also results in 
the relative non-suppression of adipocyte hormone–sensitive lipase, there is further 
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enhancement of lipolysis and increase in FFA concentration. Thus, a vicious circle of 
lipolysis, increased FFA, insulin resistance, and inflammation occurs.  
 
1.6.3 Cancer 
A large population-based cohort study including over 145,000 Austrian adults over a 
period of 9.9 years looked at the relationship between cancer and obesity (23). The 
incidence of cancer was recorded; adjustment was made for smoking and occupation. A 
linear correlation between BMI and occurrence of many cancers including colon, 
pancreatic, breast and uterine was observed consistently throughout the study (23). When 
thinking about cancer risk we do not primarily think of BMI as a risk factor, certainly not 
as much as we do about smoking, genetic influences or exposure to toxins. In many cases 
the explanation for an obesity- cancer connection may not be the weight per se, but the 
things people do that result in obesity such as eating a poor diet or not getting much 
exercise. Calle et al carried out a prospective study looking at a population of over 
900,000 American adults. All participants were cancer free at time of enrolment and each 
was followed up for 16 years. A linear correlation between BMI and deaths due to cancer 
was observed for the study period. Calle, in conclusion, postulated that 20% of all deaths 
from cancer among US women in age 50 years or over could be accounted for by the co 
existence of being overweight or obesity (95).  
As previously stated, rather than being an inert tissue, adipose tissue is an active organ 
manufacturing hormones, such as oestrogen and growth factors which promote cell 
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division. This promotion of cell division may provide greater opportunities for mutations 
to occur and the development of cancer. Overweight women are known to have an 
increased risk of endometrial and breast cancer when post menopausal due to the 
increased levels of circulating oestrogen (95, 96). Obesity has been consistently 
associated with higher risk of colorectal cancer in men (Relative Risk (RR) 1.5-2.0) and 
women (RR 1.2- 1.5) in both case control and cohort studies (97). The risk of renal cell 
cancer is 1.5 to 2.5 fold higher in overweight and obese individuals when compared to 
normal weight controls (97). Obesity is associated with a 2-3 fold increase in the 
incidence of oesophageal adenocarcinoma (98, 99). The explanation for the association 
between obesity and oesophageal adenocarcinoma is the increased occurrence of gastric 
reflux among the obese. 
 
1.7 Obesity and health implications: potential 
pathophysiological mechanisms.                 
1.7.1 Lipids 
Obesity and dyslipidaemia are interlinked (100, 101) Various lipid/lipoprotein
 
abnormalities have been observed in obese individuals, including
 elevated cholesterol, 
triglycerides, apolipoprotein B (apoB),
 and lower high-density lipoprotein (HDL) 
cholesterol levels.
 Of these indicators, changes in triglyceride and HDL cholesterol
 levels 
are most consistent and pronounced (102, 103). Some studies have demonstrated that 
central obesity is more
 strongly related to lipid/lipoprotein abnormalities than is
 general 
obesity (104-106). Hu et al examined data on 1500 adults including participants in the 
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American Strong Heart Study (107). Total obesity was assessed using BMI and also an 
estimation of central obesity using waist circumference. Lipoprotein concentrations were 
measured. Waist circumference was positively related to triglycerides
 (r = 0.14, p < 
0.001) and negatively related to HDL cholesterol
 (r = -0.23, p < 0.001). BMI was 
positively correlated with triglycerides (r
 = 0.30, p < 0.001) and negatively correlated 
with HDL cholesterol
 (r = -0.35, p < 0.001) (108). Hypercholesterolaemia is a predictor 
of coronary heart disease. The West of Scotland Coronary Prevention Study 
(WOSCOPS) has shown
 a relative risk reduction with pravastatin treatment, a lipid 
lowering drug, of 29% (95%
 CI, 15% to 40%) for coronary events and 33% (1% to 55%) 
for
 coronary deaths (109). The
 Scandinavian Simvastatin Survival Study (4S) has shown 
that
 simvastatin treatment reduced coronary morbidity by 34% (25%
 to 41%) and 
coronary mortality by 42% (27% to 54%) (110). 
 
1.7.1.1 Lipoprotein metabolism 
Lipoprotein particles
 are not homogeneous but contain discrete subfractions differing
 in 
structure, physicochemical properties, kinetic behaviour,
 and origin. The 
hypertriglyceridaemia seen with abdominal obesity and insulin
 resistance is related to the 
over secretion of triglyceride-rich
 VLDL particles, see figure 1-2. 
This watermark does not appear in the registered version - http://www.clicktoconvert.com47 
  
 
 
Figure 1-2: Lipoprotein metabolism. CETP = cholesteryl ester transfer protein;  
                                                              Chol   = cholesterol; 
                                                              HDL   = high-density lipoprotein; 
                                                              HL      = hepatic lipase;  
                                                              IDL     = intermediate-density lipoprotein;  
                                                              LDL    = low-density lipoprotein; 
                                                              LDL-R= LDL receptor; 
                                                              TG,     =triglycerides; 
                                                              VLDL =very-low-density lipoprotein.  
 
 
 An increased rate of hepatic FFA
 uptake stimulates the secretion of apo B-100; leading 
to increase in 
 numbers of apo B-containing particles (111). Apo B is the structural 
protein of atherogenic lipoproteins,
 including VLDL, intermediate density lipoproteins 
(IDL), and
 LDL. Each of these lipoproteins contains one apo B molecule,
 and the plasma 
apo B level reflects the total number of atherogenic
 particles in the blood. VLDL particles 
are exposed to lipoprotein
 lipase in the peripheral circulation, which hydrolyzes the 
triglyceride
 in VLDL particles, generating FFA. Under normal conditions,
 these FFA are 
taken up by muscle and adipose tissue for energy
 use or storage. The resultant remnant 
particles are then processed
 by the liver to form Low density lipoprotein (LDL).
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incorporates
 a spectrum of lipoproteins of differing atherogenic potential.
 Small, dense 
LDL (known as LDL-III), as distinct from the larger,
 more buoyant LDL-I and LDL-II 
particles, exhibit enhanced oxidation
 potential and reduced receptor binding. Once 
oxidized,
 these particles are believed to be highly atherogenic, promoting
 foam cell 
formation and initiating endothelial dysfunction (112) (see figure 1-3) 
 
Figure 1-3: Foam cell formation.  Diagram showing the formation of foam cells 
utilising oxidised LDL and the formation of atherosclerotic lesions. 
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The role of small LDL as a risk factor for coronary heart disease is now well established. 
Plasma triglyceride is the major determinant of small dense LDL, accounting for 40-60% 
of any variation in this fraction in the plasma (113). At normal triglyceride levels there is 
a positive correlation between LDL-II (the major LDL sub fraction) concentrations and 
that of plasma triglyceride (113). However cross sectional studies report a threshold 
effect, in that, above a certain triglyceride level, namely 1.5mmol/L in men, LDL-II 
concentrations correlate negatively with triglyceride levels. On the other hand the highly 
atherogenic LDL-III concentration which is at fairly constant levels below the threshold 
level starts to correlate positively with plasma triglyceride concentrations (113, 114). The 
dyslipidaemia of obesity characterized by low levels of high-density lipoprotein; 
increased triglycerides; increased sub fractions of small, dense LDL; and increased levels 
of apolipoprotein B-100 is now well recognised (115). The dyslipidemia associated with 
obesity is multi-factorial, and is frequently associated with a cluster of interrelated 
cardiovascular disease risk factors that has been designated the metabolic syndrome. 
Obesity is a critical determinant of this dyslipidemia, operating through a number of 
metabolic influences that include reduced insulin sensitivity and changes in fatty acid 
metabolism that are described subsequently. Variations in the nature and magnitude of 
the dyslipidemia are due to the interaction of genetic factors with environmental 
influences, most notably diet and physical activity, and possibly stress, see figure 1-4. 
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The metabolic syndrome or Syndrome X is a phenotype encompassing central adiposity, 
hyperinsulinaemia, hypertryglyceridaemia, reduced HDL concentrations and 
hypertension (87). Abdominal (visceral) adipose tissue is metabolically active and is 
largely responsible for the atherogenic dyslipidaemia, hyperinsulinaemia, hypertension, 
chronic inflammatory state, and prothrombotic state that constitute the metabolic 
syndrome, and the subsequent increased risk for cardiovascular disease and acute 
coronary events(115). 
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1.7.2 Pregnancy and lipids 
1.7.2.1   Normal pregnancy 
During the course of normal pregnancy, plasma triglyceride concentrations rise by 200-
400% while plasma cholesterol levels rise by 25-50% (116, 117). Only a few studies have 
examined lipoprotein concentrations in detail as pregnancy advances. In the first 
Fahraeus et al investigated 19 healthy women in whom the levels of plasma lipoprotein 
fractions were determined before conception, at exact gestational ages every 6 to 8 weeks 
during pregnancy, and eight weeks after delivery. The HDL-cholesterol level was 
elevated in the 14th week and showed a maximum rise by 41% in the 28th week of 
pregnancy. The LDL level decreased in early pregnancy but then increased continuously. 
The VLDL triglyceride concentration showed a continuous increase from week 14, and in 
week 36, it was three times higher than before pregnancy. During lactation, up to eight 
weeks after delivery, LDL cholesterol remained elevated, whereas the other lipoproteins 
had returned to pre pregnancy levels (116). Sattar et al undertook a longitudinal 
examination of plasma lipoprotein sub fraction concentrations and compositions in 
uncomplicated pregnancy (118). Sattar et al hypothesised that as pregnancy advanced and 
plasma triglyceride concentrations increased, the LDL subfraction profile would be 
altered with the appearance of smaller, denser particles. Secondly they hypothesised a 
triglyceride concentration threshold would exist, above which LDL-III concentration 
would escalate (118). Median concentrations of VLDL-1, VLDL-2 and IDL increased in 
parallel, maximum increase being five fold, with increasing triglyceride concentrations 
with advancing gestation. This rise in VLDL-2 and IDL are of note as they do not occur 
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in the non pregnant state with increased plasma triglyceride concentrations (118). 
Moreover and particularly relevant to our study, the higher the booking fasting 
triglyceride concentration or the steeper the gradient of triglyceride concentration with 
advancing gestation the more likely the alteration of LDL profile to the smaller denser 
species. This LDL alteration toward smaller denser profiles exhibited a threshold effect, 
with a different threshold and timing of reaching that threshold for different women 
(118). This effect has been observed by others. Belo et al concluded after their 
longitudinal study of changes in levels of oxidised LDL with advancing pregnancy that 
during human gestation the change in LDL profile was towards smaller species (119).   
Dyslipidaemia occurs in all pregnancies but not all women develop cardiovascular 
disease. It is known that oestradiol supplementation is associated with enhanced arterial 
endothelial function (120). As with advancing gestation oestradiol levels rise, one could 
hypothesise a protective influence upon the endothelium in response to the increasing 
dyslipidaemia.  
1.7.2.2   Complicated pregnancy 
Pre-eclampsia (PE) is a pregnancy exclusive multi-system disorder characterised by 
widespread endothelial dysfunction. Characteristic clinical manifestations result, namely 
hypertension due to vaso-constriction, proteinuria due to glomerular damage and oedema 
due to increased vascular permeability. A complex pathological process underlies these 
clinical manifestations with the activation of the coagulation system, platelets and 
leukocytes, along with disturbances in metabolism which integrate to cause endothelial 
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damage and dysfunction (121). This resultant damage only serves to activate further 
circulating leukocytes and coagulation system; hence a vicious circle of vascular injury 
evolves (121). The precursor for this sequence of events is sourced within the placenta, 
confirmed by the incidence of pre-eclampsia among molar pregnancy when no fetal 
tissue develops. Various theories for the mechanism of activation of these events by the 
placenta have been proposed, including fragments of syncytiotrophoblast villous 
membranes (122) or cytokine released from immune cells within the placenta which in 
turn trigger endothelial dysfunction directly by activating leukocytes (121).  
One unifying feature within the placenta of the pre-eclamptic patient is acute 
atherosclerosis. Accumulation of lipid laden macrophages surrounded by areas of 
fibrinoid necrosis in the spiral arteries are features similar to those observed in the non-
pregnant atherosclerotic vascular bed (121). Furthermore the classic lesion within the 
glomerulus is glomerular endotheliosis, with the accumulation of lipids within the 
glomerular cells. The accumulation of lipids at key sites with the pre eclamptic patient 
emphasises the potential role of lipids and lipoprotein disturbance in PE (123). (See 
figure 1-5).  
Gestational diabetes is characterised by the development of insulin resistance with 
advancing gestation. Insulin sensitivity is reduced as much as 80% during pregnancy 
(42). Placental secretion of hormones such as progesterone, cortisol, placental lactogen, 
prolactin and growth hormone are major contributors to the insulin resistant state seen in 
pregnancy. The insulin resistance which develops plays a key role in ensuring the fetus 
has an adequate supply of glucose by changing the maternal energy metabolism from 
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carbohydrates to lipids (124). The enhanced adipocte pool and increased release of 
NEFAs only serves to enhance the insulin resistance, which may account for those 
women who present clinically (see figure 1-5).  
 
Figure 1-5: Dyslipidaemia of pregnancy. Diagram adapted from Sattar et al (121).  
 
Human placental lactogen (HPL), cortisol, and sex steroids, which are also at elevated 
concentrations in pregnancy stimulates FFA release from adipose tissue (125). Normal 
pregnancy is characterised by progressive increases in triglyceride (300%) and 
cholesterol (50%) concentrations. In the late second trimester increased amounts of FFAs 
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are released into the circulation through combined stimulation of hormone-sensitive 
lipase by HPL and by increased insulin resistance (121). Oestrogen increases hepatic 
output of VLDL, and decreases hepatic lipase activity promoting accumulation of 
triglycerides in lipoproteins of densities higher than that of VLDL (126). Decreased 
adipose tissue LPL activity and decreased hepatic lipase activity impair the removal of 
triglyceride-rich lipoproteins from the circulation (126), thus leading to higher serum 
triglyceride concentrations. 
 
 
Summarized in figure 1-5 is the potential role of the dyslipidaemia of pregnancy in the 
pathogenesis of pre-eclampsia (PE). The placenta releases factor(s), such as human 
placental lactogen (hPL), which enhance peripheral lypolysis, which is already stimulated 
in normal pregnancy. The result is an increased flux to the liver of non-esterified fatty 
acids (NEFAs). This is then channelled into hepatic triglyceride synthesis so production 
of triglyceride rich lipoproteins (VLDLı) is increased over that of normal pregnancy. 
When the pathway is saturated accumulation of triglyceride within the hepatocyte occurs. 
The increased circulating levels of VLDLı promote the production of an atherogenic lipid 
profile by stimulating the production of small dense LDL (LDL III) and lowering HDL- 
cholesterol. This atherogenic lipid profile may contribute to endothelial dysfunction and 
the clinical manifestations of PE in the mother. This pathway plays a role in the 
formation of lipid laden macrophages (foam cells) in the spiral arteries of the deciduas 
basalis, and as a result, may be involved in the enhanced production by the placenta of 
inflammatory mediators in PE. 
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The regulation of lipolysis, the process for mobilization of free fatty acids (FFAs) 
through hydrolyzation of stored triglycerides, is important for the understanding of 
underlying factors behind metabolic events and disorders like obesity, diabetes, and 
insulin resistance. Activation of the sympathetic nervous system is said to activate 
lipolysis in subcutaneous adipocytes (127). This is a complex humoral response. 
 
 
1.8 Inflammation 
Adipose tissue has been proposed as a direct source of inflammatory markers collectively 
known as adipocytokines. Obesity, especially visceral obesity causes abnormalities of 
adipocytokine secretion (128). Adipocytes have been shown to be endocrine cells that 
secrete a variety of bioactive substances. These adipocytokines include, tumour necrosis 
factor alpha (TNF-α), plasminogen activator inhibitor 1 (PAI-1), and heparin-binding 
epidermal growth factor-like growth factor (128). The levels of several pro-inflammatory 
cytokines, including TNF-α, interleukin-6 (IL-6) and leptin are significantly higher in the 
plasma of obese patients (129). Visfatin is a very recently discovered visceral fat-specific 
protein that may be related to the development of obesity-related diseases such as 
diabetes mellitus and cardiovascular disease (128). In contrast to these adipocytokines, 
adiponectin, also a new-found adipose tissue-specific collagen-like protein, has been 
noted recently as an important anti-atherogenic as well as anti-diabetic protein. Visceral 
fat accumulation causes dysfunction of adipocytes including over secretion of (TNF-α), 
(PAI-1) , and heparin-binding epidermal growth factor-like growth factor, as well as 
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hypo-secretion of adiponectin, which results in the development of a variety of metabolic 
and circulatory disease (128).  
Atherosclerosis is now believed to be a disease of inflammation (130). Serum 
concentrations of inflammatory markers have been demonstrated to be predictive of 
coronary events. Ridker et al measured plasma C-reactive protein (CRP), a marker for 
systemic inflammation, in 543 apparently healthy men participating in the Physicians' 
Health Study in whom myocardial infarction, stroke, or venous thrombosis subsequently 
developed, and in 543 study participants who did not report vascular disease during a 
follow-up period exceeding eight years (131). The men in the quartile with the highest 
levels of CRP values had three times the risk of myocardial infarction (relative risk, 2.9; 
P<0.001) and two times the risk of ischemic stroke (relative risk, 1.9; P=0.02) when 
compared with the men in the lowest quartile (131). IL-6 has also been shown to be 
independently predictive of myocardial infarction risk despite adjustment for CRP levels 
(132). Leptin plays an important role in regulating adipose tissue mass. Leptin is a 
peptide hormone that is primarily synthesized and secreted by adipocytes (133). One of 
the major functions of this hormone is the control of energy balance by binding to 
receptors in the hypothalamus, leading to reduction in food intake, elevation in 
temperature and energy expenditure (133). Consistently elevated levels of leptin are 
found among obese individuals and significant correlations are found between serum 
leptin concentration and BMI, percentage body fat and abdominal subcutaneous adipose 
tissue (134).  Furthermore, a resistance to circulating leptin in its ability control energy 
balance seems to be apparent among those who are obese (135). Leptin resistance is a 
hallmark of obesity, but its aetiology is unknown.  
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1.8.1 Pregnancy and inflammation 
1.8.1.1   Normal pregnancy 
The behaviour of inflammatory markers during pregnancy is under-investigated. 
However any work that has been done on normal pregnancy consistently reports 
pregnancy to be a pro inflammatory state (136). With the aim of determining 
physiological levels of pro inflammatory markers during normal pregnancy a  
longitudinal study carried out in Greece found IL-6, TNF-α CRP to rise with advancing 
gestation (137). Other cross sectional studies show that IL-6 and IL-1 levels correlate 
positively with advancing gestation (138). Ramsay et al observed the concentrations of 
IL-6 and CRP in obese pregnant women to be elevated when compared with non-obese 
pregnant controls. IL-6 was found to be 50% higher while CRP was almost double when 
compared with lean controls (139).  
 
1.8.1.2   Complicated pregnancy 
Substantial evidence now exists to support the theory that pre-eclampsia is connected to 
abnormalities within the inflammatory process with advancing gestation. Granulocytes 
and monocytes are activated (140-142) resulting in increased release of pro-inflammatory 
cytokines such as TNFα, IL-6 and soluble phospholipase A2 (143, 144). An increase in 
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cell adhesion molecules, VCAM-1 and ICAM-1, has been demonstrated in women with 
pre-eclampsia also suggesting a state of inflammation and endothelial activation. Greer et 
al have provided further evidence supporting the link between inflammation and 
endothelial activation (145). A significant correlation between IL-6 and VCAM-1 
(r=0.539, p<0.005) among patients with pre-eclampsia was observed by this group (145). 
This evidence supports the key role of the pro-inflammatory cytokine IL-6 as being 
pivotal in the pathophysiology of endothelial dysfunction and the development of pre-
eclampsia. 
1.9 Microvascular function 
The human vasculature rather than being an inert transport system is a complex and vital 
organ that can regulate its own tone and structure via numerous cellular mechanisms 
(146). The endothelium plays the role of gatekeeper in this process, sensing and 
responding to stimuli and activating various vasoactive systems that function as 
mediators. Locally generated vasoactive substances such as angiotensin II and nitric 
oxide (NO) appear to be important determinants of vessel function and structure. 
Vasoactive substances generated within the endothelium influence cell proliferation and 
cell death in a complex interplay that, when disturbed, can result in structural alteration 
known as vascular remodelling. Normal vascular homeostasis is maintained by a balance 
between vasoconstrictors such as angiotensin II and vasodilators such as nitric oxide. 
Endothelial dysfunction involves an imbalance between vasoactive substances such that 
perturbations in the regulation of tone, haemostasis, and vessel structure result in the 
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development of cardiovascular diseases, such as hypertension, atherosclerosis, and heart 
failure (147).  
An animal study in 1980 by Furchgott et al demonstrated that the isolated arteries relaxed 
in response to acetylcholine (ACh) but only in the presence of an intact endothelium 
(148). They went on to propose that, ACh, acting on muscarinic receptors endothelial 
cells, stimulates release of a substance(s) that causes relaxation of the vascular smooth 
muscle. This substance became referred to as endothelium derived relaxant factor 
(EDRF). Further work identified this factor to be Nitric Oxide (149). NO is derived from 
the terminal guanidine atom of L-arginine, a reaction catalysed by the calcium dependant 
enzyme nitric oxide synthase (NOS). The products of this reaction are NO and L-
citruline. The NO diffuses into the adjacent smooth muscle activating guanylate cyclase, 
which increases cyclic guanosine 5-monophosphate (cAMP) stimulating the outward 
transport of calcium and therefore relaxation of vascular smooth muscle (see figure 1-6). 
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Figure 1-6: The pathway to endothelium dependent vasodilation via the 
nitric oxide system. 
 (Ach= Acetylcholine, NOS = Nitric Oxide Synthase, NO = Nitric Oxide, GTP = Guanosine 
triphosphate, cGMP= cyclical guanosine 5-monophosphate). 
 
NO has other properties apart form vasodilation. It also inhibits platelet aggregation, 
smooth muscle cell migration and proliferation, adhesion molecule expression and 
therefore monocyte adhesion. Therefore NO plays a crucial role in protecting the vessel 
wall against the development of atherosclerosis and thrombosis (150).  
Clinical studies report that the presence of endothelial dysfunction is a significant 
predictor of future cardiovascular events (151, 152). The vast majority of evidence to 
date indicates that microvascular endothelial function is impaired in the early stages of 
atherosclerosis and it is this endothelial dysfunction which is an important factor leading 
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to atherosclerosis and its complications. The vascular endothelium is often the target for 
pathogenic injury.  Impairment of endothelium derived NO in atherosclerotic leads to 
vasoconstriction or rather lack of vasodilation activity. Platelet aggregation, thrombus 
formation, increased smooth muscle proliferation and enhanced leukocyte adhesion to 
and invasion through the endothelium are features which are postulated to follow. All of 
these changes are observed during the course of atherosclerotic disease.  Activation of 
endothelial cells is another important factor in the pathological pathway of 
atherosclerosis (153, 154). Activated endothelial cells express adhesion molecules such 
as vascular cell adhesion molecule-1 (VCAM-1) and monocyte chemo attractant protein-
1. Expression of these molecules promotes the platelet aggregation process and 
subsequent thrombus formation (155, 156). 
1.9.1 Lipids and vascular function  
An increasing number of studies have demonstrated the correlation between 
dyslipidaemia and vascular dysfunction (157). Therapeutic lowering of serum 
cholesterol, LDL and oxidised LDL has been shown to result in an improvement in 
endothelium dependent vasodilation in the forearm of patients with 
hypercholesterolaemia (157). Clinical trials such as The West of Scotland Coronary 
Prevention Study (WOSCOPS) (109) and The
 Scandinavian Simvastatin Survival Study 
(4S) (110) have also shown that the treatment of serum lipids can improve clinical 
outcomes. Others have demonstrated the improvement of endothelial dysfunction in 
atherosclerotic arteries in 6 to 12 months among treatment groups (158, 159). These 
findings have important clinical implication in the treatment of high risk patients. 
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Native LDL has little effect on essential function of cells within the arterial wall. When 
LDL is metabolized by the endothelial cells, however, the normal component 
antioxidants (e.g. α-tocopherols and β-carotene) are exhausted, the polyunsaturated 
phospholipids are converted into reactive hydroxyfatty acids, lysophosphatidycholine is 
formed, and the proteins in the apolipoprotein-B 100 moiety undergo modification and 
fragmentation so that the ligand can no longer bind to the classic LDL receptor. 
Eventually, this “oxidised” LDL molecule becomes more negatively charged, and binds 
to alternative sites e.g. the scavenger receptor, and becomes capable of a wide variety of 
toxic effects, leading to cell dysfunction and hence vessel wall dysfunction (160). 
Consistently in animal models these characteristic cell dysfunctions have been shown to 
be associated with the development of atherosclerosis in large arteries (112).   
Oxidised LDL can rapidly impair endothelium-dependent dilation. This probably occurs 
through a number of mechanisms, including direct inactivation of NO by excess 
production of oxygen-derived free radicals, reduced transcription of nitric oxide synthase 
mRNA, and post-transcriptual destabilisation of mRNA (161). The decrease in 
availability of NO is accompanied by many other important vascular cell dysfunctions. 
There is an increased platelet adhesion, stimulation of plasminogen activator inhibitor, 
inhibition of plasminogen activator, induction of procoagulant tissue factor mRNA, 
inhibition of mRNA transcription of thrombomodulin caused by degradation by 
lysosomes, and finally stereochemical alterations in heparin sulphate proteoglycans 
(160). These changes impair the anti-platelet and anticoagulant properties of the 
endothelium and initiate thrombus formation (162). Upregulation of adhesion molecules, 
activation of protein kinase C, and diminished available NO are all likely to play a role in 
This watermark does not appear in the registered version - http://www.clicktoconvert.com64 
proinflammatory changes that lead to accumulation of monocyte, macrophages and T-
lymphocytes.  
Evidence supports the fact that increased levels of oxidised LDL or greater susceptibility 
of LDL to oxidation is related to the severity of coronary atherosclerosis (163). Clinical 
investigations have shown that increases in serum cholesterol and/or LDL or decreases in 
HDL are associated with loss of endothelium-dependent dilation to acetylcholine in 
forearm vessels (164).  Furthermore, recent evidence reveals small, dense LDL particles 
are more susceptible to oxidation and are particularly efficient at inducing endothelial 
dysfunction (157). Inhibition of oxygen free radicals can lead to significant improvement 
in endothelium-dependent vasodilation (157). The diminished levels of NO contribute to 
inflammation within the atherosclerotic plaques due to the increased adherence and 
migration of monocytes, formation of lipid-laden macrophages, and increased expression 
of plasminogen activator inhibitor and tissue factor, especially in the areas surrounding a 
lipid core. These factors add to the fragility of the plaque, increasing risk of rupture and 
release of thrombogenic core initiating intravascular thrombus formation (165). 
HDL has been demonstrated to protect against abnormal responses to ACh (166) and, in 
isolated strips of rabbit aorta, HDL reversed LDL induced endothelial dysfunction (167). 
Serum triglyceride has been demonstrated to have a significant and independent 
relationship with the incidence of major coronary events as shown by the eight year 
follow up data from the PROCAM study (168). In a large meta-analysis of eight 
population-based prospective studies, a 1 mmol/l increase in serum triglyceride 
concentration was equivalent to a 14% and 37% increase in relative risk of coronary heart 
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disease in men and women respectively (169). The mechanism by which triglycerides 
exert their influence on the development of atherogenesis may be variable, including 
effects on endothelial cell function, macrophage loading, thrombogenesis and 
determination of LDL size, i.e. defining the smaller denser atherogenic particle size 
(170). 
 
1.9.2 Inflammation and vascular function 
Some of the most commonly measured inflammatory markers, such as C-reactive protein, 
fibrinogen and serum amyloid A, originate in the liver, and their production is stimulated 
by systemic cytokines such as IL-1, IL-6 and TNF-α. Cytokines are produced at several 
extra hepatic sites, such as the heart, vessel walls, macrophages, and adipose tissue. Other 
types of inflammatory markers are produced at these sites. The heart secretes troponin T 
and I and creatinine kinase MB in response to injury. The atherosclerotic vessel wall 
produces soluble adhesion molecules, such as ICAM-1 and VCAM-1. Macrophages 
secrete phospholipases in response to inflammation. 
Atherosclerosis is now considered an inflammatory disease (171). For the last 20 years 
evidence has been accumulating that serum levels of inflammatory markers can be used 
to predict cardiovascular events (131). Packard et al in the West of Scotland Coronary 
prevention Study evaluated whether the levels of certain markers are predictive of the 
risk of coronary events among men with hypercholesterolaemia (172). Levels of C- 
reactive protein and fibrinogen were both predictive of the risk of coronary events; 
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however, the strength of association was significantly reduced when other, traditional 
cardiovascular risk factors were considered (172).  
Interleukin-6 levels even after adjustment for C-reactive protein levels have been shown 
to be predictive for risk of myocardial infarction (132). A recent report from the Rural 
Health Study has shown that elevated concentrations of IL-6 predict total and 
cardiovascular mortality over a 5 year period, the association being independent of 
prevalent vascular disease, smoking and traditional risk factors, and stronger than, but 
additive to, that for CRP (173). 
As previously stated, adipose tissue is a source of cytokines such as IL-6, IL-1 and TNF-
α. Studies consistently show a strong correlation between inflammatory marker levels 
and the levels of body fat, markers of insulin resistance and other indicators of the 
dysmetabolic state including central obesity, hypertension and insulin resistance (Figure 
1-7) (165, 174). 
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Figure 1-7. The roles and regulation of IL-6. (From (165)) 
 
The proposed link between inflammation and increased risk of coronary disease is 
endothelial dysfunction. As mentioned previously the cell wall itself produces cell 
adhesion molecules, ICAM-1 and VCAM-1. These cell surface molecules are expressed 
and up-regulated in response to stimulation by cytokines. Their soluble component can 
actually be quantified in the blood. Their purpose is recruitment of circulating 
inflammatory cells and the eventual transmigration of the inflammatory cell through the 
endothelium, an action thought to be the initiating step in the development of 
atheromatous deposits. It has been demonstrated that ICAM-1 levels are an independent 
predictor of adverse cardiovascular events (175).  
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1.9.3 Pregnancy and vascular function 
Maternal vascular resistance and blood pressure are normally reduced significantly 
during pregnancy, reaching a nadir by around 20 weeks’ gestation. Both factors then rise 
again towards term (176, 177). Blood pressure falls during pregnancy despite a 50% rise 
in blood volume and 40% rise in cardiac output. This is almost certainly due to reduced 
peripheral vascular resistance. Maternal circulation has been shown to be relatively 
unresponsive to angiotensin-II, a vasoconstrictor (178). This impaired response is further 
confirmed by the improvement of responsiveness to angiotensin-II after the 
administration of prostaglandin synthetase inhibitors such as indomethacin and aspirin 
(179). This finding implies that pregnancy is associated with a down-regulation in 
response to a number of vasoconstrictors. Pregnancy has also been demonstrated to be 
associated with an increased synthesis of endothelium-derived vasodilators. Prostacyclin 
(PGI2) has been proposed to result in increased peripheral vasodilation and reduced 
constrictor response (180). PGI2 synthesis during pregnancy is most certainly increased; 
however this increased production appears to be confined to particular vascular beds, 
particularly the uterine circulation (181). Interestingly patients who develop pregnancy 
induced hypertension exhibit a lesser rise in prostacyclin biosynthesis when compared 
with healthy controls (182). 
There is considerable evidence that nitric oxide (NO) synthesis is increased in animal 
pregnancies. NO may be released in response to receptor-mediated stimuli such as ACh 
or to physical forces such as shear stress on the vessel wall. Pregnant guinea pigs 
demonstrate increased calcium dependant nitric oxide synthase (NOS) activity in a 
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variety of tissues, and isolated carotid and uterine arteries from these animals showed 
enhanced relaxation to the endothelium dependant vasodilator, acetylcholine (183). 
Another possible mechanism for up-regulation of NO production in pregnancy is its 
increased synthesis by oestrogen (184). Weiner et al demonstrated NOS activity to be 
reduced by tamoxifen, and oestrogen receptor antagonist, while treatment with oestradiol 
increased NOS activity (184). Few studies on this subject involve human subjects 
however one study has demonstrated an increased in excretion of cGMP, the second 
messenger responsible for mediating NO-induced vasodilation, among pregnant healthy 
women (185). Furthermore increased nitrate turnover has been demonstrated among 
healthy pregnant women on a tightly controlled nitrate intake (186). This data adds to the 
suggestion that there is an increase in NO synthesis during healthy pregnancy.  
McCarthy et al dissected arteries from biopsy specimens of subcutaneous fat obtained 
from pregnant women during caesarean section and from non pregnant women 
undergoing gynaecological surgery (187). This study failed to demonstrate any 
difference in acetylcholine-mediated relaxation in arteries from pregnant women as 
compared with non-pregnant (187). However previous work had suggested that increased 
receptor-mediated, endothelium-dependent vasodilatation may play a role in reducing 
pressor sensitivity and increasing vasodilatation in animal pregnancy (188). Enhanced 
relaxation has been demonstrated in response to bradykinin and shear stress, but not to 
acetylcholine among pregnant rats (189). Knock et al investigated bradykinin-mediated 
vasodilator function in small arteries from normotensive pregnant and non-pregnant 
women (190). Arteries from normotensive pregnant women demonstrated enhanced 
relaxation to bradykinin compared with those from non-pregnant women (p < 0.05). This 
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study provides evidence for an increase in bradykinin-mediated nitric oxide synthesis 
from the vascular endothelium of small arteries from the peripheral circulation of 
normotensive pregnant women which may account for increased vasodilation during 
pregnancy.  
Underlying all of this conflicting evidence one must accept that endothelium dependant 
vasodilators are likely to pay a central role in the maternal cardiovascular response. Some 
consideration should however be given possible structural alteration of the non-
contractile protein matrix of the artery (191). Alterations in structure may add further to 
improvements in arterial wall distensibility (192). 
Additional insight into the importance of the endothelial response has also been gained 
from animal experiments in which shear stress has been acutely or chronically altered. 
Increasing shear stress in the rat by surgical construction of an aortocaval shunt results in 
increased cyclic guanosine 3‘5‘-monophosphate (presumably as a result of increased 
nitric oxide release), (193) and elevated shear increased endothelial nitric oxide synthase 
(eNOS) messenger RNA (mRNA), protein, and activity in high-shear stressed aortas 
compared with sham-operated controls (194). These increases were followed by vessel 
structural expansion (193). This structural increase in vascular lumen to normalize shear 
was prevented in the rat model by inhibition of nitric oxide synthase (NOS) with N-
[omega]-nitro-l-arginine-methyl ester (195)The central role of eNOS in shear-mediated 
structural remodeling was confirmed by Rudic et al (196) when, in wild-type mice, the 
common carotid artery responded to surgically induced decrease in flow by reducing 
caliber to normalize shear stress to its preoperative level, whereas it failed to do so in 
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mutant mice that lacked the gene for eNOS (196)In a baboon polytetrafluoroethylene 
graft fistula model, elevated shear stress was associated with increased expression of 
eNOS, a lower degree of neointimal and smooth muscle proliferation, and even induced 
regression of previously established neointima (197). In contrast with their high-shear 
counterparts, low-shear grafts exhibited greater smooth muscle cell proliferation and 
higher levels of platelet-derived growth factor–A protein and mRNA (198) The 
connection between high shear stress and low intimal proliferation has been further 
clarified in rodent experiments showing that focal increases in shear stress in the aorta 
resulted in corresponding decreases in angiotensin-converting enzyme activity (199) 
Shear stress has also been associated with the endothelial proliferative state in animal 
studies. Endothelial cell proliferation increased 18-fold within 48 hours of reduction in 
shear stress (200) Decreasing shear stress was followed by endothelial cell loss and 
desquamation, altered morphology with decreased elongation, decrease in actin stress 
fibers, greater monocyte attachment to and migration across the endothelial layer, (201) 
and increased endothelial surface expression of vascular cell adhesion molecule 1 (202). 
The increased endothelial cell loss in response to decreased shear has recently been 
suggested to be the result of apoptosis, which remains unabated until the shear 
normalization has been restored (203). These in vivo experiments obtained in various 
species using different methods to alter hemodynamics help establish a framework to 
understand the propensity for intimal hyperplasia and atherosclerosis initiation in areas of 
low shear stress and the protective effect of elevated shear stress in sheltered regions of 
the vasculature. 
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1.10 Insulin resistance 
Insulin resistance is an impairment of insulin signalling, arising from post-receptor 
defects in propagation of the message evoked by the binding of insulin to the receptor 
(204). The term insulin resistance refers to the inability of circulating insulin to maintain 
normal homeostasis of glucose. Higher levels of insulin are circulated in order to 
maintain normoglycaemia, resulting in a hyperinsulinaemia. Insulin is an important 
metabolic hormone synthesized by pancreatic β cells, which stimulates glucose uptake in 
various organs, particularly muscle, adipose tissue, and the liver, and inhibits lipolysis in 
adipose tissue. The initiating step in the insulin-signalling cascade is the binding of 
insulin to the insulin receptor on the plasma membrane of insulin-sensitive tissues. 
Insulin evokes a broad array of metabolic responses and, accordingly, insulin resistance 
can be defined in a myriad of ways. The most logical starting point when defining insulin 
resistance is in relation to altered patterns of glucose metabolism. However disorders of 
lipid and fatty acid metabolism, altered patterns of protein and amino acid metabolism, 
blunted haemodynamic responses, changes in electrolyte homeostasis, and alterations of 
growth at a cellular level are all interlinked in the complex influences of insulin. The 
insulin resistance syndrome describes a collection of abnormalities of metabolism with 
insulin resistance as the primary abnormality giving rise to dyslipidaemia, essential 
hypertension, impaired glucose intolerance and type 2 diabetes.  
Himsworth et al were among the first to recognise insulin resistance by observing the 
ability of insulin to blunt the rise in plasma glucose following glucose infusion (205). The 
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group noticed very varied responses to insulin. Among lean, young adult patients with 
diabetes, insulin substantially blunted the rise in glucose following glucose 
administration; yet in obese, older patients, insulin injections had only a marginal impact. 
In retrospect, it is clear that Himsworth made a fundamental observation as to the 
differences between type 1 diabetes, a disease of insulin deficiency, and type 2 diabetes, a 
disease characterised by insulin resistance. 
In type 2 diabetes, insulin resistance and resultant hyperinsulinaemia is proposed as a 
mechanism by which cardiovascular complications such as hypertension arise (206). 
Essential hypertension is prevalent among older individuals, and approximately 50% of 
persons with hypertension can be considered to have insulin resistance and 
hyperinsulinaemia (207). It appears likely that insulin resistance and hyperinsulinaemia 
predispose to, rather than result from, hypertension. Insulin resistance is associated with 
abnormalities in lipoprotein metabolism, hypercoagulability, and endothelial function, 
which probably account in part for the increased cardiovascular risk among hypertensive 
patients. Others suggest the mechanism by which insulin resistance exerts its 
cardiovascular risk is due to increased blood glucose concentrations. The increased 
glycation of the glucose results in products which quench NO and therefore impair 
vascular function (208). This theory is however disputed by animal studies which report 
impaired vascular function only at supra-physiological glucose levels (209). Human 
studies have revealed not only no correlation between HbA1c values and vascular 
function (210), but also no vascular function impairment at moderate levels of 
hyperglycaemia (211).  
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The direct mechanism linking insulin resistance and increased cardiovascular risk 
remains uncertain. Serne et al demonstrated an inverse relationship between blood 
pressure and insulin sensitivity as well as a strong positive relationship between 
microvascular dysfunction and insulin insensitivity (212). They propose that adipose 
tissue is the primary link between all of these factors. 
Adipose tissue contributes non-esterified fatty acids (NEFAs), which impair insulin 
action in both the liver and skeletal muscle (213). Added to this the inhibitory effects of 
NEFAs on nitric oxide synthase may contribute to the impaired vascular function 
observed in obese patients (214). The accumulation of fat in the abdominal region is 
thought to be a critical determinant of whole-body insulin resistance (215). It is widely 
accepted that the accumulation of fatty acids in insulin-sensitive non-adipose tissues, 
such as muscle and liver, can impair insulin-mediated glucose uptake in these tissues. 
Besides acting as a source of fatty acids, fat cells produce hormones that modulate insulin 
action. There is evidence suggesting that TNF-α and resistin may impair insulin action in 
vitro, although whether these or other cytokines are more relevant to humans is not 
known (216). 
 Adiponectin is a large, abundant plasma protein (present in concentrations of 5–30 nmol 
in humans) that circulates in higher concentrations in females than in males (217). Plasma 
adiponectin concentrations are directly associated with insulin sensitivity and inversely 
with visceral or intra-abdominal, obesity. Adiponectin plasma levels are lower in patients 
with type 2 diabetes and atherothrombotic cardiovascular disease than in healthy controls 
(217-219). Despite the fact that adiponectin is secreted from adipose tissue, circulating 
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adiponectin levels are lower in obese individuals than in lean individuals, due to its 
strong association with insulin sensitivity (217, 218). Consistent with this finding, 
adiponectin levels have been shown to increase with weight loss. Adiponectin appears to 
improve insulin sensitivity by increasing fat oxidation and lowering lipid levels in muscle 
and liver. 
Resistin is another adipocyte-derived hormone, the circulating levels of which are 
increased in genetic and diet-induced obesity in mice (216). This study found that 
treatment with recombinant resistin impaired insulin action in wild-type mice and that 
neutralizing anti-resistin antibodies improved insulin sensitivity and blood glucose levels 
in diabetic obese mice (216). Although it has been proposed that resistin may be the link 
between obesity and diabetes (216), its role in human insulin resistance remains 
controversial. 
 
1.10.1  Pregnancy and insulin resistance 
Alterations in maternal metabolism during pregnancy are required for supply of adequate 
nutrition for the fetus. Thus, in normal pregnancy, insulin resistance develops and assists 
in the provision of energy substrate for the baby. This insulin resistance leads to higher 
levels of glucose and free fatty-acids, constrained by increased secretion of maternal 
insulin. Pregnancy is associated with decreased phosphorylation of insulin-receptor-
substrate-1 (220, 221). Insulin action changes over the course of pregnancy. At 12–14 
weeks' gestation, insulin sensitivity is slightly increased but then declines for the rest of 
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the pregnancy, with insulin resistance being highest late in the third trimester (222). 
Insulin sensitivity improves with delivery of the placenta. Thus gestational diabetes, 
when the level of insulin resistence is too high to accommodate glucose metabolism 
within normal limits, typically appears late in the second trimester and resolves 
immediately postpartum. The time course for changes in insulin action suggests a 
hormonal cause for insulin resistance. In the past, human placental lactogen, human 
placental growth hormone, progesterone, cortisol, and prolactin were the prime suspects. 
Certainly, all rise in late pregnancy, causing insulin resistance, and return to pre-
pregnancy values promptly postpartum. 
1.10.2  Pregnancy and Free Fatty Acids 
Stewart et al described fatty acid composition throughout pregnancy and in the post 
partum (223). Fatty acids are an important component of cell membrane and therefore are 
essential to tissue development (reviewed in (224)). The fetus is reliant on placental 
transfer of fatty acids from the mother to support growth (225, 226). The essential fatty 
acids 18:2n-6 (linoleic acid) and 18:3n-3 (alpha linoleic acid) undergo elongation and 
desaturation to form long chain polyunsaturated fatty acids (LCPUFA), which are 
commonly found in membranes, particularly in the brain. In order for the fetus to accrue 
the LCPUFA’s for tissue formation the mother must mobilse and make available key 
fatty acids. Maternal LCPUFA status is critical in determining essential fatty acid status 
in their newborn (225, 227, 228).  
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Palmitoleic acid 16:1n7 to be increased with advancing gestation and reduced in the post 
partum (223). However interestingly we noted the change in 16:1n7 with advancing 
gestation to be negatively correlated to maternal booking body mass index (BMI) and 
waist circumference. 16:1n7 is synthesised from 16:0 by stearyl CoA desaturase (SCD) 
(229). The activity of SCD is down regulated by leptin (230). Leptin, a polypeptide 
hormone produced by adipose and other endocrine tissues activity has a clear and well 
established association with obesity (231, 232). As obesity is associated with increased 
levels of leptin one would assume our data to be in conflict with the literature, however a 
degree of leptin resistance in pregnancy has been suggested, possibly mediated from the 
soluble isoform of the leptin receptor from the placenta, resulting in an increase in the 
amount of bound and therefore unavailable leptin within the maternal circulation with 
advancing gestation. this potential for leptin resistence in pregnancy may account for the 
unexpected inverse relationhip between 16:1n7 and obesity in pregnancy.  
 
Ramsay et al have examined metabolism in the third trimester of pregnancy among both 
lean and obese mothers (139). Obesity in pregnancy has implications for morbidity and 
mortality in both mother and baby. The incidence maternal complications, such as 
pregnancy-induced hypertension or preeclampsia, are significantly greater if the mother 
is overweight, defined by BMI in early pregnancy, or centrally obese, as assessed by 
waist circumference (41, 233). Maternal obesity also increases the risk of metabolic 
complications, such as gestational diabetes. Furthermore, some data suggest that 
adiposity in the mother may critically influence the programming of metabolic pathways 
of her fetus and its risk for diabetes and cardiovascular disease in later life (78). Our 
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group reported a dyslipidemic pattern consistent with the metabolic syndrome among 
obese mothers in the third trimester of pregnancy (139). We therefore wanted to test 
whether there was a difference in third trimester maternal erythrocyte fatty acid 
composition. 
 
 
 
 
 
 
 
 
 
1.11 Hypothesis and aims 
HYPOTHESIS            
1) Microvascular endothelial dependent vasodilatation will increase in pregnancy with 
advancing gestation, but to a lesser degree in women with pre-pregnancy obesity as 
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defined by an increased BMI. A difference in vascular function between lean and obese 
women will exist in early pregnancy but this will become less dramatic with advancing 
gestation suggesting a beneficial effect of pregnancy to vascular function.  
2) The levels of circulating lipids and inflammatory cytokines will increase throughout 
pregnancy and negatively correlate with vascular function. This will provide some insight 
into potential mechanisms underlying vascular dysfunction.  
3) Fatty acid concentrations, particularly long chain polyunsaturated fatty acids (PUFA) 
would decrease throughout pregnancy in favour of shorter more saturated fatty acids and 
again this would happen earlier and more dramatically in obese women.  
 
AIMS 
 
My aim was to use this unique opportunity of extreme metabolic and vascular stress (i.e. 
pregnancy) to study potential pathophysiological processes associated with vascular 
disease in obese women. Obesity has significant correlations with hyperinsulinaemia, 
hypertriglyceridaemia, decreased high density lipoprotein and elevated blood pressure.  
Advances in laser Doppler imaging technology in the non-invasive assessment of 
microvascular function allow us to objectively quantify vascular function within these 
women. Previous work has examined these factors in the third trimester but as yet no 
group has identified if there is a pregnancy specific effect in obese patients. Therefore 
longitudinal data is required. Therefore we aim to perform a longitudinal study 
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throughout pregnancy and the postnatal period in lean and obese women as defined by 
BMI. The following will be measured: 
·  Microvascular function using laser Doppler perfusion imaging. 
·  Fasting cholesterol, triglyceride, VLDL, LDL, sub fractions and Erythrocyte 
membrane fatty acid status 
·  Inflammatory markers including IL-6, CRP, IL-1, TNF-α as well as ICAM-1, 
VCAM-1, PAI-1 and PAI-2. 
·  Adipocyte derived proteins such as leptin and adiponectin. 
 
 
 
 
 
 
 
 
Chapter Two 
 
Materials and Methods 
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2  Materials and Methods 
2.1 Subjects 
Women (n=60) were recruited from the antenatal clinic at booking visit in the first 
trimester of pregnancy. Women were selected on the basis of a negative medical or 
complicated obstetric history. Thirty women with a maternal booking BMI of less than 30 
kg/m² were randomly recruited from the clinic at booking. While a further thirty women 
with a maternal booking BMI of greater than or equal to 30 kg/m², were randomly 
recruited to the study. The women who declined from taking part were those women who 
could not commit to extra hospital visits to take part.  All women booked for antenatal 
care at The Princess Royal Maternity Hospital, Glasgow. In order to be eligible for 
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inclusion in the study none of the women had a positive medical history including cardiac 
and metabolic disease. If any of the women developed pre eclampsia or any other 
complication of pregnancy she was excluded from the study. None of the women 
recruited developed such complications. Ethical approval for this study was granted by 
the Glasgow Royal Infirmary Research Ethics Committee.  All subjects gave informed 
consent to participate.  
 
2.2 Experimental design 
The women were asked to attend for their first “study visit” during the first trimester. All 
women attended for participation after an overnight fast (>10 hours) and underwent 
testing between 0900 and 1100 hours. Patient characteristics were recorded at this visit 
from patient notes. Fasting bloods were collected. Patient height, weight, waist 
circumference and hip circumference were measured. Waist circumference was measured 
at the level of the umbilicus. Hip circumference was measured at the widest point over 
the buttocks. Waist and hip circumference were measured in duplicate to the nearest 0.5 
cm. If the difference between the two measurements was greater than 2 cm, a third 
measurement was taken and the mean of the two closest measurements was calculated. 
WHR was defined as waist circumference divided by hip circumference. All 
measurements were taken by the same examiner. Body mass index (BMI) was calculated 
as booking weight (kg), divided by height (m) squared.  Deprivation (DEPCAT score), a 
measure of socio-economic status (234), was assigned using the Scottish Area 
Deprivation Index for Scottish postcode sectors, 1998. At this visit further arrangements 
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were made for the patient to attend in the second trimester and then again in the third 
trimester. At time of delivery all patients were seen by the lead examiner and 
arrangements made for a postnatal visit at three months. Details of gestation of delivery, 
mode of delivery, fetal sex, birth weight and placental weight were recorded from the 
patients’ notes. Birth weights of offspring were normalised by gestation at birth, fetal sex 
and maternal parity (235) with a greater centile indicating a larger normalised birth 
weight.  At each time point maternal venous blood was collected in EDTA, citrate, 
serum, lithium heparin and fluoride oxlate tubes and .sampled into 1mg/ml EDTA and 
packed blood cell collected by low speed centrifugation 
2.3 Iontophoresis 
Experiments were performed with subjects supine in a quiet room with an ambient 
temperature of 22±1°C. (See figure 2-1). I performed all of the Iontophoresis scanning. 
No history of peripheral vascular abnormalities such as Raynauds syndrome, 
dermatological diseases or systemic disease processes such as diabetes mellitus.   
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Figure 2-1. Experimental set up of the Laser Doppler imager. 
 
This technique is based on the principle that a charged molecule
 migrates across the skin 
under the influence of an applied electrical
 field. (Current x time = charge, in Coulombs). 
Iontophoresis
 of acetylcholine (ACh) examines endothelial function. Because
 binding to 
muscarinic receptors, with subsequent generation
 of nitric oxide (NO), requires intact 
endothelial cells responses to ACh are therefore said to be endothelium-dependent. 
Vasodilatation
 is ultimately mediated by action of NO on vascular smooth muscle
 (via the 
cyclic GMP pathway); and so, iontophoresis of sodium
 nitroprusside (SNP), an NO 
donor, is used as an endothelium-independent
 control. 
Scanner 
Laptop 
Laptop 
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Figure 2-2. Laser Doppler imager methodology. The scanner as shown emits a 
laser beam onto the volar aspect of the forearm. The greater the degree of vasodilation imparted 
by the applied agent the greater the velocity of the red blood cells flowing through the 
microvasculature. The higher the velocity of the red blood cells the greater the degree of 
displacement of the laser beam.  
 
 Drug delivery was achieved using a battery-powered
 constant current iontophoresis 
controller (Moor Instruments
 Ltd, MIC-1e). The chambers used for iontophoresis (Moor 
Instruments
 Ltd, ION 6) were constructed of Perspex (internal diameter, 22
 mm; area 3.8 
cm
2) with an internal platinum wire electrode.
 Two chambers were attached to the skin of 
the volar aspect of
 the forearm, avoiding hair, broken skin, and superficial veins (see 
figure 2-3). 
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Figure 2-3. Iontophoresis methodology. Chambers containing Acetylcholine and 
sodium nitroprusside are placed on the forearm in contact with the skin. The chambers are 
connected to a positive and negative charge which “push” the positively charged acetylcholine 
and negatively charged sodium nitroprusside into the microvascular space. 
 
The protocol involved incremental current delivery, with a baseline
 scan followed by four 
scans at 5 µA, four at 10 µA, four at
 15 µA, and two at 20 µA giving a total charge
 of 8 
milliCoulombs, followed by five recovery scans.
 Two and a half millilitres of 1% ACh 
(Sigma, Poole, UK) was
 introduced into the anodal chamber while 2.5 ml of 1% SNP 
(Sigma)
 was placed in the cathodal chamber. The vehicle for these drugs
 was 0.5% NaCl 
in deionized water. Responses were also observed
 with the vehicle alone as a control 
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experiment. Based on the
 raw perfusion-time integrals, the mean (± SD) between-day
 CV 
for the ACh response, measured in four subjects on 2 separate
 days, was 6.4 ± 3.3%; 
whereas the within-day, between-site
 CV, measured in both forearms on the same 
morning in four subjects,
 was 8.9 ± 5.3% (139). (see figure 2-3). 
 
Figure 2-4. Vascular responses among lean and obese.The distortion of the laser 
beam imparted by the moving red blood cells through the microvasulature is detected by 
photosensors within the scanner and interpreted by the software contained within the laptop, 
producing a series of scans. The software interprets these scans to give a value of microvascular 
function represented as area under the curve. 
 
 
Perfusion measurements being performed after an overnight fast ensured no caffeine-
containing drinks had been
 consumed before testing. Also, no over-the-counter 
medications
 were taken by any of the participants for at least 48 h before
 testing. Before 
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testing, a 10-min period of acclimatization
 was enforced, in a temperature-controlled 
room. The women were asked to lie in a semi recumbent position, with the flexor aspect 
of the forearm
 exposed on an armrest. Non-invasive measurement of skin perfusion
 was 
performed by means of a laser Doppler imaging (LDI) scanner
 (Moor Instruments Ltd, 
Axminster, UK) equipped with a red laser
 (wavelength, 633 nm; power, 1mW; beam 
diameter, 1 mm). The laser is scanned over the area to be examined,
 and backscattered 
light is collected by photodetectors and converted
 into a signal proportional to perfusion, 
in arbitrary perfusion
 units (PU). Twenty repetitive scans with an incremental 
iontophoretic
 current protocol were taken the first being a control (pre current 
administration) followed by incremental current protocol described above, of 14 scans, 
followed by a further 5 scans with no current administration. Measurement of response to 
drugs was obtained by taking raw values but an assessment
 of the overall response was 
defined as the area under the perfusion .time
 curve (AUC). As previously described by 
our group (236), correction for individual
 variation in skin resistance was performed, by 
dividing by the integral of conductance (the reciprocal of resistance) over time or more 
simply by multiplying the individual perfusion values by the integral of resistance over 
time, thereby normalising responses. 
  
2.4 Lipid analysis 
Plasma total cholesterol, triglyceride and HDL-cholesterol were determined by the 
standard Lipid Research Clinics Protocol (237). Very low density lipoprotein1
 (VLDL1) 
(Sf 60–400), very low density lipoprotein2 (VLDL2)
 (Sf 20–60), intermediate density 
lipoprotein (IDL) (Sf
 12–20), and LDL (Sf 0–12) were prepared from plasma
 by a 
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modification of the cumulative gradient ultracentrifugation
 technique described by 
Lindgren (238). The cholesteryl ester,
 triglyceride, free cholesterol, phospholipid, and 
proteins of
 the lipoprotein were assayed as described (239) and concentrations
 were 
calculated as the sum of the components (expressed as mg/dL
 plasma). Isolation of LDL 
subfractions from fasting plasma was achieved
 by density gradient ultracentrifugation 
using a discontinuous salt
 gradient (240). The LDL subfractions were displaced from the
 
tube by upward displacement and identified by continuous monitoring
 of eluate at 280 
nm. In all subjects, as in the normal population,
 three peaks of LDL were present, LDL-I, 
LDL-II, and LDL-III.
 The individual subfraction areas beneath the LDL profiles were
 
quantified using Beckman Data Graphics software (Data Graphics;
 Beckman Industries, 
Fullerton, CA). Integrated areas were subsequently
 adjusted by specific extinction 
coefficients calculated previously
 for LDL-I, -II, and -III to give percentage abundance 
(% LDL).
 The total LDL mass (all protein and lipid components) of sequentially
 prepared 
LDL (d = 1.019–1.063 g/mL) was subdivided in
 proportion to the percentage abundance 
values to give plasma
 concentration of the LDL subfractions. A proportion of the 
subfractions were carried out by me, ensurng laboratory experience. 80% of the 
subfractions were carried out by laboratory staff within the pathological Biochemistry 
laboratory. 
 
2.5 Erythrocyte membrane fatty acid extraction 
Preparation of a total fatty acid extract from erythrocyte membranes was performed by a 
modified Folch extraction (16;17).  Packed red blood cells (400mL) were suspended in 
This watermark does not appear in the registered version - http://www.clicktoconvert.com90 
10mM Tris buffer pH 7.0, and incubated at room temperature for 30 minutes. 
Suspensions were centrifuged in a Beckman L8-60M Ultracentrifuge, Type 50.4 rotor, at 
49,000rpm, at 4 °C for 30 minutes.  The erythrocyte pellet was re-suspended in 200mL of 
distilled H2O and 150mL was transferred to a clean glass screw top tube.  Methanol: 
toluene (4:1, 2mL) containing heneicosanoic acid internal standard (0.2mg C21H42O2/ml 
toluene), was added followed by 200mL of 100% acetyl chloride while mixing.  Tubes 
were capped and sealed with Teflon tape before heating at 100 °C for one hour.  After 
cooling, 10% K2CO3 (3mL) was slowly added to each tube followed by 100mL toluene.  
After centrifugation at 3000rpm for 8 minutes at 5 °C, the upper toluene phase was 
transferred to gas chromatography (GC) vials, and stored at -20 °C until ready for 
injection. This work was carried out by my research collegue Barbara Meyer School of 
Health Sciences, University of Wollongong. Northfields Ave Wollongong Australia. 
2.5.1 Gas chromatography of fatty acids 
Methyl fatty acids (FAs) were separated (1uL injection volume), identified and 
quantitated on a Shimadzu GC 17A gas chromatograph with flame ionisation detection 
and Class VP software.  A 30m x 0.25mm-mm DB-23 fused silica capillary column 
(J&W Scientific, Folson, CA) with a film thickness of 0.25 mm was used in conjunction 
with a Hewlett-Packard 7673B on-column auto-injector.  Ultra-high purity hydrogen and 
air were used as carrier gases at a flow rate of 2mL/min.  A temperature gradient 
programme was used with an initial temperature of 150°C, increasing at 20°C/min until 
190°C, then at 5°C/min until 210°C, then at 2°C/min until 230°C and then at 4°C/min 
until 240°C (final time 18.5 min) and with an equilibration time of 1 minute.  The total 
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programme time was 22 minutes.  Identification of fatty acid methyl esters was made by 
comparison with the retention times of authentic standard mixtures (Fatty acid methyl 
ester mixture #189-19, product no. L9405, Sigma, Sweden).  This work was carried out 
by my research collegue Barbara Meyer School of Health Sciences, University of 
Wollongong. Northfields Ave Wollongong Australia. 
 
2.6 Analysis of inflammatory markers 
Plasma sensitive CRP was quantified using a double antibody sandwich ELISA with 
rabbit anti-human CRP and peroxidase conjugated rabbit anti-human CRP: DAKO A/S, 
DK-2600 Glostrup, Denmark. Plasma IL-6, IL-10 and TNF-α were measured in citrated 
plasma stored at -80°C using high-sensitivity commercial ELISA kits (R&D Systems). 
Intra-cellular adhesion molecule-1 (ICAM-1) and vascular adhesion molecule-1 (VCAM-
1) were measured in citrated plasma stored at -80°C using high-sensitivity commercial 
ELISA kits (R&D Systems). PAI-1 and PAI-2 were assayed in citrated plasma using 
commercial ELISA according to manufacturers' instructions (TintElize PAI-1 supplied by 
Alpha Laboratories and Imubind PAI-2 [American Diagnostica] - supplied by Axis 
Shield). I carried out some of this work to ensure familiarity with the laboratory 
techniques. Laboratory staff carried out the majority of the testing. 
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2.7 Statistical analysis 
Values for biochemical variables are given as mean ± standard deviation unless otherwise 
stated.  Normality testing was carried out using the Ryan-Joiner test in Minitab (vs13.0).  
2.7.1 Lipoprotein analysis 
Triglyceride and VLDL¹ levels were log transformed to achieve normality. A general 
linear model was used based on the following formula:  
OUTCOME =   α    +   βt * BMI   + Vt   
Where, α is a constant, βt is the slope, which can be different for different time points and 
t= 1, 2, 3. BMI is the maternal body mass index, and Vt is the effect of visit t. When 
appropriate and β was constant for all visits, model estimates were pooled and a single 
slope was used. Associations between BMI and triglyceride levels were made by 
calculating the Pearson correlation coefficient (r) and associated p- values. T tests were 
used for comparison of all parameters. The SPSS (version 11.5) statistical package was 
used.I carried out the Statistical analysis with the help of my supervisers. 
2.7.2 Endothelial function and inflammatory markers 
Data were analysed as log10 or square root transformed data as the raw values were not 
normally distributed. Dose response curves were expressed as mean ± SEM and
 were 
compared using two-way ANOVA. Post hoc analysis using Bonferroni correction was 
utilised. Analysis was also performed using the area under the perfusion time curve 
(AUC). Two sample t tests were used to assess any significant differences between the 
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lean and obese groups. Differences in endothelial function and inflammatory markers 
over time were tested using a repeated measures analysis in the general linear model 
(Minitab Vs 13.32). For multivariate analysis, the general linear model was used to 
examine the independent effects of time of sampling, obesity and plasma markers of 
inflammation and endothelial function on microvascular function, PAI-1/PAI-2 ratio, 
PAI-1 and PAI-2. Percent contribution to the variation (adjusted means squared, divided 
by the total means squared, expressed as a percentage) is quoted along with the level of 
significance. 
2.7.3 Erythrocyte fatty acid composition and concentration 
analysis 
Values for biochemical variables are given as mean ± standard deviation unless otherwise 
stated. Normality testing was carried out using the Ryan-Joiner test in Minitab (vs13.0). 
Percent 14:0, 16:0, 17:0, 18:0. 20:0. 24:0, 14:1n7, 16:1n7, 17:1n7, 18:1n9, 20:1n9, 
20:2n6, 22:2n6, 22:5 n6, 20:5n3, and 22:3n3 were transformed to log values to achieve 
normality before significance testing. Absolute 12:0, 14:0, 17:0, 20:0, 20:1n9, 22:2n6 and 
22:3n3 were transformed to log values and absolute 17:1n7, 18:2n6 and 20:5n3 were 
transformed to square root values to achieve normal distribution. For summary measures, 
i.e. total of values at different gestations, % MUFA, total n-9, n6/n3 ratio and 
20:4n6/22:6n3 were transformed to log values and total n-7 transformed to square root 
values to achieve a normal distribution. Statistical analyses were performed using JMP 
statistical analysis program (Version 5.1, SAS Institute, Cary, NC, USA). Each of the 
erythrocyte fatty acids were assessed for differences between the 1
st
, 2
nd 
and 3
rd 
trimester 
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by using One way Analysis of Variance with comparison for all pairs using Tukey-
Kramer HSD. Paired Student’s t-tests were used for the comparison between the first 
trimester and the post-partum values. Linear relationships between variables were 
estimated using Pearson’s product moment correlation coefficients. Statistical 
significance was set at α = 0.005 for all analyses unless otherwise stated.
This watermark does not appear in the registered version - http://www.clicktoconvert.com95 
 
Chapter Three 
 
Lipoprotein changes in healthy pregnancy 
and their relationship to maternal BMI. 
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3  Lipoprotein changes in healthy pregnancy and 
their relationship to maternal BMI. 
 
3.1 Introduction 
Obesity has become pandemic in the U.S. with currently two in three American adults 
being classified as overweight or obese (3). Similar trends are now being seen among the 
European population with 10% of children and 20% of adults in the UK now being 
classified as clinically obese (7). In line with this, our maternity hospital has observed a 
greater than three fold increase in the proportion of women with a booking body mass 
index (BMI) >30kg/m
2 over the past decade (2). With obesity comes an increased risk of 
miscarriage (26), an increased risk of neural tube defects and other congenital 
abnormalities (28). Metabolic complications of pregnancy such as gestational diabetes, 
pregnancy induced hypertension and pre eclampsia are also more prevalent among obese 
mothers (42) (35) (39).  
In healthy pregnancy plasma triglyceride concentrations rise by 200-400%, while plasma 
cholesterol levels rise by 25-50% with advancing gestation. This physiological and 
temporary dyslipidaemia occurs presumably to accommodate the raw materials required 
for fetal development and growth. Many groups have established the pattern of 
dyslipidaemia in pregnancy [Fahraeus, 1985 #1; Piechota, 1992 #2], however fewer have 
analysed this phenomenon longitudinally (118, 119) or considered a detailed analysis of 
lipoprotein subclasses and, to our knowledge, none have correlated the degree of change 
to maternal BMI. Lipoprotein particles, rather than being homogenous, contain discrete 
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subfractions differing in structure, physiochemical properties, kinetic behaviour and 
origin (118). Low density lipoprotein (LDL), for example, incorporates a spectrum of 
lipoproteins of differing atherogenic potential. Small dense LDL (known as LDL-III) is 
more susceptible to oxidation than the larger and more buoyant subfractions (LDL-I and 
LDL-II particles) (112). Once oxidized these LDL III particles are believed to be highly 
atherogenic (112). Plasma triglyceride is the major determinant of small dense LDL, 
accounting for 40- 60% of the variability of this fraction (113) (241) (242).  
In the non-pregnant state, obesity is associated with a triglyceride rich dyslipidaemia 
characterised by an increase in small dense LDL particles (243). These particles are 
readily taken up by macrophages to form foam cells and atheromatous plaques (244). 
LDL III, being more susceptible to oxidation, provokes the release of chemotactic and 
prothrombotic factors more readily. The dyslipidaemia of obesity characterised by low 
levels of HDL; increased triglycerides; increased subfractions of small, dense LDL; and 
increased levels of apolipoprotein B-100 is now well recognised (115). Studies have 
demonstrated that central obesity is more
 strongly related to lipid/lipoprotein 
abnormalities than is
 general obesity (104-106). These adverse lipid/lipoprotein
 profiles 
in obese individuals are important, because they may
 be responsible for their increased 
risk for cardiovascular disease
 (CVD). 
By examination of the detailed dyslipidaemic response to pregnancy and its correlation to 
maternal BMI we hope to further define the link between obesity and the metabolic 
complications of pregnancy. The aim of this study is to examine changes in lipoprotein 
subclasses throughout pregnancy and to study the influence of maternal BMI over a wide 
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range (18-46 kg/m
2). The study of these physiological modifications throughout 
pregnancy may provide better understanding into the proposed mechanisms of pregnancy 
related disorders such as pre eclampsia or pregnancy induced hypertension, which are 
more prevalent among obese mothers. Furthermore we hope to add insight to the concept 
of an adverse in utero environment which may promote cycling of vascular risk factors 
through generations (245).  
 
3.2 Results 
3.2.1 Maternal characteristics 
Table 3-1 summarises the baseline first trimester clinical characteristics of all subjects 
within the study. All 60 women were seen in the first trimester of pregnancy. One woman 
miscarried at 15 weeks’ gestation, while another woman moved her antenatal care to 
another unit at 18 weeks’ gestation. 54 women attended for the second trimester visit, 
while 49 attended for the third trimester visit, hence 49 women attended all three 
trimester antenatal visits for examination. 
 
 
 
 
This watermark does not appear in the registered version - http://www.clicktoconvert.com99 
Characteristic  (N= 60)  Mean ( Standard deviation) 
Maternal Age (years)  28.7 (5.3) 
Smokers n (%)  23 (38.3%) 
Booking maternal BMI (kg/m
2)  29.1 (6.4) 
Waist circumference (cm)  92.5 (18.1) 
Waist hip ratio  0.83 (0.13) 
Primigravidae n (%)  28 (46.7%) 
Gestation at visit 1 (weeks) 
 
Gestation at visit 2 (weeks) 
 
Gestation at visit 3 (weeks) 
 
12.4 (1.5) 
 
26.1 (1.3) 
 
35.5 (1.3) 
Gestation at delivery (days)  284 (7) 
Birth weight centile  56.9 (35.9) 
Placenta weight (g)  741 (188) 
Table 3-1: Patient baseline, delivery and fetal characteristics. 
 
3.2.2 Gestational changes in maternal plasma lipids and 
lipoproteins  
There were significant increases in total cholesterol, triglyceride, VLDL cholesterol and 
LDL cholesterol over the three trimesters (Table 3-2). For these lipids and lipoproteins 
the greatest increase took place between T1 and T2 (all P<0.001) and there were no 
significant differences between T2 and T3 on post hoc testing. Plasma HDL levels did 
not change with advancing gestation (table 3-2).  
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Lipid 
First 
Trimester 
(T1) 
Mean (SE) 
Second 
Trimester 
(T2) 
Mean (SE) 
Third 
Trimester 
(T3) 
Mean (SE) 
P Value 
(For T1 
versus T3) 
Total Cholesterol 
(mmol/L) 
 
4.7 (0.11) 
 
 
6.0 (0.14) 
 
6.0 (0.14) 
 
<0.001 
 
Triglyceride 
(mmol/L) 
1.4 (0.02)  2.5 (0.02)  2.9 (0.02)           <0.001 
 
VLDL cholesterol 
(mmol/L) 
 
0.4 (0.03) 
 
0.7 (0.04) 
 
0.8 (0.04) 
 
<0.001 
 
LDL cholesterol 
(mmol/L) 
 
2.9 (0.11) 
 
3.9 (0.13) 
 
3.9 (0.14) 
 
<0.001 
 
HDL cholesterol 
(mmol/L) 
 
1.4 (0.04) 
 
1.4 (0.04) 
 
1.4 (0.04) 
 
      1 
Table 3-2: Plasma lipid and lipoprotein levels (mean [standard errors]) with 
advancing gestation.  
 
3.2.3 Gestational changes in LDL subfractions  
LDL mass increased between the first and second trimesters by 25.7 % (p<0.001) and 
then fell slightly with advancement into the third trimester but significance was not 
reached (Table 3-3).The rise in LDL mass was predominantly due to the significant rise 
in LDLIII mass (Table 3-3), which increased by 53% (P=0.002) between the first and 
second trimester. There was no significant alteration in mean percentages of LDL I with 
advancing pregnancy (Table 3-3). LDL II percentage decreased from 57.6% in the first 
trimester to 50.4% (P=0.006) in the second trimester. Conversely the proportion of LDL 
III rose markedly from 27.8% in the first trimester to 37.2% in the second trimester 
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(P=0.005). The mean proportions of LDL I, II and III did not change between the second 
and third trimester.  
 
 
 
First 
Trimester 
(T1) 
Mean (SE) 
Second 
Trimester (T2) 
Mean (SE) 
Third 
Trimester 
(T3) 
Mean (SE) 
P Value 
(For T1 
versus T3) 
LDL Subfractions 
 
       
Total LDL mass  
(mg/dL) 
132.4 (7.54)  166.5 (7.26)  153.1 (5.75)  0.039 
 
LDL I mass 
 
18.5 (1.64) 
 
21.6 (2.12) 
 
19.1 (1.97) 
 
0.823 
 
LDL II mass 
 
75.6 (4.20) 
 
83.5 (5.73) 
 
81.1 (4.97) 
 
0.398 
 
LDL III mass 
 
39.3 (4.51) 
 
60.1 (4.97) 
 
52.2 (4.00) 
 
0.044 
% LDL I 
 
14.6 (1.19)  12.5 (0.93)  12.1 (0.92)  0.128 
 
% LDL II 
 
57.6 (1.53)  50.4 (2.15)  52.8 (2.38)  0.080 
% LDL III  27.8 (1.87)  37.2 (2.76)  35.1 (2.72)  0.024 
Table 3-3: Changes in LDL subfractions with advancing gestation.  
 
3.2.4 VLDL subfraction and IDL composition and concentration 
changes with advancing gestation. 
The large, triglyceride-rich VLDL1 more than doubles in concentration (P<0.001) 
between the first and second trimester and does not rise significantly between the second 
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and third trimester (Table 3-4). The cholesterol rich VLDL2 also nearly doubles between 
the first trimester and the second trimester (P<0.001) with no significant further change in 
the third trimester (Table 3-4). IDL concentration rises significantly between the first and 
second trimester from a mean of 78.3mg/dL to 128.9mg/dL (p<0.001). There is a then a 
further increase in IDL concentration in the third trimester to 153.4mg/dL. 
 
 
First 
Trimester 
(T1) 
Mean (SE) 
Second 
Trimester (T2) 
Mean (SE) 
Third 
Trimester 
(T3) 
Mean (SE) 
P Value 
(For T1 
versus T3) 
VLDL Subfractions  
and IDL: mg/dL    
 
VLDL 1  22.0 (1.76)    48.4 (3.52)                                                          50.1 (3.84)         <0.001 
VLDL 2  74.5 (6.21)  142.3 (9.66)  159.4 (11.6)  <0.001 
IDL  78.3 (6.58)  128.9 (6.32)  153.4 (11.5)  <0.001 
LDL  86.2 (4.49)  121.3 (6.04)  109.5 (6.24)  <0.001 
Table 3-4: changes in VLDL and IDL subfractions with advancing gestation  
 
VLDL1 composition is altered with advancing gestation. Percentage triglyceride rises 
with advancing gestation however the most significant rise occurring from 40.9% in the 
first trimester to 51.1% in the second (p<0.001) (table 3-5). Percentage esterified 
cholesterol within VLDL1, falls steadily with advancing gestation from 21.2% in the first 
trimester to 14.9% in the second trimester and 10.6% in the third trimester (T1 versus T3 
p<0.001) (table 3-5). The composition of VLDL2 also changes with advancing gestation 
in that percentage triglyceride again rises with advancing gestation however not to the 
same extent as that seen in VLDL1 and steadily across all three trimesters (Table 3-5). 
Percentage esterified cholesterol falls steadily with advancing gestation across all three 
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time points (Table 3-5). IDL composition changes again show an increase in percentage 
triglyceride from 14.7% in the first trimester to 18.5% in the third trimester (p<0.001), at 
the expense of falling esterified cholesterol from 33.8% in the first trimester to 30.8% in 
the third trimester (p<0001) (Table 3-5).   
                                          First                 Second                Third                 P value 
                                   Trimester (T1)    Trimester (T2)   Trimester(T3)     T1 vs. T3 
 
                       
VLDL 1 
% Protein 
                 
13.9 (0.65) 
 
                  
13.2 (0.58) 
 
                
14.8 (0.47) 
 
                
<0.001 
VLDL 2  19.3 (0.57)  17.4 (0.47)  19.1 (0.78)  <0.001 
IDL  22.2 (0.39)  21.4 (0.32)  22.4 (0.44)  <0.001 
LDL  26.2 (0.29)  26.1 (0.27)  26.6 (0.27)  <0.001 
 
                       
VLDL 1 
% Free 
Cholesterol 
6.9 (0.36) 
 
                    
6.1 (0.15) 
 
                      
6.0 (0.11) 
 
                            
0.033 
VLDL 2  7.2 (0.13)  7.2 (0.11)  7.0 (0.11)   
IDL  7.9 (0.14)  7.9 (0.09)  7.8 (0.11)   
LDL  7.8  (0.11)  7.4 (0.09)  7.1 (0.11)   
 
                       
VLDL 1 
% Esterified 
Cholesterol 
21.2 (0.98) 
 
                   
14.9 (0.69) 
 
                
10.6 (0.59) 
 
             
<0.001 
VLDL 2  25.4 (0.66)  22.8 (0.52)  19.7 (0.54)  <0.001 
IDL  33.8 (0.48)  32.8 (0.44)  30.8 (0.48)  <0.001 
LDL  38.5 (0.29)  37.9 (0.34)  36.8 (0.40)   
 
                       
VLDL 1 
% 
Triglyceride 
40.9 (1.38) 
 
                   
51.1 (1.03) 
 
                 
54.3 (0.77) 
 
            
<0.001 
VLDL 2  28.2 (0.94)  33.6 (0.65)  35.3 (0.73)  <0.001 
IDL  14.7 (0.40)  17.4 (0.46)  18.5 (0.42)  <0.001 
LDL    6.7 (0.19)    8.8 (0.32)    9.9 (0.33)   
 
                       
VLDL 1 
% 
Phospholipid 
17.1 (0.41) 
 
                        
14.7 (0.22) 
 
                
14.3 (0.19) 
 
              
<0.001 
VLDL 2  19.9 (0.24)  18.9 (0.18)  18.8 (0.21)   0.002 
IDL  21.3 (0.23)  20.4 (0.14)  20.5 (0.16)   0.005 
LDL  20.8 (0.12)  19.7 (0.13)  19.5 (0.14)   
Lipid 
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Table 3-5: Table showing changes in composition of VLDL¹, VLDL ², IDL      
and LDL with advancing gestation 
 
 
3.2.5 Influence of maternal booking BMI on lipids with advancing 
gestation. 
Triglyceride was positively correlated to booking BMI in the first trimester, (r = 0.31; P= 
0.016) however this relationship is lost in the second and third trimester. The degree of 
change in plasma triglyceride was negatively correlated to maternal booking BMI. The 
women who booked for antenatal care with higher BMI values started pregnancy with 
high triglyceride levels with rose by 44% with advancing gestation. However those 
women who booked for antenatal care with lower BMI values started pregnancy with 
lower plasma triglyceride concentrations which rose by 136% with advancing gestation 
(Figure 3-1). 
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Figure 3-1: Changes in plasma triglyceride with advancing gestation as 
influenced by maternal  booking BMI. Note the reduced degree of change among 
those with higher booking maternal BMIs as compared with those with lower maternal booking 
BMIs as demonstrated by the vertical arrows. 
The influence of maternal BMI and length of gestation on LDL mass was investigated 
using a General Linear Model. BMI values were divided into tertiles of 18-26kg/m², 26-
32kg/m² and 31-46.3kg/m². A mean BMI for each tertile was calculated. The pattern of 
change in LDL III mass with advancing gestation was plotted for each mean tertile 
maternal booking BMI (Figure 3-2). All women experience a significant rise in LDL III 
mass between the first and second trimesters. By the third trimester the influence of 
maternal booking BMI becomes evident. As shown in figure 3-2 women with a high 
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booking BMI (mean 36.1 kg/m²) continue to maintain their LDL III mass concentration 
achieved in the second trimester while those with a lower booking BMI (mean 
22.6kg/m²) tend to reduce LDL III mass by the third trimester to near first trimester levels 
or lower. 
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Figure 3-2: Changes in plasma LDL III mass with advancing gestation 
dependent on booking maternal BMI. Three mean maternal BMIs are represented. 
Note the difference in behaviour of LDL III mass concentration as dictated by maternal booking 
BMI in the third trimester. 
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3.3 Discussion  
Various lipid/lipoprotein
 abnormalities have been observed in obese individuals, 
including
 elevated cholesterol, triglycerides, apolipoprotein B (apoB),
 and lower high-
density lipoprotein (HDL) cholesterol levels.
 Of these indicators, changes in triglyceride 
and HDL cholesterol
 levels are most consistent and pronounced (102, 103). The aim of 
the present study was to define the pattern of dyslipidaemia experienced with advancing 
gestation of pregnancy. By recruiting women with a large range of maternal booking 
BMI (18-46 kg/m
2) we were able to study the influence of pre pregnancy obesity on the 
metabolic lipid response to pregnancy.  
Plasma triglyceride (100% rise), total cholesterol (30% rise), VLDL cholesterol (100% 
increase) and LDL cholesterol (36% increase) levels increased significantly with 
advancing gestation. We demonstrated that the significant rise occurred by the second 
trimester and that the levels tended to plateau until the end of the third trimester. HDL 
cholesterol levels did not change with advancing gestation. Sattar et al reported a more 
than 200% rise in plasma triglyceride between the first and third trimesters of pregnancy 
and the increase occurred uniformly throughout pregnancy. This group also reported a 
70% rise in plasma cholesterol between the first trimester and the third trimester however 
the majority of this increase had occurred by 25 weeks gestation (118). Sattar et al also 
observed no significant change in plasma HDL with advancing gestation in keeping with 
our findings (118). This investigation included 10 women and the range of BMI was 20-
28kg/m², therefore the differences between our observations could be due to the inclusion 
of women with a high BMI in the current study. As our data shows pre pregnancy 
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maternal BMI has a direct influence on the dyslipidaemia of pregnancy. A cross sectional 
study carried out by Piechota et al reported a 2.7 fold increase in plasma triglyceride by 
the third trimester however the majority of this rise had occurred by the second trimester. 
This group also reported a 43% rise in total cholesterol with 80 % of this rise having been 
achieved by the second trimester; these are findings comparable to ours. Piechota also 
reported a 36% rise in plasma LDL cholesterol of 36% by the third trimester, agreeing 
with our findings (117). Ninety percent of the LDL cholesterol increase was achieved by 
the second trimester (117).  
As pregnancy advanced, the mass of the triglyceride-rich lipoproteins VLDL1 and 
VLDL2 increased in parallel, with the biggest changes observed between first and second 
trimester. The parallel increase in VLDL1 and VLDL2 are in agreement with findings of 
two previous studies (118, 246). These findings further enhance the uniqueness of the 
dyslipidaemia of pregnancy. In the non pregnant state a rising plasma triglyceride is 
associated with a preferential rise in VLDL1 over VLDL2 (242). In the general population 
increased concentrations of VLDL1 are associated with insulin resistance and increased 
risk of coronary heart disease. The ratio of VLDL1 to VLDL2 with the increased 
triglyceride concentrations of the third trimester would be predicted from studies in non-
pregnant subjects to be as high as 2 to 1 (242). However with advancing gestation and 
rising triglyceride levels the ratio remains the same, possibly a protective mechanism 
exclusive to pregnancy. The percentage triglyceride content of these lipoprotein 
subfractions increased at the expense of a decreased contribution to mass from 
cholesteryl esters and, to a lesser extent, phospholipid. These data suggest that the large 
amount of triglyceride mobilised during pregnancy is carried by all the main triglyceride-
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rich lipoprotein fractions and is not due to an up-regulation of the production of one 
specific VLDL fraction. One previous study has demonstrated that the administration of 
potent oestrogens promotes a balance between VLDL subclasses (247). Pregnancy is a 
state of high oestradiol levels that may therefore contribute to the unique pattern of 
VLDL subclasses in response to increasing triglyceride levels. 
The compositional analysis of VLDL1 indicated that lean women exhibited a greater 
increase in the triglyceride to cholesteryl ester ratio of these particles. This would be 
consistent with lean women having less triglyceride in the VLDL1 fraction at baseline 
and hence more capacity to increase the particle triglyceride content. Changes in LDL 
subfractions were also observed. There was a shift in the LDL subfraction profile towards 
smaller, denser LDL III as might be expected with the increase in circulating plasma 
triglyceride concentration. An increase in the triglyceride content of LDL in the presence 
of hepatic lipase leads to hydrolysis of the triglyceride in the core of the particle and a 
shrinkage in particle size (248) this effect has been observed by others. Belo et al 
concluded after their longitudinal study of changes in levels of oxidised LDL with 
advancing pregnancy that during human gestation the change in LDL profile was towards 
smaller species (119).   
Plasma cholesterol was not found to correlate with maternal booking BMI at any time 
point. Plasma triglyceride correlated positively and plasma HDL correlated negatively 
with maternal booking BMI in keeping with previous reports in the literature regarding 
non-pregnant individuals (249). The relationship between plasma triglyceride and 
booking BMI was gradually lost with advancing gestation. During pregnancy it was 
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observed that women with a lower booking BMI started pregnancy with lower plasma 
triglyceride and as pregnancy advanced their triglyceride levels increased by a large 
amount; women with a BMI of 20kg/m
2 having a predicted 157% increase in plasma 
triglycerides (Figure 3-1). Women with a higher booking BMI had higher triglyceride 
levels in the first trimester increasing to about the same levels as those seen in lean 
women by the third trimester. Women with a BMI of 40kg/m
2 had a predicted rise in 
triglycerides of 75% (Fig 3-1). Since mobilisation of maternal fat stores is a key step in 
providing nutrient for the growing fetus, the lesser response to the physiological demands 
of pregnancy observed in those with higher maternal booking BMI values may indicate a 
decreased ability to metabolically adapt to pregnancy. On the other hand lean women 
show a greater metabolic flexibility with lower starting levels of plasma triglycerides but 
a larger response to pregnancy. Since maximum triglyceride levels attained during 
pregnancy are similar in lean and obese women these data would indicate that any 
adverse metabolic risk associated with obese pregnancy is more likely related to the 
quality of the increased lipid rather than the quantity. 
When the pattern of change in LDL III mass was examined according to maternal BMI, 
LDL III mass levels behaved differently with advancing gestation dependent on maternal 
booking BMI. All women experienced a rise in plasma LDL III mass between the first 
and second trimester. With advancement into the third trimester however, those with a 
higher maternal booking BMI continued to experience a rise in LDL III mass while those 
with lower booking maternal BMI values experienced a fall in LDL III mass levels. 
Since, in the third trimester, both lean and obese women experience an increase in plasma 
triglyceride levels to above the threshold of 1.5mmol/L (113) at which LDL III becomes 
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the dominant subfraction, an alternative explanation must be sought for the increased 
LDL III levels observed in obese women. In a study of identical twins, discordant for 
obesity, hepatic lipase activity was found to be higher in the obese twin (250). Thus 
higher hepatic lipase activity in obese pregnancy might explain the increased formation 
of LDL III. A link between LDL III levels and hepatic lipase activity would be consistent 
with the special case in pregnancy of pre eclampsia. This condition is characterised by a 
maternal dyslipidaemia more exaggerated than that of obesity (251). Women with pre 
eclampsia have significantly higher LDL III and hepatic lipase activity compared to 
weight-matched controls (251). A study of hepatic lipase activity in lean women 
indicated that in these women hepatic lipase activity declines throughout gestation and 
was strongly negatively correlated to oestradiol levels (126). Hepatic lipase is known to 
be regulated by sex hormones: native or alkylated oestrogens decrease its activity and 
progestagens with androgenic properties are known to increase it (252). It is therefore 
possible that differences in the reproductive steroid hormone environment between lean 
and obese women may influence hepatic lipase activity and hence LDL III levels.  
LDL III is easily oxidised and once oxidised it is highly atherogenic. Oxidised LDL may 
lead to endothelial dysfunction by a combination of inducing adhesion molecule 
expression on the artery wall and by infiltrating the artery wall where it can be ingested 
by macrophages leading to foam cell formation. This mechanism may explain the link 
between obese pregnancy and endothelial dysfunction (139). A higher proportion of 
small, dense LDL in obese women also supports our hypothesis that obese women have a 
poorer “quality” of lipid in the face of gestational hypertriglyceridaemia. The delivery of 
poorer quality lipids to the fetus via the placenta may contribute to an adverse in utero 
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environment and go some way to explaining the cycling of vascular risk factors between 
generations that has been proposed for obese pregnancy (253).  
We have demonstrated that the obese mother has an altered dyslipidaemia during 
pregnancy when compared to the lean woman. Increased LDL III mass in the third 
trimester may alter the in utero lipid environment for the fetus of the obese mother. Much 
previous work alluding to the concept of fetal programming refers to the adverse in utero 
effects of under-nutrition. Our work adds to the debate regarding the issue of quality of 
fetal nutrition in utero as opposed to the quantity. The fetus which receives fat 
transported from a maternal lipid pool including easily oxidised highly atherogenic LDL 
III particles in the third trimester may be exposed to higher levels of oxidised fats which 
could contribute to poor future endothelial function in the offspring. The abnormal blood 
flow as a result of the atherogenic environment may have detrimental long term effects 
on the developing child. Low birth weight babies are known to have a deficit in the 
number of nephrons, therefore there may be a cellular effect on many structures incluing 
vasculature. low birth weight (LBW) occurs more frequently in disadvantaged 
communities among whom there is often a disproportionately high incidence of adult 
cardiovascular disease, hypertension, diabetes mellitus, and kidney disease. Indeed, many 
epidemiologic studies have found an inverse association between LBW and higher blood 
pressures in infancy and childhood, and overt hypertension in adulthood. Multiple animal 
models have demonstrated the association of LBW with later hypertension, mediated, at 
least in part, by an associated congenital nephron deficit. Although no direct correlation 
has been shown between nephron number and birth weight in humans with hypertension, 
nephron numbers were found to be lower in adults with essential hypertension, and 
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glomeruli tend to be larger in humans of lower birth weight. We know that oxidative 
stress has the abilty to alter DNA. This may then predispose to the development of 
disease in later life. 
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Chapter Four 
 
Longitudinal assessment of erythrocyte fatty 
acid composition and concentration 
throughout pregnancy and in the post partum 
period. 
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4  Longitudinal assessment of erythrocyte fatty 
acid composition and concentration throughout 
pregnancy and in the post partum period. 
 
4.1 Introduction 
Fatty acids are important constituents of cell membranes and therefore essential for tissue 
formation (reviewed in (224)).  The long chain polyunsaturated fatty acids (LCPUFA) 
commonly found in membranes, especially in the brain, are derived via elongation and 
desaturation from the essential fatty acids 18:2n-6 (linoleic acid) and 18:3n-3 (alpha-
linolenic acid) (reviewed in (225)).  In pregnancy the fetus is reliant on placental transfer of 
fatty acids from the mother to support growth (225, 226).  The mother must therefore 
mobilise key fatty acids and make them available for accretion by the fetus (254).  
Maternal LCPUFA status during pregnancy is critical in determining essential fatty acid 
status in the newborn (225, 227, 228). 
Al et al have assessed the fatty acid status of mothers longitudinally throughout pregnancy 
by analysing plasma phospholipid fatty acid content.  Focussing mainly on the essential 
fatty acids and their long chain derivatives, they observed that the percentage of 18:2n-6 
did not change during pregnancy whereas the percentage of 20:4n-6 (arachidonic acid) 
decreased (255). Maternal plasma phospholipid 22:6n-3 (docosahexaenoic acid) percentage 
rose until 18 weeks and thereafter declined during pregnancy concomitant with an increase 
in umbilical plasma phospholipid 22:6n-3 content (255). These observations were 
consistent across populations selected from five different countries despite the variation in 
maternal essential fatty acid status between countries (256). Similar changes in total plasma 
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fatty acid compositions were observed longitudinally in pregnancy by Montgomery et al 
(257). It has been suggested (228, 258) that, in the populations studied and under their 
prevailing dietary conditions, the decline in plasma 22:6n-3 in late gestation indicates that 
the mother may be unable to meet the fetal demand for essential long chain polyunsaturated 
fatty acids. 
While plasma phospholipid fatty acid status has been used to indicate fatty acid 
mobilisation, these fatty acids will be derived mainly from plasma lipoproteins and their 
measurement is open to confounding by maternal fasting status.  Erythrocyte fatty acid 
composition is most likely to represent an integrative measure of the fatty acid status over 
the preceding three months (the half life of an erythrocyte is 120 days).  Indeed it has been 
suggested that erythrocytes may act as a potential storage vehicle for 20:4n-6 and 22:6n-3 
(259). Montgomery (257) observed similar changes in erythrocyte fatty acids during 
pregnancy to those seen for plasma fatty acids.  In a cross-sectional study, Ashby et al 
(260) observed a 2
nd trimester increase in the erythrocyte content of the essential fatty acids 
22:6n-3, 20:5n-3 (eicosapentaenoic acid), 20:4n-6 and 18:2n-6 followed by a decline in the 
3
rd trimester in the absence of any significant changes in plasma fatty acids.  Maternal 
plasma and erythrocyte 22:6n-3 and 22:5n-6 (docosapentaenoic acid) declined between 24 
weeks’ gestation and three months post partum in African-American women while 20:5n-3 
and 20:4n-6 increased over the same period (261). 
Most of longitudinal studies of changes in maternal fatty acid status in pregnancy have 
focussed primarily on the LCPUFA changes during gestation and have not emphasised 
changes in shorter chain and saturated fatty acids nor have changes in maternal fatty acid 
status across all trimesters been compared with the post-partum period.  In this study we 
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report a full maternal erythrocyte fatty acid profile assessed at each trimester throughout 
pregnancy and at 4 months post-partum. 
4.2 Results 
 
4.2.1 Patient Characteristics 
Baseline, first trimester, characteristics of the pregnant women studied are shown in Table 
5-1.  The characteristics of the women studied here are fairly typical for the Glasgow 
population when compared with booking characteristics of women enrolled in the Glasgow 
Outcome APCR and Lipid (GOAL) Pregnancy Study (262) (Table 5-1).  However the 
women studied here have a 3.5kg/m
2 higher body mass index (BMI) than the mean for the 
Glasgow population. 
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Characteristic  Total 
n=47 
GOAL (18) 
n = 4218 
Age (years) 
 
28.7 (5.0)  28.4 (5.8) 
Smokers n (%) 
 
17 (36.2)  1701 (40.3) 
Deprivation index n (%)   
Affluent (DEPCAT score(14) 1-2) 
Intermediate (3-5) 
Deprived (6-7) 
 Not known 
 
 
5 (10.6) 
17 (36.2) 
24 (51.1) 
1 (2.1) 
 
445 (10.6) 
1788 (42.4) 
1754 (41.6) 
231 (5.5) 
Parity n (%)       
0 
1-2 
 >2 
 not known 
 
 
24 (51.1) 
20 (42.6) 
3 (6.4) 
0 
1 
842 (43.7) 
1352 (32.1) 
289 (6.9) 
735 (17.4) 
BMI  (kg/m
2) 
 
28.4 (6.1)  24.9 (4.7) 
Waist (cm) 
 
90.0 (15.5)  80.1 (10.5) 
Waist hip ratio  0.83 (0.11) 
 
Not recorded 
Gestation at delivery (days) 
 
279 (10)  274 (15) 
Mode of delivery n (%)                 
Vaginal delivery 
Assisted delivery 
Elective Caesarean section 
Emergency Caesarean section 
 
 
29 (61.7) 
8 (17.0) 
4 (8.5) 
6 (12.8) 
 
31 (45.2) 
6 (13.0) 
5 (5.5) 
5(5.5) 
Fetal Sex n (%)     
Male 
Female 
 
27 (57.4) 
20 (42.6) 
 
Not recorded 
Birth weight centile 
 
56.8 (33.2)  51.1 (29.6) 
Placental weight (g) 
 
770 (185)  674 (202) 
Table 4-1 Patient baseline and delivery characteristics for the current study 
and for women recruited to the Glasgow Outcome, APCR and LIPID (GOAL) 
Pregnancy Study (262). 
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4.2.2 Gestational changes in maternal erythrocyte fatty acid 
composition  
Maternal erythrocyte fatty acid profiles are shown for each trimester of pregnancy 
expressed both as percentage total fatty acids (Table 5-2) and as absolute concentration 
(Table 5-3). There was a significant decrease in maternal 18:0 during pregnancy expressed 
as percentage total fatty acids however this was not reflected in a change in the absolute 
amount of this fatty acid.  The significant increases in percentage of total fatty acids for 
22:5n6, 18:3n3 and 22:6n3 were reflected in increases in the absolute amounts of these 
fatty acids of 25% (p=0.0003), 41% (p=0.0007) and 20% (p=0.0005) respectively. 
Furthermore increases in the absolute amount of 16:1n7 (22%, p=0.0005) and 24:1n9 
(13%, p=0.0032) were observed in the absence of a significant change in their percentage 
contribution to total fatty acids.  The rise in all these fatty acids took place mostly between 
the first and second trimester with second and third trimester differences being non-
significant on post hoc testing.   
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Table 5-2 Mean (SD) erythrocyte fatty acid composition (% total fatty acids) in each 
trimester of pregnancy and 4 months postpartum. Gestation (mean [SD]) at sampling: 
first trimester 12.5 (1.3) weeks; second trimester 26.1 (1.3) weeks; third trimester 35.3 
(1.3) weeks; post partum 18.1 (3.0) weeks post delivery. 
 
Fatty 
Acid 
(%) 
Trimester 
1 
n=46 
Trimester 
2 
n=47 
Trimester 
3 
n=47 
P* 
 
Post 
partum 
n=38 
P** 
T1 vs 
post 
partum 
SAFA             
12:0  0.00 
(0.00) 
0.02 
(0.09) 
0.02 
(0.08) 
0.75  0.06 
(0.18) 
0.043 
14:0  0.61 
(0.27) 
0.63 
(0.30) 
0.62 
(0.26) 
0.95  0.43 
(0.21) 
0.0002 
16:0  21.9 (2.2)  22.0 (2.4)  22.2 (1.4)  0.70  20.3 
(0.90) 
<0.0001 
17:0  0.35 
(0.19) 
0.31 
(0.22) 
0.33 
(0.21) 
0.81  0.40 
(0.20) 
0.98 
18:0  15.7 
(1.44) 
14.8 
(1.50) 
14.5 
(1.30) 
<0.0001  15.3 
(0.62) 
0.08 
20:0  0.72 
(0.14) 
0.70 
(0.18) 
0.63 
(0.15) 
0.0059  0.70 
(0.18) 
0.45 
22:0  1.72 
(0.41) 
1.56 
(0.36) 
1.49 
(0.37) 
0.012  1.94 
(0.28) 
0.0061 
24:0  3.20 
(0.71) 
3.30 
(0.54) 
3.29 
(0.54) 
0.54  3.64 
(0.51) 
0.0010 
MUFA             
14:1 n7  0.00 
(0.03) 
0.02 
(0.10) 
0.01 
(0.05) 
1.00  0.03 
(0.10) 
0.67 
16:1 n7  0.86 
(0.23) 
1.01 
(0.27) 
1.00 
(0.23) 
0.0057  0.74 
(0.32) 
0.0113 
17:1 n7  0.04 
(0.11) 
0.04 
(0.11) 
0.06 
(0.13) 
0.65  0.14 
(0.23) 
0.320 
18:1 n9  14.5 (1.7)  14.8 (2.0)  14.8 (1.7)  0.60  13.1 (1.1)  <0.0001 
20:1 n9  0.60 
(0.13) 
0.64 
(0.23) 
0.56 
(0.12) 
0.0088  0.55 
(0.20) 
0.0397 
22:1 n9  0.17 
(0.24) 
0.14 
(0.23) 
0.17 
(0.23) 
0.80  0.22 
(0.24) 
0.34 
24:1 n9  4.93 
(0.75) 
5.13 
(1.00) 
5.22 
(0.80) 
0.29  4.59 
(0.58) 
0.0275 
PUFA 
n6 
           
18:2 n6  8.60 
(1.05) 
8.91 
(1.12) 
8.90 
(0.93) 
0.27  9.75 
(0.97) 
<0.0001 
18:3 n6  0.17 
(0.17) 
0.11 
(0.15) 
0.11 
(0.14) 
0.16  0.08 
(0.16) 
0.023 
20:2 n6  0.38 
(0.16) 
0.41 
(0.21) 
0.41 
(0.17) 
0.36  0.29 
(0.25) 
0.47 
20:3 n6  1.83 
(0.41) 
2.03 
(0.51) 
1.95 
(0.43) 
0.12  1.97 
(0.43) 
0.13 
20:4 n6  13.7 (2.5)  12.7 (2.2)  12.9 (1.4)  0.054  15.4 (1.0)  0.0001   
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22:2 n6  0.04 
(0.15) 
0.01 
(0.07) 
0.01 
(0.05) 
0.65  0.04 
(0.13) 
0.43 
22:4 n6  2.70 
(0.75) 
2.68 
(0.79) 
2.84 
(0.70) 
0.51  3.08 
(0.47) 
0.0088 
22:5 n6  0.54 
(0.22) 
0.67 
(0.21) 
0.68 
(0.20) 
0.0024  0.54 
(0.22) 
0.82 
PUFA n3             
18:3 n3  0.19 
(0.15) 
0.33 
(0.20) 
0.29 
(0.18) 
0.0009  0.23 
(0.23) 
0.31 
20:5 n3  0.80 
(0.45) 
0.85 
(0.46) 
0.71 
(0.41) 
0.32  0.87 
(0.40) 
0.21 
22:3 n3  0.37 
(0.32) 
0.38 
(0.27) 
0.41 
(0.33) 
0.73  0.62 
(0.79) 
0.098 
22:5 n3  2.01 
(0.41) 
2.01 
(0.49) 
2.08 
(0.31) 
0.65  2.23 
(0.45) 
0.021 
22:6 n3  3.29 
(0.92) 
3.79 
(0.98) 
3.85 
(0.70) 
0.0043  2.79 
(0.68) 
0.0060 
* One way Analysis of Variance, across trimesters 1, 2 & 3, with comparison for all 
pairs using Tukey-Kramer HSD. ** t-test  
SAFA, saturated fatty acids, MUFA, monounsaturated fatty acids, PUFA, 
polyunsaturated fatty acids.   
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Table 5-3  Mean (SD) erythrocyte fatty acid concentration (pmol/ml blood) in each trimester of 
pregnancy and 4 months postpartum. Gestation (mean [SD]) at sampling: first trimester  12.5 
(1.3) weeks; second trimester 26.1 (1.3) weeks; third trimester 35.3 (1.3) weeks; post partum 
18.1 (3.0) weeks post delivery. 
Fatty 
Acid 
(pmol/ml) 
Trimester 1 
n=46 
Trimester 2 
n=47 
Trimester 3 
n=47 
P* 
 
Post 
partum 
n=38 
P** 
T1 vs post 
partum 
SAFA             
12:0  0.0 (0.0)  0.8 (3.1)  0.7 (2.9)  0.81  2.0 (6.6)  0.048 
14:0  16.8 (7.4)  17.6 (8.6)  19.1 (9.1)  0.64  12.0 (6.4)  0.0002 
16:0  541.7 (90.5)  552.9 (94.2)  599.0 (114.1)  0.016  507.5 (77.7)  0.070 
17:0  8.2 (4.5)  7.3 (5.4)  8.6 (5.8)  0.39  9.5 (5.0)  0.93 
18:0  353.1 (69.0)  334.3 (58.8)  351.7 (63.0)  0.28  344.8 (53.7)  0.55 
20:0  14.6 (3.5)  14.5 (4.5)  13.9 (3.7)  0.61  14.5 (4.3)  0.75 
22:0  32.2 (9.5)  29.7 (8.0)  29.9 (7.8)  0.30  36.7 (7.2)  0.020 
24:0  54.6 (10.6)  57.5 (11.0)  61.1 (11.5)  0.020  64.2 (14.9)  0.0009 
MUFA             
14:1 n7  0.1 (1.0)  0.7 (3.3)  0.4 (1.8)  0.55  0.8 (2.8)  0.17 
16:1 n7  21.3 (5.8)  25.5 (7.6)  27.2 (8.4)  0.0005  18.2 (8.3)  0.047 
17:1 n7  1.0 (2.8)  1.0 (2.8)  1.8 (3.7)  0.48  3.3 (5.4)  0.015 
18:1 n9  329.2 (78.3)  339.1 (72.1)  365.0 (80.5)  0.072  294.3 (47.1)  0.018 
20:1 n9  12.3 (3.4)  13.4 (4.8)  12.5 (3.5)  0.58  11.3 (4.8)  0.087 
22:1 n9  3.5 (4.7)  2.7 (4.3)  3.4 (4.6)  0.63  4.5 (4.9)  0.58 
24:1 n9  85.0 (15.7)  89.7 (20.0)  98.0 (19.0)  0.0032  80.6 (16.6)  0.22 
PUFA n6             
18:2 n6  196.2 (42.2)  206.6 (49.6)  219.7 (42.4)  0.041  222.6 (41.9)  0.0054 
18:3 n6  3.7 (3.8)  2.6 (3.3)  2.7 (3.7)  0.30  1.9 (3.8)  0.038 
20:2 n6  8.0 (3.4)  8.6 (4.5)  8.9 (4.1)  0.54  6.3 (5.3)  0.072 
20:3 n6  37.9 (9.5)  43.0 (13.1)  44.1 (10.9)  0.020  41.3 (11.1)  0.13 
20:4 n6  291.1 (81.4)  272.1 (65.5)  290.9 (53.8)  0.30  326.4 (57.2)  0.027 
22:2 n6  0.9 (2.9)  0.2 (1.4)  0.2 (1.0)  0.54  0.8 (2.5)  0.23 
22:4 n6  52.5 (17.9)  52.2 (16.5)  58.5 (15.7)  0.12  60.2 (12.7)  0.028 
22:5 n6  10.4 (4.3)  13.0 (4.5)  13.9 (3.7)  0.0003  10.8 (4.8)  0.70 
PUFA n3             
18:3 n3  4.4 (3.5)  7.7 (5.0)  7.4 (4.8)  0.0007  5.1 (5.4)  0.44 
20:5 n3  16.8 (9.9)  18.2 (10.1)  16.1 (9.1)  0.61  18.3 (9.0)  0.37 
22:3 n3  7.3 (6.6)  7.4 (5.1)  8.1 (6.7)  0.61  9.8 (5.5)  0.28 
22:5 n3  39.0 (10.6)  39.5 (10.9)  43.4 (8.7)  0.073  43.7 (11.1)  0.048 
22:6 n3  64.0 (19.7)  74.5 (21.0)  80.5 (19.4)  0.0005  54.6 (16.0)  0.021 
* One way Analysis of Variance, across trimesters 1, 2 & 3, with comparison for all 
pairs using Tukey-Kramer HSD. ** t-test  SAFA, saturated fatty acids, MUFA, 
monounsaturated fatty acids, PUFA, polyunsaturated fatty acids.   
This watermark does not appear in the registered version - http://www.clicktoconvert.com123 
4.2.3 Correlation of gestational changes in maternal erythrocyte 
fatty acids with maternal characteristics 
The change in absolute amount of 16:1n7 between the 1
st and 3
rd trimester was inversely 
correlated with booking BMI (r=-0.41, p=0.005) (Figure 5-1) and booking waist 
circumference (r=-0.40, p=0.006) (Fig 5-2).  
Figure 4-1: Correlation between the absolute concentration of 16:1n7 and 
booking BMI between the first and third trimester 
-20
-15
-10
-5
0
5
10
15
20
25
30
15 20 25 30 35 40 45 50
Booking BMI (kg/m2)
C
h
a
n
g
e
 
i
n
 
1
6
:
1
 
(
p
m
o
l
/
m
l
 
b
l
o
o
d
)
 
Figure 4-2 Correlation between the absolute concentration of 16:1n7 and 
waist circumference between the first and third trimester. 
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r=-0.402, p = 0.006 
r=-0.408, p = 0.005 
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 Thus there appears to be a link between the accumulation of 16:1n7 and maternal central 
obesity.  Change in 16:1n7 concentration was also weakly correlated with accumulation of 
18:3n3 (r=0.37, p= 0.012).  There were weak correlations between change in 24:1n9 and 
22:6n3 concentrations and placental weight (r=0.33, p=0.024 and r=0.35, p=0.017 
respectively).  Finally change in absolute amount of 22:6n3 was strongly associated with 
changes in absolute amounts of 24:1n9 (fig 5-3)  and 22:5n6 (Fig 5-4) (r=0.70, p<0.001 and 
r=0.46, p=0.001 respectively) between the 1
st   and 3
rd trimester.
 
Figure 4-3:  Relationship between change in 22:6n3 concentration (pmol/mL 
blood) and changes in 24:1n9 concentration (pmol/mL blood) between the 1
st 
and 3
rd trimester (3
rd-1
st trimester). 
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r=0.699, p < 0.001 
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Figure 4-4:  Relationship between change in 22:6n3 concentration (pmol/mL 
blood) and changes in 22:5n6 concentration (pmol/mL blood) between the 1
st 
and 3
rd trimester (3
rd-1
st trimester). 
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 There were no relationships between changes in these fatty acids and maternal age, 
smoking status, deprivation category, parity, mode of delivery, gestation at delivery, fetal 
sex or birth weight centile. 
 
4.2.4 Comparison of first trimester and post-partum maternal 
erythrocyte fatty acid composition  
 
In order to investigate whether fatty acids returned to baseline (trimester 1) pregnancy 
levels within 4 months after delivery, first trimester fatty acid composition was compared 
with erythrocyte fatty acid composition in samples collected a mean of 18 weeks after 
delivery (Tables 5-2 and 5-3).  The percentage contribution to total fatty acids was lower 
post partum than in trimester 1 for 14:0, 16:0, 18:1n9 and 22:6n3 and higher post partum 
for 24:0, 18:2n6 and 20:4n6.  However a reduction in absolute amounts was only seen for 
14:0.  Four months post partum, 14:0 was 29% lower (p=0.0002) than during the 1
st 
r=0.464, p = 0.001 
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trimester in pregnancy.  An increase in absolute amount was only observed for 24:0 which 
was 15% higher (p=0.0009) than during the 1
st trimester in pregnancy.   
 
 
4.2.5 Comparison of summary fatty acid measures during 
pregnancy and post-partum 
Table 5-4 shows the summary measures during pregnancy and post-partum period.  During 
pregnancy, the n6/n3 ratio decreased by 11% (p=0.0019) and the 20:4n6/22:6n3 ratio 
decreased by 23% (p<0.0001) but of these two ratios, only the 20:4n6/22:6n3 ratio 
increased by 24% in the post-partum period (p<0.0001).  The percent MUFA of total fatty 
acids decreased by 8% in the post-partum period (p<0.0001), which is reflected in the total 
n9 fatty acids (9%, p<0.0001).  Conversely, the percent PUFA of total fatty acids increased 
by 9% in the post-partum period (p<0.0001), which is reflected in an increase in the n6 
PUFA (11%, p<0.0001).  The unsaturated index (p=0.0013), the average chain length 
(p=0.0006) and the C20-22 (p=0.0005) were all significantly higher in the post-partum 
period. 
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Table 5- 4 Summary measures for % fatty acids  
 
Fatty Acids 
 
Trimester 
1 
n=46 
Trimester 
2 
n=47 
Trimester 
3 
n=47 
P* 
 
Post 
partum  
n=38 
P** 
T1 vs post 
partum 
% saturated 
 
46.6 (3.7)  45.6 (3.0)  45.4 (2.4)  0.16  44.8 (1.1)  0.0077 
% unsaturated 
 
53.4 (3.7)  54.4 (3.0)  54.6 (2.4)  0.16  55.2 (1.1)  0.0077 
% MUFA 
 
20.5 (1.7)  21.2 (1.8)  21.2 (1.7)  0.07  18.8 (1.1)  <0.0001 
%  PUFA 
 
33.0 (4.3)  33.2 (3.9)  33.4 (2.5)  0.85  36.3 (1.5)  <0.0001 
Total n-9 
 
19.5 (1.6)  19.9 (1.7)  20.0 (1.5)  0.21  17.8 (1.0)  <0.0001 
Total n-7 
 
1.03 (0.29)  1.22 (0.38)  1.21 (0.32)  0.0062  1.03 (0.54)  0.63 
Total n-6 
 
27.0 (3.7)  26.7 (3.0)  26.9 (2.1)  0.82  30.3 (1.3)  <0.0001 
Total n-3 
 
6.0 (1.2)  6.6 (1.3)  6.6 (0.9)  0.0127  6.1 (1.0)  0.70 
n6/n3 ratio 
 
4.7 (1.0)  4.2 (0.8)  4.2 (0.6)  0.0019  5.1 (0.9)  0.0212 
Unsaturated 
index 
147.7 
(16.8) 
148.7 
(16.4) 
149.3 
(10.8) 
0.86  157.1 (5.7)  0.0013 
Average chain 
length 
18.6 (0.2)  18.6 (0.2)  18.6 (0.2)  0.86  18.7 (0.1)  0.0006 
C20 –22 
 
29.31 (4.2)  28.9 (4.5)  28.9 (3.2)  0.96  31.8 (2.0)  0.0005 
20:4n6/22:6n3 
 
4.4 (1.4)  3.6 (1.0)  3.4 (0.7)  <0.0001  5.8 (1.4)  <0.0001 
* One way Analysis of Variance, across trimesters 1, 2 & 3, with comparison for all 
pairs using Tukey-Kramer HSD. ** t-test  SAFA, saturated fatty acids, MUFA, 
monounsaturated fatty acids, PUFA, polyunsaturated fatty acids. 
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4.3 Discussion 
 This paper describes clearly the changes in fatty acids that occur throughout pregnancy 
(1
st, 2
nd and 3
rd trimester) and during the post-partum period (4 months post-partum).  
Comparison of our selected group with the large cohort of Glasgow women (n=4218) 
indicates that the women sampled were typical of the general Glasgow population apart 
from being more obese (Table 5-1).  The fatty acids that increased significantly during 
pregnancy were 18:3n3, 22:5n6, 22:6n3, 16:1n7 and 24:1n9 (Tables 5-2 and 5-3).  Because 
these changes were observed predominately between the 1
st and 2
nd trimester they must be 
initiated soon after implantation, especially if one considers that changes in erythrocyte 
composition integrate changes in fatty acid metabolism over the preceding 120 days. 
 
Our data on changes in 22:6n3 are broadly consistent with previous observations that 
22:6n3 is mobilised from maternal stores in order to supply the growing fetus (255-257). 
However we did not observe a decline in 22:6n3 levels between the 2
nd and 3
rd trimester 
which may indicate that our pregnant population is not deficient in 22:6n3 as has been 
suggested for other populations (228, 258). This would be supported by the significant 
decline in the n6/n3 ratio during pregnancy indicating an enrichment of maternal 
erythrocyte LC n3-PUFA.  An increased ratio of 22:5n6/22:6n3 ratio has been reported to 
reflect an omega-3 or 22:6n3 deficiency (263).  The calculated mol/mol 22:5n6/22.6n3 
ratios in our population (1
st trimester 0.16, 2
nd trimester 0.17, 3
rd trimester 0.17 and 
postpartum 0.20 mol/mol) were normal according to the cut-off values of >0.22mol/mol for 
22:6n3 marginality and >0.48mol/mol for 22:6n3 deficiency suggested by Fokkema et al 
(263). 
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The 41% (p=0.0007) increase in maternal erythrocyte 18:3n3 during pregnancy that we 
observed is most likely due to its role as a precursor for 22:6n3 synthesis.  This large 
increase in 18:3n3 during pregnancy has either been reported, but not commented on (228, 
256, 261) because the focus of research was on LCPUFA, or was not detected (257) or 
reported (255).  18:3n3 can be derived from green vegetables in the diet however it is 
unlikely that dietary changes explain the large accumulation seen in the women we studied 
since the population served by our hospital consumes a habitually poor diet low in fruit and 
vegetable content (264). However in the absence of detailed dietary intake information this 
explanation cannot be discounted.  An alternative explanation might be increased 
mobilisation of 18:3n3 from maternal stores in order to provide substrate for LC n3-PUFA 
synthesis.  Women tend to partition less 18:3n3 to b-oxidation then men (265) thus 
increasing availability for conversion to LCPUFAs.  18:3n3 can be elongated and 
desaturated to 20:5n3, 22:5n3 and 22:6n3 in women of child-bearing age (266) but only to 
20:5n3 and 22:5n3 in men (267).  Women taking synthetic oestrogens had an increased 
capacity to convert 18:3n3 to 22:6n3 (266).  This gender difference underlines the potential 
importance of the capacity to synthesise 22:6n3 during pregnancy and lactation and it is 
possible that the rise in oestrogen during pregnancy regulates the conversion of 18:3n3 to 
LCPUFA (265).  Fetal liver (268) can convert 18:3n3 to 22:6n3 but there is little evidence 
that placenta does so (269).  It is possible that increased maternal 18:3n3 levels may 
provide substrate to the fetal liver synthetic pathways.  The physiological relevance of the 
conversion from 18:3n3 can be questioned as 18:3n3 supplementation during pregnancy 
did not result in increased maternal or fetal DHA levels (270).  However it is possible that 
if fetal 22:6n3 utilisation is efficient then additional 22:6n3 flux may not be detectable as 
changes in steady state levels in cord blood.  Also all the women in the study were 
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Caucasian, and differences in deprivation scoring using DEPCAT were not significant 
between the two groups. 
 
Nervonic acid (24:1n9) was also increased during pregnancy (Table 5-3) and it is well 
documented that 24:1n9 is important in neural development, particularly for myelination 
(271-273).  The increased levels of 24:1n9 could be explained by an increased mobilisation 
of this fatty acid for fetal neural development from mid gestation and particularly during 
the post-partum period (272).  22:6n3 is also important for proper neural development 
(reviewed in (274, 275)) and is also increased during pregnancy (Table 5-3).  The strong 
correlation between 22:6n3 and 24:1n9 (r=0.70, p<0.001) (Figure 5-3) suggests that the 
synthesis and/or transport of these two fatty acids may be coordinated.  Interestingly the 
change in concentrations of these fatty acids during pregnancy was correlated to placental 
weight. 
 
16:1n7 (palmitoleic acid) was also increased during pregnancy and is reduced in the post-
partum period (Table 5-3).  16:1n7 was negatively associated with booking BMI and waist 
circumference (Fig 5-1 and Fig 5-2) indicating a relationship between levels of this fatty 
acid and central obesity.  This relationship may be apparent in our study due to the wide 
range of booking BMI (18.0 – 46.3 kg/m
2, Fig 1).  16:1n7 is synthesised from 16:0 by 
stearyl CoA desaturase (SCD) (232) an enzyme whose expression is downregulated by 
leptin (230) and whose activity is associated with obesity (231, 232).  Our observation in 
pregnancy of an inverse association between the product of SCD and obesity is at odds 
with these published data.  This discrepancy could be explained if 16:1n7 were not a good 
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index of SCD activity in pregnancy or if leptin metabolism were different in pregnancy.  It 
has been suggested that maternal leptin resistance may occur in pregnancy (276, 277).  
There is a well-recognised increase in maternal leptin in pregnancy (276, 278) which is 
even higher in obese pregnant women (139).  Since leptin levels are increasing at a time 
when fat stores are accumulating this is in contradiction to leptin’s role as a satiety signal.  
It has been proposed that an increase in the amount of a soluble isoform of the leptin 
receptor derived from the placenta results in an increased proportion of bound, and hence 
unavailable, leptin in the maternal circulation with advancing gestation (277, 279).  This 
potential for leptin resistance in pregnancy may account for the counterintuitive inverse 
association between 16:1n7 and obesity in pregnancy observed using the two independent 
measures of BMI and waist circumference.  The association between fatty acid metabolism 
in pregnancy and obesity warrants further investigation especially in light of the increased 
booking BMI observed over the last decade in our hospital (2). 
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5  Longitudinal assessment of maternal endothelial 
function and markers of endothelial and 
placental function throughout pregnancy in lean 
and obese mothers. 
 
5.1 Introduction 
Pre-pregnancy obesity is becoming a common occurrence in obstetric management. 
Changes in the treatment of obesity-related infertility have resulted in more of these women 
achieving a pregnancy. Furthermore, as estimated by the World Health Organisation in 
2000, 300 million people worldwide are clinically obese. In the U.S. the incidence of 
obesity is reported to have risen from 13% to 27% between 1980 and 1999 (280). 
American trends are now being seen among the European population with 10% of children 
and 20% of adults in the UK being classified as clinically obese (7). In line with this, our 
maternity hospital has observed a greater than three fold increase in the proportion of 
women with a booking body mass index (BMI) >30kg/m
2 over the past decade (2). 
 
Increasing evidence relates impaired endothelial vasomotor function to coronary heart 
disease (170). Endothelial function can be assessed in the peripheral circulation and this 
has been shown to correlate with endothelial function within the coronary circulation (158, 
281). Our group previously demonstrated that microvascular function in the third trimester 
of pregnancy (139) was better in lean compared to obese women. The study design 
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however did not permit identification of the dynamics of this phenomenon, i.e. whether it 
was a pregnancy-specific effect.  
 
In healthy pregnancy several components of the metabolic syndrome are acquired; insulin 
resistance, hypertriglyceridaemia, an upregulation of the inflammatory cascade and an 
increase in coagulation factors. These changes impact substantially not only on 
carbohydrate and lipid control pathways, but also on vascular endothelial function. Several 
soluble markers produced by the endothelium, once activated, can be measured in 
peripheral blood. These soluble markers of endothelial activation include the adhesion 
molecules  ICAM-1 and VCAM-1 (282), and the haemostatic factors vWF (283) and PAI-1 
(284). The inflammatory response observed in pregnancy shifts from a Th1, mostly 
cellular, response to a Th2, mostly humoural response (285) and successful pregnancy is 
the result of a balance between the two responses. Some cytokines are more indicative of 
the Th1 response (TNFα) and some of the Th2 (IL-6) response. The influence of obesity on 
these factors throughout pregnancy and in the post-natal period has not been assessed 
longitudinally. 
Khan et al have shown that by 6 months of age, offspring of dams fed a lard-rich diet in 
pregnancy and suckling develop a phenotype that is similar to that of human metabolic 
syndrome: hypertension, dyslipidaemia, insulin resistance obesity and blunted 
endothelium-dependent vasodilatation (286) (287, 288). Armitage et al went further to 
demonstrate that adult OHF animals exhibit reduced aortic endothelium-dependent 
vasodilatation and increased aortic stiffness (289). This was accompanied by reduced 
smooth muscle cell number and endothelial cell volume.  
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This finding of increased aortic stiffness in OHF supports the hypothesis that disturbances 
to maternal nutrition altered aortic function in offspring. A study of adult humans of low 
birthweight were shown to have reduced conduit artery compliance in the trunk and legs, as 
assessed by pulse wave velocity  (290).  
Armitage et al also observed reduced endothelium-dependent vasodilatation in the aorta 
from OHF (289). It is proposed that endothelial dysfunction may initiate many of the 
abnormalities clustering in the metabolic syndrome (291) and in the larger vessels this 
deficit is intimately involved in atherogenesis (292). The present data also showed a 
reduction in endothelial cell layer volume, evidence of altered endothelial cell morphology.  
 
 
We hypothesise that microvascular endothelial function is up-regulated in both lean and 
obese women with advancing gestation; however the degree of improvement will be less in 
obese women when compared to lean counterparts. The aim of this Chapter was to use a 
non-invasive measure of microvascular endothelial function, laser Doppler imaging (LDI), 
in lean and obese subjects at intervals throughout their pregnancy. We examined the 
relationship between changes in endothelial function with advancing gestation and BMI. In 
addition, we assessed plasma markers of endothelial function, inflammation and placental 
function (PAI-1/PAI-2 ratio) and their association with microvascular function. 
 
 
5.2 Results 
Patient characteristics 
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The demographics of the subject groups are shown in Table 3-1. The groups were well 
matched for age, parity and smoking status. Of note both first trimester diastolic and 
systolic blood pressures, although remaining within the normal range, were significantly 
higher in the obese women. First trimester BMI as well as waist circumference were 
significantly different between the two groups. There was no significant difference in 
gestation, or number of weeks post partum, at each visit between the groups. Babies born 
to obese mothers had a significantly greater birth weight centile when compared to those 
born to lean mothers. None of the women developed clinical evidence of hypertension or 
other metabolic complications of pregnancy. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5-1; Baseline characteristics of study subjects. 
 
 
Parameters 
 
Lean (n=30) 
 
Obese (n=30) 
 
P value 
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Mean ± S.D.  Mean ± S.D. 
 
Age (years) 
 
28.5 ± 5.1 
 
28.7 ± 1.1 
 
0.87 
 
Smokers (%) 
 
36.7% 
 
40.0% 
 
0.88 
 
Primigravidae (%) 
 
40% 
 
40% 
 
1 
 
Booking BMI (kg/m²) 
 
24.0 ± 2.9 
 
34.2 ± 4.5 
 
<0.001 
 
Waist circumference 
(cm) 
 
 
79.4 ± 7.3 
 
 
105.6 ± 16.1 
 
 
<0.001 
 
Booking Blood pressure 
(mmHg) 
              Systolic 
 
 
 
112.7 ± 11.4 
 
 
 
123.7 ± 10.7 
 
 
 
0.001 
              
              Diastolic 
 
 
65.5 ± 7.7 
 
72.7 ± 9.7 
 
0.002 
 
Gestation at    Visit 1 
 
12.2 ± 1.8 
 
12.6 ± 1.0 
 
0.33 
                        
 ( weeks)        Visit 2 
 
26.2 ± 1.2 
 
26.0 ± 1.4 
 
0.65 
 
                       Visit 3 
 
35.5 ± 1.4 
 
35.5 ± 1.3 
 
0.91 
 
Number of weeks post-
natal. 
 
 
18.2 ± 3.0 
 
 
15.9 ± 1.9 
 
 
0.06 
 
Birth weight centile 
 
52.3 ± 34.7 
 
74.1 ± 20.5 
 
0.003 
 
Vaginal deliveries (%) 
 
83.3% 
 
63.3% 
 
0.059 
 
 
 
5.2.1 Endothelial dependent vasodilator response 
The response to ACh (expressed as the AUC) showed a highly significant difference 
(P<0.001, 2-way ANOVA) between the lean and obese groups (Fig 3-1). Post hoc analysis 
(Bonferroni correction) revealed that the response of the obese group was significantly 
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lower (P<0.05) at each trimester (51%, 41% and 39% respectively) when compared to the 
lean group and when tested at 4 months post partum (115% lower; P<0.01). Two-way 
ANOVA revealed that the ACh response differed significantly (P<0.001) between the 
different time points, with the third trimester differing from the other time points (P<0.05, 
Bonferroni).  Within the obese group, the third trimester response differed significantly 
from all other time points tested but within the lean group the third trimester response only 
differed significantly from second trimester response (P=0.04). Post partum, the ACh 
response did not decline significantly for the lean women but there was a significantly 
reduced response among the obese women (P<0.001). 
 
 
5.2.2 Endothelial independent vasodilator response 
Analysis of SNP data revealed a similar pattern with time as the ACh response (Fig 3-2) 
with a highly significant difference between the time points tested (P<0.001, 2-way 
ANOVA). However, within the lean group the third trimester response differed 
significantly from all other time points while among the obese women third trimester 
response differed only significantly from the second trimester and post-natal. There is also 
a small but significant difference between the two groups, lean response being greater than 
obese (p=0.021). Interestingly the SNP response post-natal declined significantly for both 
groups (P<0.001).  
Figure 5-1: Endothelial dependent vasodilation in response to iontophoresis 
of Acetylcholine (ACh) in lean women (n=30) versus obese women (n=30), 
measured longitudinally with advancing gestation.  
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Figure 5-2: Endothelial independent vasodilation in response to 
iontophoresis of sodium nitroprusside (SNP) in lean women (n=30) versus 
obese women (n=30), measured longitudinally with advancing gestation. 
Means ± SEM. 
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5.2.3 Soluble plasma markers of inflammation and endothelial 
activation 
All of the measured inflammatory markers changed throughout pregnancy and the post-
natal period apart from IL-10 in both groups and IL-6 in the obese (Table 2). For TNFα, 
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IL-10, sVCAM-1 and vWF there were no differences at any time point between the lean 
and obese groups. Only plasma CRP levels differed between lean and obese women at all 
time points tested with plasma CRP levels being significantly higher in the obese. Plasma 
IL-6 and sICAM-1 levels were significantly higher in obese women in early pregnancy 
(first and second trimester), but not in late pregnancy or the post-natal period (Table 3-2). 
PAI-1 levels were significantly lower in the obese in the first trimester and higher in the 
obese women in the post-natal period. PAI-2 levels were significantly lower in the obese in 
the first trimester.  
 
 
 
 
 
 
 
Table5-2: Changes in plasma concentrations of soluble markers of 
inflammation and endothelial function with advancing gestation in lean and 
obese pregnant women. Median and interquartile ranges are shown. * Difference 
testing was carried out using two sample t-test on transformed data. # Differences 
between time points was carried out on transformed data using repeated measures 
ANOVA in a general linear model. 
Inflammatory Marker  Lean 
Median  
(IQ range) 
Obese 
Median  
(IQ range) 
P value 
Lean vs. obese* 
IL-6  
(pg/ml) 
 
<0.001# 
 
0.36# 
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             1
st Trimester  0.80 (0.50-0.93)  1.55 (1.10-2.65)  <0.001 
             2
nd Trimester  1.00 (0.70-1.60)  1.80 (1.10-3.13)  0.001 
             3
rd Trimester  1.60 (1.10-2.00)  2.00 (1.38-3.05)  0.074 
             Post-natal  0.85 (0.60-1.38)  1.55 (1.05-3.18)  0.110 
TNF α  
(pg/ ml) 
 
0.003# 
 
<0.001# 
 
 
             1
st Trimester 
 
1.25 (1.00-1.80) 
 
1.20 (0.98-1.60) 
 
0.36 
             2
nd Trimester  1.50 (1.05-1.90)  1.20 (0.98-1.50)  0.39 
             3
rd Trimester  2.00 (1.38-2.48)  1.70 (1.40-2.48)  0.70 
             Post-natal  1.60 (1.10-2.40)  1.40 (1.20-2.00)  0.38 
CRP  
(mg/L) 
 
<0.001# 
 
<0.001# 
 
 
             1
st Trimester 
 
3.25 (1.45-4.99) 
 
8.43(3.87-13.1) 
 
0.001 
             2
nd Trimester  3.38 (1.47-5.61)  8.58 (4.23-12.6)  0.002 
             3
rd Trimester  3.11(1.54-4.16)  4.80 (3.01-12.6)  0.028 
             Post-natal  1.02 (0.69-2.26)  4.76 (1.48-11.2)  0.003 
IL-10  
(pg/ml) 
 
0.51# 
 
0.33# 
 
 
             1
st Trimester 
 
1.10(0.80-1.53) 
 
1.00 (0.83-1.10) 
 
0.19 
             2
nd Trimester  1.10 (0.90-1.45)  0.95 (0.83-1.20)  0.055 
             3
rd Trimester  1.10 (0.98-1.60)  1.00 (0.80-1.20)  0.86 
             Post-natal  1.20 (0.80-1.60)  1.10 (1.00-1.50)  0.69 
sICAM-1 
(ng/ml) 
 
<0.001# 
 
0.029# 
 
 
             1
st Trimester 
 
147 (125-164) 
 
176 (143-206) 
 
0.003 
             2
nd Trimester  178 (151-228)  204 (175-244)  0.020 
             3
rd Trimester  170 (138-193)  174(151-207)  0.20 
             Post-natal  159 (138-203)  205 (146-223)  0.085 
sVCAM-1 
(ng/ml) 
 
<0.001# 
 
<0.001# 
 
 
             1
st Trimester 
 
281 (230-314) 
 
318 (260-354) 
 
0.10 
             2
nd Trimester  347 (323-387)  355 (334-386)  0.54 
             3
rd Trimester  371 (342-394)  377 (334-428)  0.71 
             Post-natal  307 (253-381)  305 (262-354)  0.46 
vWF 
(mU/ml) 
              
 
 
<0.001# 
 
 
<0.001# 
 
             1
st Trimester  852 (658-1187)  769 (502-1319)  0.84 
             2
nd Trimester  1407 (854-1982)  1615 (1053-2012)  0.27 
             3
rd Trimester  2309 (1744-3009)  2497 (1877-3209)  0.79 
             Post-natal  667 (511-840)  602 (504-930)  0.82 
PAI-1 
(ng/ml) 
 
<0.001# 
 
<0.001# 
 
             1
st Trimester  12.2 (8.5-17.6)  5.9 (13.1-17.3)  0.010 
             2
nd Trimester  36.9 (32.4-73.1)  34.5 (26.8-40.0)  0.15 
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             3
rd Trimester  67.0 (52.3-103.1)  72.5 (51.3-123.6)  0.59 
             Post-natal  8.6 (6.0-10.1)  11.5 (6.218.3)  0.049 
PAI-2 
(ng/ml) 
 
<0.001# 
 
<0.001# 
 
             1
st Trimester  36.5 (23.5-72.3)  18.5 (13.8-33.7)  0.001 
             2
nd Trimester  312 (232-417)  314 (269-445)  0.79 
             3
rd Trimester  491 (369-710)  450 (346-648)  0.48 
             Post-natal  1.6 (0.5-4.1)  1.0 (0.4-3.7)  0.65 
 
TNFα is a cytokine indicative of the Th1 response whereas IL-6 is a cytokine indicative of 
the Th2 response. A ratio of TNFα/IL-6 was calculated to indicate the extent of the switch 
from the Th1 response to the Th2 response in pregnancy (Figure 3-2). Lean women had a 
higher TNFα/IL-6 ratio in the first trimester which declined in trimesters two and three and 
then rose in the post-natal period. In obese women the TNFα/IL-6 ratio did not change 
throughout pregnancy or in the post-natal period (p=0.26) and was significantly lower in 
obese than lean women at all time points apart from trimester three. 
 
 
 
 
 
 
 
 
 
 
Figure 5-3. Plasma TNFα/IL-6 ratio throughout pregnancy and in the post 
natal period.  Means and SE are shown. Ratios were significantly higher in the 
lean compared to the obese at all time points apart from trimester 3. 
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5.2.4 Relationships between endothelial function and markers of 
inflammation. 
In a multivariate analysis using the general linear model, time of sampling and 
categorisation as lean or obese contributed to both endothelial-dependent and endothelial-
independent microvascular function. However time of sampling had most impact on 
endothelial-independent function (18.5% [adjusted sum of squares expressed as a 
percentage of total means squared], p<0.001 for SNP response; 9.8%, p<0.001 for ACh 
response) and obesity had most impact on endothelial dependent microvascular function 
(1.7%, p=0.046 for SNP response; 19.3%, p<0.001 for ACh response).  The association 
between inflammatory and soluble markers of endothelial function, independent of 
trimester, was tested in a general linear model. None of the markers listed in Table 3-2 
predicted variability in endothelial-independent microvascular function. However 
endothelial-dependent microvascular function was predicted by IL-6 (10.7%, p<0.001), 
CRP (7.1%, p<0.001), IL-10 (2.0%, p=0.043) and sICAM-1 (5.0%, p=0.001). When these 
markers were entered into a multivariate model together with time of sampling, time of 
sampling (11.2%, p<0.001), IL-6 (4.0%, p=0.002) and IL-10 (2.4%, p=0.018) were 
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significant independent contributors to variation in endothelial-dependent microvascular 
function. To test whether these inflammatory markers might explain the effect of obesity 
on endothelial-independent function, whether subjects were lean or obese was also entered 
in the multivariate model. IL-6 and IL-10 were no longer significant and obesity explained 
6.8% (p<0.001) of the variability in endothelial-dependent microvascular function. 
5.2.5 Index of placental function 
PAI-1/PAI-2 ratio has been proposed as an index of placental function (293, 294). PAI-
1/PAI-2 ratios during pregnancy are shown in Figure 3-3 for lean and obese women. In the 
first trimester obese women had a significantly higher PAI-1/PAI-2 ratio indicating poorer 
placental function at this early time point (obese median [IQ range] 0.87 (0.54 – 1.21) vs. 
lean 0.30 [0.21 – 0.47], P<0.001). There were no differences in PAI-1/PAI-2 ratio in the 
second and third trimester.  The higher ratios seen in obese women in the first trimester 
predominately reflect the lower PAI-2 levels in trimester one rather than a higher PAI-1 
level (Table 3-2). Factors contributing to PAI-1/PAI-2 ratio, PAI-1 and PAI-2 variability in 
the first trimester were analysed in a multivariate model including first trimester vWF, 
sICAM-1, sVCAM-1, IL-10, IL-6, TNFα and CRP. First trimester body mass index (7.6%, 
p=0.012), first trimester IL-10 (8.2%, p<0.001) and first trimester sVCAM-1 (0.73%, 
p=0.007) contributed to first trimester PAI-1/PAI-2 ratio. When consider separately, PAI-1 
levels were explained partly by first trimester BMI (11.8%, p=0.012) and first trimester 
vWF (8.9%, p=0.028) whereas PAI-2 levels were explained by IL-10 alone (16.9%, 
p=0.001). 
 
 
 
This watermark does not appear in the registered version - http://www.clicktoconvert.com145 
Figure 5-4 PAI-1/PAI-2 ratios with advancing gestation.  Means (standard error) 
are shown. Ratios were significantly higher in the obese compared to the lean in 
the first trimester only. 
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5.3 Discussion 
We examined both in vivo microvascular function and markers of endothelial activation 
prospectively throughout pregnancy in healthy lean and obese women. Microvascular 
endothelial-dependent vasodilatory responses were found to be lower at all time points in 
obese subjects compared with lean counterparts and obesity had more impact on 
endothelial-dependent than endothelial-independent microvascular function in multivariate 
analysis. These observations provide evidence of the detrimental effect of obesity on 
endothelial-dependent microvascular function, and that the effect is sustained throughout 
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pregnancy. Impaired endothelial-dependent microvascular function was demonstrated 
using a well tolerated non-invasive, in vivo method of assessment, suitable for use in 
pregnant patients. Although laser Doppler imaging combined with iontophoresis assesses 
the cutaneous microcirculation, in this case the forearm, the technique has been 
demonstrated to be a valid surrogate for evaluating function in other vascular beds. 
Impaired cutaneous responses to iontophoretically administered ACh are observed in 
patients with hypercholesterolaemia (295) and diabetes mellitus (210, 296). Assessment of 
endothelial function in peripheral vessels has also been shown to correlate directly to 
dysfunction within the coronary vasculature (281).  The current findings expand our earlier 
observations of third trimester microvascular endothelial dysfunction in obese individuals 
(139). Microvascular endothelial dysfunction has also been demonstrated in type 2 
diabetes, a condition strongly linked with obesity (296, 297).  
 
Endothelium-independent vasodilatation was also significantly less in the obese women but 
the difference was of small magnitude. These data support the claim that obesity imparts 
vascular dysfunction by impacting not only directly upon the endothelium but also further 
downstream at the level of the smooth muscle. However, the smaller magnitude of 
difference between the two groups in SNP response in comparison to ACh response may 
suggest endothelial- dependent dysfunction to be the more important consequence of 
obesity. Multivariate analysis indicated that time of sampling during pregnancy had a large 
impact on endothelial-independent microvascular function. This observation might suggest 
that there are key changes in vascular smooth muscle cell biology associated with 
pregnancy per se. 
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During pregnancy, maternal peripheral blood lymphocytes secrete more Th2 cytokines and 
less Th1 cytokines than non-pregnant individuals (298). Furthermore trophoblast, decidua, 
chorionic and amniotic membranes can all act as a source of Th2 cytokines (285). Overall 
this leads to a change in the balance from Th1 to Th2 response that is typical of pregnancy 
(285). We have previously shown that obese women have higher third trimester plasma 
levels of the Th2 cytokine IL-6 and of CRP, an inflammatory mediator whose production is 
induced by IL-6, in obese compared to lean pregnant women (139). We expand this 
observation in the current study and show that plasma CRP levels are higher in obese 
compared to lean pregnant women at all time points measured and that plasma IL-6 and 
sICAM-1 levels are higher in early pregnancy in the obese. First trimester CRP was 
significantly higher than post-natal levels (P=0.001) indicating a very early increase of 
CRP levels associated with pregnancy, consistent with the report of elevated CRP levels at 
4 weeks’ gestation (299).   
 
We used TNFα/IL-6 ratio as a guide to the relative contributions of the Th1 and Th2 
response during pregnancy in the lean and obese individuals. In lean pregnant women we 
clearly see a high ratio in trimester 1, indicating more contribution from Th1 response. The 
ratio declines in the second and third trimester indicating a switch to a greater contribution 
from the Th2 response (Fig 2). In the post-natal period the ratio switches back to a greater 
Th1 contribution. Interestingly the obese women have a lower ratio than the lean women at 
all time points, apart from the third trimester, and the response to pregnancy is level. This 
suggests that the obese women are already predominately showing a Th-2 response and that 
there is no “Th1/Th2 switch” in pregnancy. It has been proposed, at least for preeclampsia, 
that an increase in maternal inflammatory response might provoke endothelial dysfunction 
(300). Using a multivariate model we found that none of the measured markers of 
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inflammation or endothelial activation explained the endothelial-independent 
microvascular response. However endothelial-dependent microvascular function was 
predicted by IL-6 and IL-10 levels, an effect which was lost if presence of obesity was 
added into the model. This suggests that the excessive Th2 response observed in obese 
pregnant women is linked to their endothelial-dependent vascular dysfunction. 
 
To our knowledge we have demonstrated for the first time the dynamics in PAI-1/ PAI-2 
ratio with advancing gestation among lean and obese women. PAI-1/PAI-2 ratios were 
similar in later pregnancy (second and third trimester) in lean and obese women. However 
the PAI-1/PAI-2 ratio was hugely elevated (2.7 fold, p=0.001) in obese women in the first 
trimester. This was predominately due to the approximately two-fold lower first trimester 
PAI-2 levels in the obese women in the presence of higher first trimester PAI-1 levels in 
the lean. This raises the interesting possibility that, in the first trimester, placental 
growth/function is impaired in the obese pregnant woman but that a recovery in 
growth/function is achieved by the second trimester. In order to investigate possible 
mediators of this effect we carried out multivariate analysis of potential predictors of first 
trimester PAI-1 and PAI-2 levels. First trimester IL-10 levels predicted PAI-2 levels 
independent of BMI although this may merely indicate that placenta is a quantitatively 
important site of IL-10 production. It is possible that first trimester expression of a 
predominately Th2 response in obese individuals has adverse consequences for 
establishment of the placenta. An abnormally raised PAI-1/PAI-2 ratio also predates the 
onset of preeclampsia (301) a condition characterised by abnormal placentation and 
widespread endothelial dysfunction (187, 190, 302). Obesity is a significant risk factor for 
preeclampsia. Perhaps in preeclampsia, this early compromised placental growth/function 
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demonstrated in obese women persists among those who develop preeclampsia, while it 
recovers in those women who do not. 
 
In conclusion we have employed a well-tolerated, non-invasive technique for the 
assessment of endothelial function longitudinally throughout pregnancy. We have 
demonstrated reduced endothelium-dependent and -independent vasodilation among obese 
mothers when compared to lean counterparts. We observed a significantly higher PAI-1/ 
PAI-2 ratio in the first trimester in obese women; however these women went on during 
pregnancy to improve their PAI-1/PAI-2 ratio to levels comparable to their lean 
counterparts. We provide evidence that the increased risk of preeclampsia associated with 
obesity can be explained in part by chronic pre-existing endothelial activation and 
impairment of endothelial function secondary to increased production of inflammatory Th-
2 cytokines. We also hypothesise that early impaired placental growth/function is 
characteristic of obese pregnancy and if not recovered may further explain the elevated risk 
of hypertension and preeclampsia among obese mothers. 
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Chapter Six 
 
Conclusion. 
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6  Conclusion 
 
6.1 Obesity in pregnancy 
 
The mechanisms by which obesity influences pregnancy and its outcomes are poorly 
understood. Examining the physiological changes experienced during pregnancy and how 
these changes are influenced by maternal obesity will provide further insight into the 
mechanism by which obesity imparts an increased risk of adverse maternal and fetal 
outcome. 
 
6.2 Obesity and metabolic syndrome 
The metabolic syndrome is a spectrum of metabolic abnormalities, commonly observed in 
the centrally obese, associated with insulin resistance. It is manifest as relative 
hyperglycaemia, hyperlipidaemia, and disturbance of coagulation. In the non-pregnant, 
central obesity and the metabolic syndrome are key factors underlying cardiovascular 
disease and type 2 diabetes (86, 87). An increase in plasma FFA concentrations in normal 
subjects, to levels comparable to those in the obese, also results in the induction of 
oxidative stress, inflammation, and vascular dysfunction, in addition to causing insulin 
resistance (94). Markers of inflammation such as C-reactive protein, interleukin-6, and 
raised white cell count have also been found to be independent predictors of cardiovascular 
events and diabetes.  
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6.3 Metabolic changes in pregnancy 
The normal physiological response to pregnancy represents a time when several 
components of the metabolic syndrome are acquired: a relative degree of insulin resistance, 
a gestational hyperlipidaemia, and increased coagualability. Normal pregnancy also 
involves up-regulation of the inflammatory cascade and an increase in white cell count. 
Thus pregnancy provides a unique opportunity to look at temporary metabolic and 
inflammatory disturbances. There is a lack of knowledge within the literature with regard 
to the direct influence of obesity on metabolism during pregnancy. Most studies look at a 
limited number of metabolic parameters or involve the third trimester only. We 
hypothesised that the type of metabolic change experienced during pregnancy is linked to 
adverse outcome. If this is the case then the influence of obesity on the extent of metabolic 
adaptation during pregnancy may explain the impact of obesity on adverse pregnancy 
outcome. Furthermore the timing of alterations in particular metabolic changes may be 
related to whether adverse outcomes are manifest in early or late pregnancy.  
This thesis attempts to address the lack of detailed knowledge on the impact of obesity on 
pregnancy metabolism.  A longitudinal study is presented to establish the timing and 
degree of perturbation of a wide range of metabolic and physiological parameters. We 
wished to identify whether there are early changes in metabolism that may link with early 
adverse events and later changes in metabolism that may relate to late adverse outcomes. It 
was necessary to not only study the degree of metabolic change, but also the timing of such 
changes.  
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6.4 Metabolic changes and vascular function 
Successful adaptation of vascular function both at the level of the maternal systemic 
circulation and at the placenta is imperative for healthy pregnancy. In early pregnancy 
placentation and the establishment of a healthy maternal-fetal circulation is necessary in 
order to avoid early miscarriage. Suboptimal invasion of trophoblasts and insufficient 
remodelling of the maternal spiral arteries leads to a dysfunctioning vascular network 
within the placenta resulting in poor placental perfusion and intrauterine growth restriction 
(IUGR). The poor placental perfusion can evoke the release of factors which, on exposure 
to the maternal circulation, give rise to preeclampsia. Preeclampsia is a multisystem 
disorder, exclusive to pregnancy, in which systemic endothelial dysfunction, platelet 
aggregation and reduced placental perfusion is the underlying pathology. The origins of pre 
eclampsia are thought to lie at least partly within the placentation process a view supported 
by the prompt recovery post partum and the increased incidence among those with 
hydatidiform moles or multiple pregnancies. Thus the establishment of the placental 
circulation can also influence fetal and maternal outcome in later pregnancy. 
Maternal vascular endothelial function is known to improve with advancing gestation. This 
improvement in endothelial function is necessary to accommodate the increased vascular 
volume as well as the increased coagulabilty present during pregnancy. The functional 
adaptation of the maternal cardiovascular system to meet the requirements of the mother 
and the growing fetus is a prerequisite for a successful pregnancy.  Endothelial dysfunction 
is thought to contribute to maternal thrombosis a condition which is among one of the 
leading causes of maternal mortality in the UK. Adverse events such as these occur among 
women of all BMI values. By examining the degree of metabolic change among obese 
women when compared to lean, and the resultant effect on maternal endothelial function 
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with advancing gestation, further insight into the mechanisms by which these women are 
more susceptible to pathology may become evident.  
Clinical studies report that the presence of vascular dysfunction is a significant predictor of 
future cardiovascular events (151, 152). The vast majority of evidence to date indicates that 
microvascular endothelial function is impaired in the early stages of atherosclerosis and it 
is this endothelial dysfunction which is an important factor leading to atherosclerosis and 
its complications. An increasing number of studies have demonstrated the correlation 
between dyslipidaemia, inflammation and vascular dysfunction (157). (171).  By drawing 
parallels with the field of cardiovascular research we hypothesised that the metabolic 
changes experienced by the obese mother may adversely affect vascular function in 
pregnancy and this could constitute a mechanism by which obesity is associated with 
adverse pregnancy outcome. 
 
6.5 Metabolic changes in pregnancy 
6.5.1 Early Gestation 
This thesis describes the metabolic changes that occur in pregnancy and relates the degree 
of change to obesity. With advancing gestation we observed that some metabolic changes 
occur early in pregnancy while others occur late. Specifically we observed that CRP was 
elevated in the first trimester as compared to the post partum period. We also found CRP 
levels to be significantly higher among obese mothers as opposed to lean at all time points. 
Our data and those of others suggest that there is indeed an inflammatory response present 
early in the first trimester. From as early as 6 weeks’
 gestation, there are increased numbers 
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of circulating monocytes (303), while in first trimester decidua there
 is a massive influx of 
pro-inflammatory macrophages and natural
 killer (NK) cells (304).  In the first trimester,
 
raised CRP levels have been reported (305) and Sacks et al provided evidence of a mild 
systemic maternal inflammatory
 response from as early as 4 weeks’ gestation (299). The 
interaction between the invading trophoblast and
 maternal inflammatory cells is a key stage 
of early pregnancy
 and may be a factor in some cases of miscarriage. This is interesting in 
the context of our observation that CRP levels are higher in obese mothers who are more 
prone to early miscarriage. It is possible that an exaggerated inflammatory response as 
early as four weeks’ gestation could indicate a failing pregnancy.  
It is important to recognize that adipocytes
 and myofibers produce proinflammatory 
cytokines, TNF  and IL-6,
 in response to antigen challenge. When the immune system is 
challenged, an important flow of energy is required. As a result, cytokines TNF are 
recruited to induce lipolysis [1] and to mobilize energy. Conversely, when adipose tissue 
stores are depleted, energy sparing becomes a priority, even at the cost of imposing a 
decrease in the level of immunologic surveillance. As stated, these cytokines
 have a notable 
history of inducing insulin- and growth hormone-resistance
 in adipose tissue and skeletal 
muscle. Both adipocytes and macrophages within fat secrete
 numerous hormones and 
cytokines that may contribute to the characteristic
 pathophysiologic changes seen in the 
metabolic syndrome, and
 local inflammation within adipose tissue may be the sentinel
 
event that causes systemic insulin resistance and systemic inflammation,
 two of the cardinal 
features of the metabolic syndrome. Pregnancy as described throughout this thesis 
physiologically resembles the metabolic syndrome. In the obese mother the excess 
adipocyte secretion of inflammatory markers may account for the development of obstetric 
complications.  
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6.5.2 Late gestation  
Most evidence regarding the inflammatory response is from the third trimester,
 and 
investigators have postulated that an abnormal inflammatory
 response causes pregnancy 
complications such as pre-eclampsia (306) or preterm labour (307). CRP levels are raised 
in women with pre-eclampsia (308), in women with ruptured membranes complicated
 by 
chorioamnionitis (309) and in women who develop
 preterm labour (307). Women with 
higher CRP levels
 at 9–13 weeks are more likely to develop gestational diabetes
 mellitus 
(310) and pre-eclampsia (311). Higher CRP levels are associated with increasing BMI 
(312) an observation consistent with the present study. Furthermore we observed that 
endothelial function is influenced by changes in type 2 inflammatory cytokines in our study 
women. Thus the greater degree of inflammatory response observed in obese women may 
explain the higher risk of preeclampsia, GDM and other late pregnancy complications in 
obese pregnancy. 
Obesity was associated with late gestation LDL III concentrations in our study. LDL III is 
an easily oxidised lipoprotein that is highly atherogenic and may provoke endothelial 
dysfunction. We observed LDL III levels to rise in all individuals between the first and 
second trimester. However with advancement into the third trimester maternal BMI had a 
direct influence on the behaviour of LDL III concentrations. Those mothers with BMI 
values in the lowest tertile experienced a fall in LDL III concentration in the third trimester 
while those mothers with BMI values in the middle tertile have LDL III concentrations that 
plateau in the third trimester. Most strikingly, those women with BMI values in the highest 
tertile experienced a further significant increase in LDL III concentration in the third 
trimester of pregnancy. It is possible that this elevated LDL III concentration in the 
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maternal circulation of the obese mother contributes to the increased susceptibility of late 
complications of pregnancy such as pre eclampsia and gestational diabetes.  
 
6.6 The impact of obesity on metabolism throughout 
pregnancy 
When comparing lean and obese not only did we observe a difference in the relative 
concentrations of lipoproteins such as LDLIII, with advancing gestation we also found that 
maternal BMI had a direct influence on the degree of total changes in lipid concentration as 
pregnancy advanced. We observed that obese women started pregnancy with already 
elevated lipids such as triglyceride and cholesterol and as pregnancy advanced their lipids 
increased. Interestingly we found that lean women experienced a much more extreme 
change in lipid profile, from a lower baseline, with advancing gestation. Lean women 
started pregnancy with lower lipid levels than their obese counterparts but by the end of 
pregnancy their lipid levels had increased dramatically to levels similar to those of the 
obese women. Thus lean women exhibited large dynamic response to pregnancy while the 
response among the obese women was somewhat attenuated largely because they start from 
a higher baseline value.  
Human metabolism needs to be highly adaptable in order to cope with the impact of the 
physiological changes associated with pregnancy. This adaptability requires a clear ability 
to utilize lipids and carbohydrate fuels and to switch from one energy source to 
another(313). This cellular capacity is termed “metabolic flexibility” and is impaired in 
obesity(314).. In obese individuals this relative metabolic inflexibility is manifest in a 
range of metabolic pathways and tissues including the impairment of early phase post 
This watermark does not appear in the registered version - http://www.clicktoconvert.com158 
prandial insulin secretion coupled with failure to suppress hepatic glucose production and 
NEFA efflux from adipose tissue. Among the obese there is a failure of skeletal muscle to 
appropriately move between use of lipid in the fasting state and use of carbohydrate in the 
insulin stimulated post prandial state. Impaired transition from fatty acid efflux to storage 
in response to a meal is also evident among obese (314). It has become increasingly clear 
that reduced capacity for fuel usage in, for example, skeletal muscle, is characteristic of the 
metabolic syndrome and a fundamental component of metabolic inflexibility. We have 
observed an analagous phenomenon in pregnancy whereby lean women are highly 
adaptable to the metabolic changes required for pregnancy whereas obese women have a 
much reduced ability to respond. In a similar way to lean individuals being metabolically 
flexible in response to the stimulus of a meal we observed that lean mothers are more 
flexible in their response to pregnancy. One might speculate that the obese mother is less 
able to mobilise fats from stores in order to provide nutrition to her developing fetus.  
It is also interesting to note that in our study lean mothers demonstrated a clear Th1/Th2 
switch in response to pregnancy whereas obese mothers did not. We used TNFα/IL-6 ratio 
as a guide to the relative contributions of the Th1 and Th2 response during pregnancy in 
the lean and obese individuals. In lean pregnant women we clearly saw a high ratio in the 
first trimester, indicating more contribution from Th1 response. The ratio declined in the 
second and third trimester indicating a switch to a greater contribution from the Th2 
response. In the post-natal period the ratio switched back to a greater Th1 contribution. It is 
tempting to speculate that the flexibility of physiological adaptation to pregnancy may 
extend beyond metabolic responses to inflammatory response. Furthermore endothelial-
dependent microvascular function was predicted by IL-6 and IL-10 levels in a multivariate 
statistical model, an effect which was lost if presence of obesity was added into the model. 
This suggests that the excessive Th2 response observed in obese pregnant women is linked 
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to their endothelial-dependent vascular dysfunction. Thus metabolic inflexibility in obese 
pregnancy may extend to inflexibility of the inflammatory adaptive response and to an 
inadequate vascular adaptation. As discussed earlier, a failure to make adequate vascular 
adaptations to pregnancy could results in both early (miscarriage, IUGR) and late gestation 
(preeclampsia, GDM) adverse pregnancy outcomes. 
6.7 The impact of obesity on placental function 
To our knowledge we have demonstrated for the first time the dynamics in PAI-1/ PAI-2 
ratio with advancing gestation among lean and obese women. PAI-1/PAI-2 ratio was 
hugely elevated in obese women in the first trimester, predominately due to lower PAI-2 
levels. PAI-1/PAI-2 ratios were similar in later pregnancy in lean and obese women. This 
raises the interesting possibility that, in the first trimester, placental growth/function is 
impaired in the obese pregnant woman (as indicated by low PAI-2 levels) but that a 
recovery in growth/function is achieved by the second trimester. It is possible that first 
trimester expression of a predominately Th2 response in obese individuals has adverse 
consequences for establishment of the placenta. An abnormally raised PAI-1/PAI-2 ratio is 
also known to predate the onset of preeclampsia (301) and obesity is a significant risk 
factor for preeclampsia. Perhaps in preeclampsia, this early compromised placental 
growth/function demonstrated in obese women persists among those who develop 
preeclampsia, while it recovers in those women who do not. Whether the impact of obesity 
relates to vascular development in the placenta or to trophoblast invasion is worthy of 
further investigation.  
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6.8 Consequence of obese pregnancy for the offspring 
Metabolic changes experienced during pregnancy are now known from this study to be 
quite different throughout the pregnancy for lean women as compared to obese. For 
example the area under the lipid.gestational time curve is higher in obese women; 3
rd 
trimester LDLIII levels are high in obese women and in general the maternal metabolic 
response to pregnancy is less flexible in obese mothers. Since there are differences in both 
the concentrations and the quality of metabolites circulating in maternal blood we would 
hypothesis that the nutrient mixture delivered to the fetus via the placenta would also be 
affected. Hence we propose that the offspring of lean and obese pregnancies experience 
different in utero environments.  
The issue of fetal programming is an area widely debated. Pettit's long-term follow-up 
studies of the Pima Indians showed that a diagnosis of diabetes during gestation 
significantly increases the risk of both adolescent obesity and glucose intolerance, in 
contrast with that of children of the same woman when her glucose tolerance was normal 
during gestation (93). Montgomery et al looked at health scores of 7 to 16 year olds (315). 
The data was correlated to rates of exposure to cigarette smoking in utero. Montgomery 
concluded in utero exposure due to smoking during pregnancy may increase the risk of 
both diabetes and obesity through programming, resulting in lifelong metabolic 
dysregulation, possibly due to fetal malnutrition or toxicity. Smoking during pregnancy 
may represent another important determinant of metabolic dysregulation and type 2 
diabetes in offspring (315).  
One of the most interesting clinical observations in the past decade has been the association 
between low birthweight and hypertension, coronary-artery disease, and non-insulin-
dependent diabetes (NIDDM) in adult life (316-318). Hattersley et al propose that the 
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association between low birthweight and adult insulin resistance is principally genetically 
mediated. Genetically determined insulin resistance could result in low insulin-mediated 
fetal growth in utero as well as insulin resistance in childhood and adulthood Low 
birthweight, measures of insulin resistance in life, and ultimately glucose intolerance, 
diabetes, and hypertension, would all be phenotypes of the same insulin-resistant genotype. 
Central to this fetal insulin hypothesis is the concept that insulin-mediated fetal growth will 
be affected by fetal genetic factors that regulate either fetal insulin secretion or the 
sensitivity of fetal tissues to the effects of insulin. The fetal insulin hypothesis offers an 
alternative explanation for the consistent association between impaired fetal growth and 
insulin resistance during life and the link with hypertension and vascular disease. Both 
genetics and the fetal environment are likely to be important in determining fetal growth, in 
the same way as both genetic and environmental influences are important in adult disease 
susceptibility. 
Barker et al suggest undernutrition at different stages of pregnancy leads to phenotypes 
characterised by low birthweight, or low birthweight relative to placental weight, or 
thinness at birth, or shortness at birth with subsequent failure of infant growth. Each of 
these phenotypes is associated with a particular pattern of metabolic abnormalities in adult 
life. The abnormalities may depend on the different timing of the undernutrition and its 
different effects on organs and tissues according to their stage of development. This group 
went further to suggest that adaptation by the fetus exposed to periods of under nutrition 
change the body's physiology, structure, and metabolism, they may lead to cardiovascular 
disease in later life. 
Catalano et al question whether or not obesity begets obesity (245). We have reported an 
increased CRP concentration among obese women at all time points. Pregravid obesity 
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represents a state of chronic inflammation. On the basis of these observations, one could 
hypothesize that increased maternal pregravid obesity is a state of increased insulin 
resistance and inflammation as estimated by CRP. During gestation, obese women make 
available increased nutrients to the fetus, resulting in increased placental growth in early 
gestation and increased somatic growth, particularly fetal adipose tissue in late gestation. 
The worldwide epidemic of adolescent and adult obesity may not only be a result of our 
lifestyle of inadequate activity and poor diet; it may also be propagated and enhanced at a 
much earlier stage in life because of an abnormal metabolic milieu in utero during 
gestation 
 
In pregnancy the fetus is reliant on placental transfer of fatty acids from the mother to 
support growth. These fatty acids are used both as a source of energy and as building 
blocks for membranes. In chapter five we examined a full maternal erythrocyte fatty acid 
profile assessed at each trimester throughout pregnancy and at 4 months post-partum. Many 
short chain and long chain fatty acids were shown in our study to increase with advancing 
gestation.  The 41% increase in maternal erythrocyte 18:3n3 during pregnancy observed by 
our group is most likely due to its role as a precursor for 22:6n3 synthesis. DHA (22:6n3) 
and nervonic acid (24:1n9) are important in neural development, as a structural component 
of membranes and for myelination respectively. Increased mobilisation of these fatty acids 
for fetal development was correlated indicating the importance of the fetal fatty acid in 
utero environment for the development of the brain. 
Palmitoleic acid, 16:1n7 was also increased during pregnancy and concentrations of this 
fatty acid correlated negatively to booking BMI and waist circumference. This introduces the 
concept that the quality of fatty acids delivered to the placenta for transfer to the fetus can be 
influenced by obesity. Essential fatty acids are important for membrane synthesis and 
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membrane composition can influence membrane functions such as insulin signalling. 
Enrichment of cell membranes with LC n-3 PUFA can improve insulin sensitivity via a 
number of mechanisms. An increase in unsaturation index of cell membranes, particularly in 
muscle, has been associated with insulin sensitivity (319) (320) probably by affecting 
molecular insulin signalling. Changes in fatty acid composition may also affect insulin 
resistance by acting as ligands for peroxisomal proliferator activated receptors (PPARs). 
PPARs regulate expression of a wide array of genes involved in lipid metabolism and 
inflammation (321). LC n-3 PUFAs also have important roles in inflammation. EPA can 
displace arachidonic acid, a precursor of prostaglandins and leukotrienes, from cell 
membranes reducing inflammatory response. EPA can also be metabolised to anti-
inflammatory mediators (322). Maternal insulin resistance has been related to membrane 
phospholipid fatty acid composition in breast-fed children, suggesting that maternal 
metabolism may impact on the degree of insulin resistance in the offspring (323). 
Furthermore, growth-restricted animals have a composition of 22:6 n-3 in skeletal muscle 
membrane very close to that of Pima Indians, supporting the relevance of membrane 
composition in programming (324). 
 
6.9 Future Research 
We have raised a lot of questions which pave the way for future research. Firstly we plan to 
examine metabolic differences between lean and obese pre pregnancy and in early 
gestation. Recruitment of women from an assisted conception programme would facilitate 
very early gestation blood sampling. The impact of these factors could then be correlated to 
both early and late pregnancy clinical outcomes for both the mother and the fetus. By 
establishment of the pre pregnancy factors critical to improvement of clinical outcome for 
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pregnancy education and pre treatment criteria could be developed to ensure the maximum 
chance of success in treatment and the avoidance of both maternal and fetal pathology in 
alter pregnancy. Intervention studies looking at the impact of pre pregnancy weight loss or 
lifestyle changes as well as the impact of lifestyle changes or dietary improvement during 
pregnancy would expand further our knowledge of the reversibility of the adverse 
influences of obesity on both maternal and fetal health.  
 
A further aspect of our work will involve the examination of PAI 1/PAI 2 ratios, along with 
other markers of placental function (hCG and placental size), from day zero of pregnancy. 
Placental function will be assessed in those who have a continuing pregnancy and among 
those who miscarry thus providing a further insight into the mechanisms of first trimester 
miscarriage. A detailed comparison or erythrocyte fatty acid composition among lean and 
obese women, particularly in early gestation, is the next stage for our work in this field. As 
the fetus is reliant on the mother for placental transfer of fatty acids for growth and 
development by examining the influence of maternal BMI on red blood cell membrane 
composition we can perhaps add further dimension to the maternal issues involved in fetal 
programming. 
We have collected adipose tissue from the abdominal fat of women who during the study 
underwent caesarean section for obstetric reasons. We also collected placental tissue from a 
high percentage of women involved in the study at delivery. Fetal blood was collected from 
the umbilical cord. This collection allows us to explore the molecular mechanisms, such as 
gene expression in both maternal adipose tissue and placental tissue, in lean and obese 
women. By establishing the placental gene expression for fatty acid transfer proteins for 
example, we would be able to ascertain molecular influences of maternal obesity on 
placental function. The maternal influence on the fetal biochemical environment will also 
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be examined in order to take further the issue of fetal programming. The long term follow 
up of the children from these pregnancies would also be an extremely interesting study and 
allow us to establish further the influences of the in utero environment on future health. 
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